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Heme proteins, in particular cytochromes P450, have been extensively used in biocatalytic 
applications due to their high degree of regio-, chemo-, and stereoselectivity in oxene-transfer 
reactions. In 2013, it was shown for the first time that engineered heme proteins can also catalyze 
analogous carbene- and nitrene-transfer reactions. Research in this field has since grown 
dramatically, with emphasis on developing new heme protein variants to increase the scope of 
biotransformations accessible through these new transfer reactions. This thesis details the expansion 
of these new-to-nature carbene and nitrene-transfer reactions to include new substrate classes 
previously unexplored with iron-porphyrin proteins, the use of non-heme metalloproteins for these 
transformations, and steps toward improving the robustness of the new-to-nature biocatalytic 
platform. Chapter 1 introduces the steps the field of biocatalysis has taken toward engineering 
enzymes with new catalytic functions and the process by which these activities are discovered and 
enhanced. Chapter 2 details the discovery and engineering of heme proteins which catalyze the 
stereodivergent cyclopropanation of unactivated and electron-deficient alkenes via carbene transfer, 
expanding the substrate classes beyond styrenyl alkenes. Chapter 3 shows the development of 
engineered variants of a heme protein (Rhodothermus marinus nitric oxide dioxygenase) for the 
diastereodivergent synthesis of cyclopropanes functionalized with a pinacolborane moiety, enabling 
product diversification through standard cross-coupling reactions. In Chapter 4, a collection of non-
heme metalloproteins is curated, and a non-heme iron enzyme (Pseudomonas savastanoi ethylene-
forming enzyme) is shown to be both amenable to directed evolution and non-native ligand 
substitution to enhance its nitrene-transfer activity. Chapter 5 describes the expansion of sequence 
space targeted for screening in the serine-ligated cytochrome P411 from Bacillus megaterium 
(P411BM3) biocatalytic platform to enhance the mutational robustness of these remarkable enzymes. 
Overall, this work provides a framework for bringing model new-to-nature reactions to their full 
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Enzymes are used in biocatalytic processes for the efficient and sustainable production of 
pharmaceuticals, fragrances, fine chemicals, and other products. Most bioprocesses exploit 
chemistry found in nature, but we have now entered a realm of biocatalysis that goes well 
beyond natural reactions. Enzymes have been engineered to catalyze reactions previously 
only accessible with synthetic catalysts. Because they can be tuned by directed evolution, 
many of these new biocatalysts have been shown to perform abiological reactions with high 
activity and selectivity. This chapter discusses examples which showcase catalyst 
improvements achieved using directed evolution, and commentary on current and future 






Chemical synthesis is integral to modern life: from the Haber-Bosch process used to fix 
nitrogen for fertilizer and feed the Earth’s growing population to ubiquitous synthetic fabrics 
to life-saving medicines, we are surrounded by the products of chemical transformations. 
Many synthetic routes, especially those for more complex molecules, are far from ideal: poor 
atom economy, harsh reaction conditions, and multiple steps that require purification of 
intermediates all lead to lower yield and increased waste. Rare metal catalysts are 
increasingly costly to obtain, and their mining and refinement has significant and negative 
environmental impacts.1 The recovery or removal of toxic catalysts from the products can 
also be a challenge. Thus both economic and environmental factors favor chemistry that is 
inherently “green.”2,3 Discussions of “green” chemistry often include biocatalysis, where 
enzymes stand out for their ability to selectively convert inexpensive starting materials into 
complex molecules under mild aqueous conditions. Enzymes have been used for organic 
synthesis for well over a century.4 However, a biocatalytic process was not possible if the 
desired enzyme could not be found in nature and made available at low cost. This has 
changed with the development of recombinant protein production technology, which has 
delivered many biocatalysts at low cost. Furthermore, enzymes have been engineered, at the 
level of their amino acid sequences, for improved performance under process conditions. The 
growing need for sustainable synthetic methods, coupled with advances in enzyme 
engineering and related process technologies, have helped drive adoption of biocatalytic 
processes in the pharmaceutical and chemical industries.5,6 
A key innovation that underlies growing interest in biocatalysis is directed evolution, a 
protein engineering method that mimics Darwinian evolution, using iterations of genetic 
variation and screening in order to accumulate performance-enhancing mutations (Figure 1-
1). Researchers have used directed evolution to increase enzyme performance under reaction 
conditions, including higher temperatures, high acidity or basicity, and high concentrations 
of organic solvents. The ranges of substrates that enzymes accept have been expanded, and 
product selectivity has been altered and optimized.7 Rather than having to design a process 




optimal manufacturing conditions.6 A beautiful example of this ability to tailor a biocatalyst 
to fit the process is Merck’s engineered transaminase that catalyzes a key step in the 
production of the antidiabetic drug sitagliptin. Through directed evolution, a transaminase 
was engineered for near-perfect enantioselectivity and high yields in 50% DMSO, 200 g L-1 
starting material, and elevated temperatures.8 Replacing the precious metal catalyst 
previously used for multi-ton-scale synthesis with the engineered enzyme dramatically 
reduced solvent waste and increased process yield. Many other industrial syntheses make use 
of engineered enzymes with enhanced stability, activity, and selectivity.6,9–13 
 
Figure 1-1. Directed evolution workflow. Variants of the gene of interest are generated and the 
corresponding protein variants are expressed in (typically bacterial) cells. The proteins are screened 
for the desired activity. Proteins with enhanced activity are used as the parent for subsequent rounds 





An exciting development is engineering that goes well beyond enhancing native enzyme 
activities or broadening the substrates accepted: enzymes have been engineered for new 
chemical transformations not known in the biological world, and new catalytic capabilities 
have even been engineered into proteins that do not have any native catalytic activity. These 
advances make it possible to take the concept of engineering a protein to fit a process to the 
next level, where biochemical syntheses are no longer limited to reaction classes known in 
nature, but can expand to include whole new transformations and entirely new classes of 
products. In this Chapter, I discuss some of the non-natural activities that have been 
engineered into proteins, the ease with which such activities have been enhanced by directed 
evolution, and the current and future implications of such non-natural enzymes for green 
chemistry.  
1.2 Non-natural activities are readily accessed from diverse starting 
points  
Directed evolution of a non-natural activity requires a starting point – it can enhance an 
existing activity, but cannot create it entirely from scratch (Figure 1-2). Although enzymes 
are often thought to catalyze reactions with great selectivity, many enzymes are in fact 
catalytically promiscuous – that is, they are able to catalyze reactions other than their native, 
biologically relevant reactions.6,14,15 It has been recognized for some time that these 
promiscuous activities are good starting points for directed evolution.16 In the initial report 
of enzymatic cyclopropanation, for example, many of the heme proteins tested – including 
wild-type proteins and previously engineered cytochrome P450 variants – catalyzed non-
natural styrene cyclopropanation at some (low) level.17 Different protein scaffolds could 
serve as starting points for directed evolution as has been observed for other reactions18–20 
and in a broader survey of P450s from nature.21 Starting points are not even limited to 
enzymes: heme-binding proteins with no native enzymatic functions also exhibit non-natural 
catalytic activities that could be improved by directed evolution. Fasan and coworkers 
showed that sperm whale myoglobin, an oxygen-binding heme protein, could be engineered 
to catalyze the cyclopropanation of styrene stereoselectively with 46,800 turnovers,18 




cytochrome c.20 In each case, engineering active and selective biocatalysts required just a 
few rounds of directed evolution. There is no evidence that these non-natural biocatalysts 
have reached their full potential either: further evolution could continue to increase these 
activities, for which the upper limits are unknown. 
An initial activity can sometimes be found by screening wild-type and/or engineered 
proteins. Another approach is to install an artificial cofactor22 to generate activity that can be 
improved by directed evolution,23–27 albeit with low throughput. Although directed evolution 
with in vitro assembly of an artificial metalloenzyme is more work than with fully genetically 
encoded catalysts, the evolution of an artificial metalloenzyme as shown by Hartwig and 
coworkers23 is testament to the efficiency and reliability of this catalyst improvement 
method.  
 
Figure 1-2. Discovery of starting points and engineering for non-natural enzymatic function. Left: 
Different strategies for finding initial enzymatic activity. Right: proteins with initial activity are 
engineered through an iterative process of mutagenesis and screening (directed evolution) to 




For some model reactions, one can even rationally design a protein with initial non-natural 
enzymatic activity.28 A recent example of pairing a rationally designed starting point with 
directed evolution comes from the Baker and Hilvert labs, who designed an active site into a 
natural TIM-barrel protein to give it trace activity for retroaldol cleavage.29 The Hilvert lab 
then used high-throughput directed evolution with detection of the fluorescent product to 
obtain an enzyme with reaction kinetics comparable to native aldolases.30,31 The 
computational design of non-natural enzymes is currently limited to relatively simple 
reactions. Should rational design extend to more difficult and especially to cofactor-
dependent modes of catalysis, this approach could provide valuable new starting points for 
future biocatalysts. 
The ease with which the non-natural activities were improved is a common theme across 
these new biocatalysts. Just a few rounds of directed evolution (each taking 1–4 weeks) 
increased the activities and/or selectivities well beyond the starting catalysts and even the 
activities of their small-molecule catalyst analogs.32 Given measurable starting activity and 
efficient analytical methods (e.g. spectroscopic or chromatographic analyses), a protein’s 
catalytic activity can be improved with no additional knowledge of the catalyst’s mechanism 
or structure beyond the DNA sequence encoding the protein. This engineering of non-natural 
activity proceeds using the same methods and with the same efficacy as the directed 
evolution of native activities. In fact, given that nature never optimized these proteins for 
such non-natural catalytic activities, there is plenty of room for improvement and activating 
mutations are relatively easy to find. 
1.3 Engineering enzymes for new-to-nature chemistry 
Many of the concepts underlying creation of non-natural enzymes, such as exploiting natural 
catalytic promiscuity,14,15,33 chemomimetic biocatalysis,34,35 computational enzyme design,28 
or introduction of artificial cofactors,22 have been part of the biocatalysis community for a 
decade or more. These approaches have enabled researchers to identify (usually low levels 
of) enzymatic activity for numerous new-to-nature chemical transformations. What has 




enzymatic activities with directed evolution to enhance and tune those activities and 
selectivities.16,36,37 
Multiple important modes of catalysis have been implemented in protein scaffolds by 
exploiting the reactivities of both canonical30,38,39 and non-canonical amino acids,40 as well 
as natural35 and artificial22,41 cofactors. Hydrolases have been particularly popular enzymes 
to explore for new chemistry due to their availability and the versatility of their hydrogen 
bonding activation modes and acyl-transfer activity.38 More than 20 years ago, visionary 
contributions showed that the acyl-enzyme intermediate can be trapped with various 
nucleophiles such as amines.42 Subsequent optimization of the acyl donor improved this non-
natural activity43 and enabled chiral synthesis of various amines on a multi-ton scale.44 
Similarly, hydrogen bonding in a halohydrin dehalogenase was harnessed for selective 
epoxide opening with cyanide. Directed evolution of a weakly active wild-type enzyme 
yielded a biocatalyst that was stable and highly efficient under process conditions.45 
Various activation modes from organocatalysis46 have been explored in proteins.30,39,47–50 
Inspired by aminocatalysis, active-site proline and lysine residues were recently exploited 
for biocatalytic C–C bond formations: Michael(-type) additions,47,49 aldol reactions,30 and 
Knoevenagel condensation reactions.50 In an outstanding report, Hilvert and coworkers 
demonstrated that directed evolution can convert proof-of-concept low level activity into an 
impressive biocatalyst.30 An artificial aldolase (class I aldolase mimic) performing enamine-
catalyzed aldol reactions via an active-site lysine was evolved to perform aldol reactions with 
high yields, high enantioselectivities, and up to 28,500 total turnovers under preparative-
scale conditions (Figure 1-3a). In another example, the protonation machinery of a squalene 
hopene cyclase was harnessed for Brønsted acid-catalyzed activation of carbonyls, epoxides, 
and alkenes at neutral pH in water (Figure 1-3b). Several valuable cyclohexanoids have been 
synthesized with very high stereoselectivity, and active-site engineering improved the 
activity and selectivity of the biocatalyst. Further enzyme engineering might provide a broad 





Figure 1-3. New catalytic activation modes engineered in proteins and their putative catalytic 
intermediates. Examples include (a) enamine-catalyzed aldol reaction, (b) Brønsted acid-catalyzed 
Prins/Ene-reaction, (c) photo-catalyzed radical dehalogenation of halolactones, (d) heme-catalyzed 
cyclopropanation of olefins, (e) heme-catalyzed intermolecular C-H amination, (f) Ir(Me)-
protoporphyrin IX-catalyzed insertion of carbenes into C-H bonds and (g) olefin metathesis using 





Hyster and coworkers shone a whole new light on non-natural biocatalysis by using 
photoexcitation of nicotinamide-dependent enzymes in enantioselective radical 
dehalogenations of halolactones (Figure 1-3c).51 The nicotinamide cofactor of 
ketoreductases, whose native function is carbonyl reduction, was utilized as photoreductant 
and hydrogen source. Cofactor photoexcitation leads to electron transfer to the substrate 
which forms a prochiral radical intermediate upon dehalogenation. The intermediate 
generates a chiral lactone upon hydrogen-atom transfer from the photoexcited cofactor. 
Accessing radical intermediates via photoredox processes within an evolvable protein 
scaffold provides a new level of control over challenging radical-mediated reactions, as has 
been shown in novel “ene” reductase-photoredox catalyst systems for cyclization52 and 
hydrogenation53 reactions. 
New-to-nature biocatalysis involving transition metals has flourished in the years following 
the seminal contribution of Coelho et al.,17 who demonstrated that a heme protein can be 
engineered to generate and selectively transfer a reactive carbene intermediate to an olefin to 
make cyclopropanes. Efficient carbene-transfer enzymes have been evolved in the laboratory 
with astonishing ease.32 Since 2013, the scope of non-natural reactions of heme proteins has 
expanded dramatically to include an array of carbene- and nitrene-transfer reactions, such as 
aldehyde olefination, Doyle-Kirmse reaction, olefin aziridination, and C–H amination.32 
Further work has demonstrated that enzyme-catalyzed carbene-transfer reactions are not 
limited to -diazoester carbene precursors: Fasan and coworkers described synthesis of 
trifluoromethyl-substituted cyclopropanes by selectively transferring trifluoromethylcarbene 
to olefins,54 and the Arnold group has reported the use of α-trifluoromethylated diazo 
compounds in biocatalytic organoborane55,56 and fluoroalkane57 syntheses. Biocatalytic 
carbene-transfer chemistry has been applied in the synthesis of several important 
cyclopropane drug precursors, including ticagrelor (Figure 1-3d),19,58 levomilnacipran,59 and 
grazoprevir.60 In addition to cyclopropanation, engineered cytochromes P411 have been 
shown to perform truly remarkable cyclopropenation and bicyclobutanation reactions;61 




terminal alkynes and, with further protein engineering, P411BM3 variants could also 
cyclopropenate internal alkynes.62 Direct alkylation of sp3 C–H bonds is limited primarily to 
methylation in nature, and biocatalytic approaches have required the use of enzymes binding 
noble-metal-substituted porphyrins.24 Arnold and coworkers reported an iron-porphyrin 
protein that is up for the challenge: through 13 rounds of directed evolution, a P411BM3 
variant was improved from a starting point of just 13 TTN for the sp3 C–H alkylation of p-
methoxybenzyl methyl ether to a biocatalyst capable of C–H functionalization of a broad 
scope of benzylic, allylic, and α-amino C–H bonds.63 
The first enzyme-catalyzed carbon–silicon bond formation was realized using a heme protein 
for carbene insertion into Si–H bonds.20 Achieved by directed evolution of a cytochrome c, 
an electron-transfer protein with no natural enzymatic activity, this novel reactivity could be 
the first step toward biological production of organosilicon compounds. Nitrene-transfer 
chemistry has also enjoyed significant success: Prier et al. reported the first example of 
enzymatic intermolecular C–H amination, which they accomplished using an engineered 
cytochrome P450.64 Efficient and highly enantioselective intermolecular amination of sp3-
hybridized C–H bonds has long been a challenge in catalysis. Using directed evolution, a 
biocatalyst for the amination of benzylic C–H bonds could be engineered to catalyze up to 
1,300 turnovers with excellent enantioselectivities (>99% ee) (Figure 1-3e). The protein 
framework tuned the earth-abundant iron to catalyze this reaction, which contrasts with the 
C–H functionalization field’s heavy reliance on precious metals. While these “new-to-
nature” reactions had not been found in natural metabolism at the time of this report, Nature 
was already using nitrene chemistry: shortly after this nitrene-transfer reaction was reported, 
researchers studying the benzastatin biosynthesis pathway determined that a cytochrome 
P450, BezE, formed an aziridine via an iron-nitrenoid intermediate.65  
Contributions from Hartwig, Clark, and coworkers have further merged transition-metal and 
enzyme catalysis by replacing native iron-porphyrin cofactors with a synthetic iridium 
porphyrin to access carbene- and nitrene-transfer activities. Directed evolution of iridium-




non-natural reactions, such as intra- and intermolecular carbene insertion into C–H bonds 
(Figure 1-3f),23,24 highly chemoselective, intramolecular C–H bond amination,25 and 
cyclopropanation of various internal vinylarenes and unactivated alkenes.26 Lewis and 
coworkers took a different approach to obtaining non-natural reactivities by covalently 
linking an alkyne-substituted dirhodium catalyst with a protein scaffold containing a 
genetically encoded azidophenylalanine. Mutations improved enantioselectivity and reduced 
side reactions in the cyclopropanation of styrenes using donor-acceptor carbene precursors.27 
These artificial metalloenzyme systems provide access to activities not yet reported in 
genetically encoded biocatalysts. But there are drawbacks to this approach. The artificial 
cofactor must be synthesized separately, and the in vitro catalyst assembly initially required 
protein purification, lowering the throughput of protein engineering and raising the cost of 
the prepared biocatalyst. Fasan and Brustad have shown methods for in vivo incorporation 
of non-native metalloporphryins into heme proteins, improving the non-natural biocatalyst 
preparation in ways that could be translated to other processes requiring cofactor 
substitutions.66,67 The Ward group solved the issue of low-throughput biocatalyst preparation 
through in vivo assembly of an artificial, ruthenium-based olefin metathesis biocatalyst. This 
artificial metalloenzyme, containing a biotinylated Hoveyda-Grubbs second-generation 
catalyst, was assembled in the cell’s periplasm, where the concentration of metathesis 
inhibitors is reduced.68 The ability to assemble this artificial metalloenzyme in vivo enabled 
the use of directed evolution to improve its activity (Figure 1-3g). In a complementary 
approach, the Lewis group developed and optimized a high-throughput screen of a dirhodium 
catalyst bioconjugated to a protein scaffold in heat-treated cell lysate, enabling combinatorial 
and random mutagenesis approaches.69 
 
1.4 Engineered proteins offer exquisite control over non-natural catalytic 
functions  
Not only can these novel, engineered enzymes catalyze reactions that previously only 
synthetic catalysts could perform, they can even outcompete their small-molecule 




evolution. Near-perfect stereoselectivities have been reported with non-natural biocatalysis, 
such as in the enantiodivergent cyclopropanation of unactivated alkenes (Figure 1-4a).26 The 
macromolecular protein structure further enables outstanding control over product selectivity 
that is very difficult to attain with other catalysts. This is demonstrated by the challenging 
catalyst-controlled, regiodivergent C–H amination achieved using heme proteins (Figure 1-
4b) 70 and the remarkable control of carbene insertion into an Si–H bond rather than an N–H 
bond in the same substrate (Figure 1-4c).20 The protein matrix can also dramatically change 
the reactivity of a metal catalyst, with profound consequences for catalytic function.71 As 
shown in enzymatic nitrene-transfer reactions,64 less reactive, earth-abundant iron can be 
activated within a heme protein to outperform catalysts that rely on precious metals (Figure 
1-3). In this context, substituting iron in natural metalloproteins with noble metals such as 
iridium23–26,72 is an exciting strategy to access new chemical space in biology, but is not 
required in all cases; further reports have shown that engineered enzymes binding iron 
porphyrin can catalyze challenging new-to-nature reactions63,73 previously only reported 
with noble-metal substituted porphyrins.41 Enzymes control substrate conformations with 
remarkable precision and offer multiple secondary interaction sites to stabilize and guide 
high-energy intermediates during complex catalytic capabilities.74,75 We expect that this 





Figure 1-4. Examples of selective syntheses catalyzed by non-natural enzymes. (a) 
Enantiodivergent cyclopropanation of unactivated alkenes. (b) Engineered P450s for challenging 
catalyst-controlled, regiodivergent C–H amination. (c) Wild-type and engineered cytochrome c for 
catalyst-controlled chemoselective carbene Si–H insertion over N–H insertion. 
1.5 Conclusions 
Whether the starting point is a natural enzyme, a designed enzyme, a protein without a native 
catalytic function, or a protein-bound artificial cofactor, directed evolution has been shown 
to improve activity and selectivity of non-natural catalytic function. Because we are just 




points will lead to the most efficient enzymes, or even whether all poor enzymes can become 
good ones. What is certain, however, is that the field has entered a vast goldmine of new 
biocatalytic possibilities, and that chemical creativity will play a major role in future 
discovery and exploitation of these remarkable biological resources. Furthermore, advances 
in directed evolution methods will continue to improve the ease of engineering these new 
capabilities. We expect that this new era of non-natural biocatalysis will highlight the 
capabilities of enzymes to activate earth-abundant metals and catalyze new-to-nature 
transformations under mild conditions. Biocatalysis will offer competitive, sustainable routes 
to making the molecules and materials we need.  
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Developing catalysts that selectively produce each stereoisomer of a desired product is a 
longstanding synthetic challenge. Biochemists have addressed this challenge by screening 
nature’s diversity to discover enzymes that catalyze the formation of complementary 
stereoisomers. I show here that the same approach can be applied to a new-to-nature 
enzymatic reaction: alkene cyclopropanation via carbene transfer. By screening diverse 
native and engineered heme proteins, we identified globins and serine-ligated P411 variants 
of cytochromes P450 with promiscuous activity for cyclopropanation of unactivated alkene 
substrates. I then enhanced their activities and stereoselectivities by directed evolution: just 
1–3 rounds of site-saturation mutagenesis and screening generated enzymes that transform 
unactivated alkenes and electron-deficient alkenes into each of the four stereoisomeric 
cyclopropanes with up to 5,400 total turnovers and 98% enantiomeric excess. These fully 
genetically encoded biocatalysts function in whole Escherichia coli (E. coli) cells in mild, 
aqueous conditions and provide the first example of enantioselective, intermolecular iron-
catalyzed cyclopropanation of unactivated alkenes. I also describe efforts toward structural 
characterization of these variants and expanding cyclopropanation of unactivated and 








The biological world is a marvelous ensemble of chiral molecules. From the amino acid and 
nucleoside building blocks that form proteins and DNA to intricate natural products produced 
by living organisms, chirality dictates how molecules interact with living systems.1 Modern 
medicines often draw inspiration from chiral natural products.2 Because alternate 
stereoisomers can have very different biological effects,3 characterization of novel bioactive 
compounds during drug candidate screening should include testing each stereoisomer.4 
Developing stereodivergent syntheses, where a set of complementary catalysts can generate 
every possible stereoisomer of the product, is therefore useful and is actively sought after in 
catalysis.5 Enzymes are green, sustainable options for stereoselective catalysis, and stereo-
complementary enzymes can often be found in nature’s diversity: lipases,6 ketoreductases,7 
and transaminases8 chosen using genome mining,9 for example, have all afforded products 
with different stereoselectivities. We show here that natural protein diversity can be 
leveraged in a similar fashion to achieve stereodivergence for a new, non-natural enzyme-
catalyzed reaction: cyclopropanation of unactivated alkenes via carbene transfer. 
Cyclopropanes are found in a variety of natural products and have been incorporated as 
motifs in agrochemical and pharmaceutical compounds (Figure 2-5). They are commonly 
biosynthesized through intramolecular cyclization of cationic or radical intermediates 
catalyzed by terpene cyclases, desaturases, or radical S-adenosylmethionine-dependent 
enzymes. The formation of cyclopropane moieties via carbene transfer to alkenes, widely 






Figure 2-5. Cyclopropane-containing pharmaceutical and agrochemical compounds.   
Previous work from this group and others has shown that iron-porphyrin (heme) proteins can 
be engineered to catalyze the cyclopropanation of styrenyl alkenes with ethyl diazoacetate 
(EDA, 1).11–14 This new-to-nature carbene transfer reaction has been applied in the synthesis 
of key pharmaceutical intermediates such as levomilnacipran,15 ticagrelor,16,17 tasimelteon,16 
and grazoprevir18 (Figure 2-5). Work from several groups has also shown that cytochromes 
P450 and myoglobins can be engineered to switch their diastereo- and/or enantioselectivity 
preference toward styrenyl olefin cyclopropanation,11,13,16 but these precedents did not yield 
all possible stereoisomers in high turnover and selectivity (Table 2-1). In addition, alkene 
cyclopropanation by heme proteins with the native iron cofactor has been limited to styrenyl 
and other activated alkenes. Unactivated, aliphatic alkenes are attractive feedstocks for 




due to their inert nature, high degree of conformational flexibility, and limited steric and 
electronic bias to guide stereocontrol.19  
Table 2-1. Literature precedent for stereocomplementary cyclopropanation of styrenyl alkenes via 
enzymatic carbene transfer. Reference numbers are given for the main text reference numbers. 
Reference Trans-cyclopropane Cis-cyclopropane 
 (R,R) (S,S) (R,S) (S,R) 
11 Not reported 
Up to 98% de, 96% 
ee 




Up to 86% de, 32% 
ee 
Up to 98% de, 97% 
ee 
Up to 78% de, 
99% ee 
Up to 42% de, 
95% ee 
16 
Up to 99.9% de, 
95% ee 
Up to 99.9% de, 
99.9% ee 
Not reported Not reported 
20 
Up to 99.5% de, 
92% ee 
Up to 99.9% de, 
99.9% ee 
Not reported Not reported 
 
State-of-the art methods for enantioselective unactivated alkene cyclopropanation often rely 
on noble metals,21–23 with only a few examples of Co-24 and Cu-based25 catalysts (Table 2-
2); no iron-based catalyst for the enantioselective intermolecular cyclopropanation of 
unactivated alkenes has been reported at the time of this work. There is precedent that iron-
porphyrin catalysts are capable of unactivated alkene cyclopropanation, albeit achirally and 
with a non-natural iron porphyrin. Two decades ago, Woo and coworkers showed that iron 
meso-tetrakis(pentafluorophenyl)porphyrin chloride (Fe(PFP)Cl) can catalyze the reaction 
of 2-ethyl-1-butene and EDA with 390 TTN; they reported the formation of cyclopropane 
products using 1-decene as well.26  
Table 2-2. State-of-the-art methods for the intermolecular cyclopropanation of unactivated alkenes 
prior to our report of the stereodivergent cyclopropanation of unactivated alkenes with heme 
proteins. Because iron-catalyzed asymmetric examples were not known, achiral examples are listed 
for iron. Enantioselective reactions are reported for other metals. 
Entry Metal 
Catalyst 
Enantioselective? Ref. Note 
1 Fe No 1 Iron porphyrin-catalyzed, achiral. Two examples involved 
unactivated alkenes. 
Fe(PFP)Cl (0.02-0.05 mol%) catalyzed the 
cyclopropanation of 2-ethyl-1-butene (100 eq.) with EDA 
in 390 TON, d.r. not reported. 






Enantioselective? Ref. Note 
2 Fe No 2 Iron porphyrin-catalyzed, achiral. One example involved 
unactivated alkenes. 
Fe(TPP)Cl (3 mol%) catalyzed the cyclopropanation of 
allyl benzene with in situ generated trifluoromethyl 
diazomethane (1.5 eq.) in water with 3.3 TON, d.r. not 
reported. 
TPP = 5,10,15,20-tetraphenyl-21H,23H-porphine 
3 Fe No 3 Iron porphyrin-catalyzed, achiral. One example involved 
unactivated alkenes.  
This example is similar to entry 2, but a different in situ 
method was used to generate the trifluoromethyl 
diazomethane. No product was detected.  
4 Fe No 4 Iron porphyrin-catalyzed, achiral. Three examples 
involved unactivated alkenes.  
Fe(TPP)Cl (10 mol%) catalyzed the cyclopropanation of 
aliphatic alkenes using in situ generated 
difluoromethylcarbene (2 eq.) in 6–8 TONs, 7:1 to 13: 1 
d.r. (trans). 
5 Rh Yes 5-
13 
All Rh-carboxylate or Rh-carboxamidate-catalyzed (0.2–2 
mol% Rh) examples of unactivated alkene 
cyclopropanation reported are trans-selective.  
The most efficient and selective examples are the 
cyclopropanation of 1-hexene (72 TTN, >20:1 d.r. (trans), 
96% e.e.), and 1-octene (70 TTN, >20:1 d.r. (trans), 90 % 
e.e.). 
7 Ir Yes 14 Ir-salen (1 mol%) catalyzed the cyclopropanation of >10 
unactivated alkenes with up to 93 TTN, 98:2 d.r. (cis 
major), 99% e.e.. 
8 Ir Yes 15 Ir(Me)PPIX in engineered myoglobin (0.5 mol%) 
catalyzed the cyclopropanation of 1-octene in 40 TON, 
91:9 er, 40:1 d.r. (trans major). 6 equivalents of EDA were 
added via syringe pump over 12 h. 
9 Ir Yes 16 Ir(Me)PPIX in engineered CYP119 enzymes catalyzed the 
cyclopropanation of a variety of unactivated alkenes 
(terminal, internal and 1,1-disubstituted) with up to 1300 
TON and 99% e.e.. 3 equivalents of EDA were added via 
syringe pump over 3 h. 
10 Ru Yes 17, 
18 
Ru-(iminophosphoranyl)ferrocene (2 mol%) catalyzed the 
cyclopropanation of 3 unactivated alkenes with up to 37 
TON, 72:28 d.r. (cis major), 98% e.e.. 
11 Co Yes 19, 
20 
All Co-catalyzed (1–5 mol% Co) examples of unactivated 
alkene cyclopropanation reported are cis-selective and 
based on Co-porphyrins. 
The most efficient and selective example is the 
cyclopropanation of phenylbutene (90 TTN, >99:1 d.r. 
(cis), 96% e.e.). 
12 Cu Yes 21, 
22 
All Cu-catalyzed (1 mol% Cu) examples of unactivated 
alkene cyclopropanation reported are trans-selective. 
The most efficient and selective example is the 






Metalloporphyrin catalysts have been used in synthetic chemistry for decades, but nature has 
used them for millions of years. Present in all forms of life on Earth, heme-binding proteins 
have diverse functions as well as promiscuous activities for which they were never selected, 
such as the ability to form reactive carbene intermediates. These heme-binding proteins have 
also been shown to bind metal-substituted porphryins for new-to-nature reactions: Hartwig, 
Clark, and coworkers cited the need for greater metal center reactivity than iron porphyrin 
could provide in order to perform unactivated alkene cyclopropanation and C–H 
functionalization reactions when they showed that heme proteins could bind an artificial 
iridium cofactor in place of iron heme for carbene transfer chemistry.22 They reported that a 
protein’s active site can confer selectivity to noble-metal, small-molecule catalysts that can 
already catalyze the reaction.27 Use of an artificial iridium cofactor (Ir(Me)PIX) required the 
lysis, purification, and in vitro metallation of the apoprotein with the Ir(Me)PIX, all of which 
add time and cost to catalyst preparation. Though it may be possible to incorporate the new 
metal in vivo,28 the synthetic, noble-metal cofactor is more expensive than the native heme, 
which is manufactured by the cell and loaded into the catalyst during protein expression in 
vivo. The use of iridium is also not ideal due to the negative impact mining and refining 
precious metals has on the environment.29  
In aqueous buffer with no protein, however, hemin can “catalyze” the formation of 3a, albeit 
with only 0.4 TTN. Our group has previously used directed evolution of iron-porphyrin 
proteins to enhance the intrinsic heme activity, accessing carbene-transfer reactions typically 
performed with noble-metal catalysts, such as intermolecular C−H amination30 and carbene 
insertion into Si−H,31 B−H,32 and C−H33 bonds. In these cases, heme’s basal activity is 
greatly enhanced, and stereoselectivity is enforced by the protein environment, enabling 
remarkable activity and selectivity enhancements through directed evolution. Different local 
heme environments can be accessed by screening natural and engineered protein diversity; 
directed evolution then fine-tunes these features. We therefore set out to create a collection 




stereodivergent unactivated alkene cyclopropanation, taking advantage of the natural 
diversity of heme proteins to identify suitable starting activity and stereoselectivity. 
 
2.1 Results and Discussion 
In order to find initial enzymatic activity for unactivated alkene cyclopropanation, we 
collected a panel of 11 heme proteins from thermophilic and hyperthermophilic bacteria and 
archaea (Supplementary Information, Table 2-7), as thermostable proteins can better 
withstand the potentially destabilizing effects of mutations and are therefore more 
‘evolvable.’34 They are also often easier to work with and better tolerate polar organic 
solvents used to solubilize substrates. These heme proteins were initially tested with 
mutations to the putative distal ligand and active-site entrance loop (similar mutations have 
been found by Fasan and coworkers to enhance myoglobin-catalyzed cyclopropanation of 
vinylarenes)12 for the cyclopropanation of 1,7-octadiene using EDA as a carbene precursor 
(Supplementary Information, Table 2-7). 1,7-Octadiene was chosen as an initial test substrate 
due to the higher apparent terminal alkene concentration. Protein variants that showed 
catalytic activity were subsequently tested as wild-type proteins for 1-octene 
cyclopropanation; 1-octene is a model substrate for unactivated alkene cyclopropanation. 
Through these experiments, wild-type Aeropyrum pernix protoglobin (ApePgb WT, UniProt 
ID: Q9YFF4) and wild-type Rhodothermus marinus nitric oxide dioxygenase (RmaNOD 
WT, UniProt ID: D0MGT2) were found to have low but measurable cyclopropanation 
activity on 1-octene (2a), catalyzing the reaction with 18 and 27 total turnovers per enzyme 
active site (TTN). Notably, ApePgb WT and RmaNOD WT displayed complementary 
diastereoselectivity, preferentially producing cis−(1R,2S)-3a and trans−(1S,2S)-3a, 
respectively.  
In addition to searching globin protein diversity for this novel activity, we also investigated 
heme proteins obtained in previous directed evolution studies. A panel of 36 variants of 
serine-ligated Bacillus megaterium cytochrome P411 (P411BM3)
35
 engineered for other non-
natural carbene- and nitrene-transfer reactions14 was tested for the ability to cyclopropanate 




because the UV-visible phenyl group enables screening by HPLC-UV. The P411BM3 variant 
P411BM3-CIS L437F T438Q L75Y L181I (P411BM3-UA) showed significant activity and 
selectivity for production of cis−(1S,2R)-3a, the third of the four possible isomers. This 
variant of a serine-ligated “P411” (P411BM3-CIS
29) had been engineered for 
cyclopropanation activity on electron-rich, non-styrenyl alkenes such as N-vinyl amides.36  
Site-saturation mutagenesis libraries were generated and screened to increase the activities 
and selectivities of the different enzymes. Because crystal structures of ApePgb and 
RmaNOD have not been reported, homology models were built to help us identify residues 
within the putative distal heme pocket, where carbenoid formation and substrate binding are 
predicted to take place (Figure 2-6). P411BM3-UA residues were selected based on the crystal 
structure of its P411BM3-CIS predecessor (PDB ID: 4H23). Individual site-saturation libraries 
were screened for increased activity and diastereoselectivity using 2b and 1 as substrates. 
Variants with enhanced diastereoselectivity in the production of 3b were regrown on larger 
scale, and their activities were tested in the cyclopropanation of 2a and 2b with EDA. 
Enzyme variants with the greatest overall selectivity enhancements against 3a and 3b were 





Figure 2-6. Homology models of proteins engineered in the study. The protein and proximal ligand 
are shown in gray. Red indicates residues at which mutations were made for the engineered 
variants. The heme cofactor is shown in blue. a) ApePgb homology model with W59A, Y60G, and 
F145W mutations in red. b) RmaNOD homology model with Q52 and the putative distal ligand 
Y32 (where mutations also enhanced activity) in red. c) P411BM3-UA homology model with V87C 
in red, as well as other mutated residues 75, 181, 437, and 438 colored. 
RmaNOD was mutated at active-site positions Y32 (the putative distal axial ligand), Q52, 
and V97 using single-site site-saturation mutagenesis. Though the Y32G mutation found in 
the Y32X site-saturation mutagenesis library showed modest improvements in activity, the 
most significant increase in activity from this first round was the Q52V mutation. This single 






ApePgb was first mutated at position Y60 (the putative distal axial ligand). This yielded the 
Y60G variant as the most active catalyst. ApePgb Y60G was then subjected to single-site 
site-saturation mutagenesis at residues W59, F73, F93, and F145 in parallel, all of which are 
positions known to modulate the gaseous ligand binding properties of the homologous 
Methanosarcina acetivorans protoglobin.31 The variant that showed the greatest increase in 
activity while maintaining high selectivity was W59A Y60G. This new variant was used as 
parent for the next round of single-site site-saturation mutagenesis at positions F73, F93, and 
F145. After verification in small-scale biocatalytic reactions, ApePgb W59A Y60G F145W 
demonstrated a significantly increased enantioselectivity, making cis (1R,2S)-3a with 89:11 
diastereomeric ratio (dr) and 99% enantiomeric excess (ee).  
P411BM3-UA was first mutated at four positions found to modulate activity for heteroatom-
substituted cyclopropanation reactions.36 A simultaneous NDT double site-saturation 
mutagenesis library at F437/Q438 and single 22-codon site-saturation mutagenesis libraries28 
at Y75 and I181 were generated and screened for improved diastereoselectivity in the 
formation of 3b. In each case, P411BM3-UA was among the most active and selective 
variants. Using P411BM3-UA as parent protein, single-site saturation-mutagenesis was 
performed at additional active-site residues V87, I263, E267, and A328, screening for 
enhanced diastereoselectivity. The most significant changes in diastereoselectivity were in 
the V87X site-saturation library, in which an enhanced cis diastereoselectivity mutation 
(V87C, producing the (1S,2R) isomer with 89:11 cis:trans dr) and a complete inversion in 
stereochemistry (V87F, producing the (1R,2R)-isomer with 4:96 cis:trans dr) were found. 
Residue 87 has often been reported to modulate the stereoselectivity of P450BM3 for 
oxygenation of various substrates.37  
With initial screening of 11 new and 36 previously engineered heme proteins, followed by 
just one to three rounds of site-saturation mutagenesis, we discovered four protein variants 
capable of cyclopropanating unactivated alkenes (RmaNOD Q52V, ApePgb W59A Y60G 




produced a distinct stereoisomer of the desired product 3a with 89:11 to <1:99 d.r. and 96 to 
>99% e.e. (Figure 2-7). The enzyme activities against unactivated alkenes are comparable to 
the state-of-the-art catalysts, with 100–490 TTN for 3a and as high as 2400 TTN for 3b, the 
substrate against which the enzymes were screened. These analytical-scale reactions were 
prepared under conditions unoptimized for product yield, but GC yields for 3b and 3c under 
these conditions are modest to good (Table 2-3). The system is straightforward and easy to 
use: the protein-expressing bacterial cells need only be resuspended to the desired 
concentration, and the alkene and diazo ester is added directly under an anaerobic 
atmosphere. When the reaction is complete, the product is extracted into organic solvents for 
analysis or purification. 
 
Figure 2-7. Stereodivergent enzymatic cyclopropanation of an unactivated alkene. The reaction of 
2a and 1 with four engineered heme proteins yields each of four stereoisomers of cyclopropane 




>99% ee. The diastereoselectivity ratio (dr) is given as cis:trans, and the enantiomeric excess (ee) 
is given for the major diastereomer. 
Table 2-3. GC yields for analytical-scale reactions reported in Figure 2-8. These yields are 
determined by comparing the GC yield to the calibration curves. These reactions were run under 








1-octene (3a) 4% 8% 7% 5% 
4-phenyl-1-butene (3b) 26% 40% 44% 4% 
benzyl acrylate (3c) 40% 91% 53% 71% 
6-bromo-1-hexene (3d)  19%   
vinyl cyclohexane (3e)  18%   
methylenecyclohexane (3f)  10%   
1-penten-3-one (3g)  41%   
2-vinylpyridine (3h)    60% 
 
The four engineered biocatalysts were tested on a range of alkenes. Their activities and 
selectivities were high on unbranched aliphatic alkenes similar to those for which they were 
engineered, but their substrate scope extends to sterically hindered and electron-deficient 
alkenes as well (Figure 2-8). Though the activity and stereoselectivity differed on different 
substrates, each catalyst accepted most of the substrates tested. It is likely that activity on 
specific substrates can be optimized further, if desired, as has been shown in many other 








Figure 2-8. Cyclopropanation substrate scope. (a) Activity and selectivity of each protein variant 
against 3a, 3b, and 3c. (b) Activity and selectivity against a variety of alkenes. The 
diastereoselectivity ratio (dr) is given as cis:trans, and the enantiomeric excess (ee) is given for the 
major diastereomer. Enzyme variant used is denoted by superscripts: 1, ApePgb AGW; 2, RmaNOD 
Q52V. General reaction conditions: whole E. coli cells (OD600 = 5 (ApePgb AGW, RmaNOD 
Q52V), OD600 = 20 (P411BM3-UA-V87C, P411BM3-UA-V87F)) in 1X-M9-N buffer, 25 mM 
glucose, 10 mM alkene, direct addition of 20 mM 1 under anaerobic conditions, 5% ethanol 
cosolvent. Modified reaction conditions: 3g OD600 = 20; 3e OD600 = 10. RmaNOD Q52V 3a, OD600 
= 10. Analytical yields for these reactions are given in Table 2-3. The absolute configurations of 
products 3b and 3c are assigned by analogy to the 3a products. Chiral separation conditions 
reported in the Supporting Information. *The benzyl ester of 3c has IUPAC naming priority, and 




We have shown that these protein variants function with the commonly used diazo carbene 
precursor EDA, which is especially useful because the ester moiety can be further 
derivatized, e.g. to form amides and other esters. It can also be reduced to alcohols and 
aldehydes, which are versatile synthetic handles for accessing a broad range of functional 
groups. Reports of trifluoromethylcarbene transfer for alkene cyclopropanation20 and 
insertion into B–H and C–H bonds,40,41 carbene transfer to silanes31 and boranes,32 and 
diazolactone carbene transfer42,43 have shown that heme proteins can be engineered to use 
different carbene precursors in new-to-nature reactions. 
The small-molecule catalyzed enantioselective preparation of cyclopropyl esters from 
electron-deficient alkenes has previously been limited to making the trans-cyclopropanes,44 
whereas strategies to directly access 1-keto,2-ester or 1,2-diester cis-cyclopropanes (or their 
corresponding carboxylates) via enantioselective cyclopropanation have not been reported. 
The biocatalysts, in contrast, enable access to the cis-1-keto-2-ester and cis-1,2-diester 
products in a single, intermolecular step using an E. coli-based platform (cis-3c, cis-3g, 
Figure 2-8). Some of these products are precursors to valuable compounds: cyclopropyl 
esters of unbranched, aliphatic alkenes are used in fragrances, for example, including the 
essential odorants in frankincense.45 Notably, the enzymes catalyze the reaction on 2-
vinylpyridine (2h), which is a difficult substrate for many catalysts due to pyridine’s 
propensity to coordinate to and inhibit metal centers. This cyclopropanation product is a 
precursor for an orphan GPR88 agonist.46 A similar vinylpyridine substrate was used in 
myoglobin-catalyzed cyclopropanation.16 
Enzymes are chemoselective and can generate desired products without additional steps to 
protect and deprotect other reactive functional groups on the same molecule. As shown in 
Figure 2-9, the enzymes described here can selectively cyclopropanate terminal alkenes in 
the presence of alcohol and carboxylic acid functional groups which often undergo 
competitive O−H insertion reactions with small-molecule carbene-transfer catalysts like 
rhodium acetate dimer.47 ApePgb AGW performed particularly well with unprotected 7-




64% isolated yield, respectively, in preparative-scale reactions. Chemo- and regioselectivity 
is even more important when functional groups cannot be protected easily. In the cases of 
1,3-(E)-pentadiene (2k) and 1,3-(Z)-pentadiene (2l), all four engineered proteins 
cyclopropanate the terminal alkene with perfect regioselectivity, likely due to higher 
accessibility of this double bond in each enzyme’s active site. The diastereoselectivity varied 
for 3k and 3l, though the enantioselectivity for the major isomer remained high. As the 
electronic properties of 2k and 2l are similar, the difference in stereoselectivity likely reflects 
steric constraints of the enzyme active sites. 
 
Figure 2-9. Selective, preparative-scale cyclopropane syntheses from various aliphatic alkenes and 
dienes. Preparative-scale reactions against substrates with free alcohol (7-octen-1-ol, 2i), free 
carboxylic acid (7- octen-1-oic acid, 2j), the two geometric isomers of penta-1,3-diene (2k, 2l), and 
ketone (5-hexen-2-one, 2m). The diastereoselectivity ratio (dr) is given as cis:trans, and the 
enantiomeric excess (ee) is given for the major diastereomer. The yields are reported for isolated 
products. Enzyme variant used is denoted by superscripts: 1, ApePgb AGW; 2, RmaNOD Q52V. 
The four final protein variants were tested under whole-cell, aerobic conditions at analytical 
scale (400 µL) for their ability to form 3a. The reactions were set up under the same 
conditions as the anaerobic analytical-scale reactions, with the exception that they were set 
up outside of the Coy anaerobic chamber. The aerobic conditions resulted in a nearly 
complete loss in cyclopropanation for the globins, with only traces of 3a detected. The 
formation of EDA dimer was also severely attenuated, suggesting that carbene formation 




loss in activity, but were still catalytically active (P411BM3-UA V87C: 140 ± 5 TTN, 95:5 dr; 
P411BM3-UA V87F: 25 ± 3 TTN, 6:94 dr). The loss of activity for globin variants but not 
P411BM3 variants could be due to the globins’ high affinity for gaseous ligands like O2, CO, 
and NO,48 whereas some engineered P411BM3 variants have previously been shown to 
function, albeit with attenuated catalytic activity, in aerobic conditions.15 In addition to being 
tested as anaerobic and aerobic whole-cell catalysts, the final protein variants were tested as 
sonicated cell lysates and as purified proteins. In cell lysate, the proteins have decreased in 
activity relative to whole-cell catalysis (approximately 2-fold for RmaNOD Q52V and 
ApePgb AGW, 5-fold for P411BM3 variants). The enzymes also had decreased activity as 
purified proteins (2-fold for RmaNOD Q52V, 5-fold for ApePgb AGW, approximately 30-
fold for P411BM3 variants). In both lysate and purified protein, the catalysts maintained their 
stereoselectivity. Decreased activity in lysate and purified protein relative to whole-cell 
reactions has been observed in many enzyme-catalyzed carbene transfer reactions34,35 and is 
likely due to reduced carbene transfer-based enzyme inactivation in whole cells36. Whole 
cells could also contribute to the stabilization of the protein (through proper macromolecular 
crowding effects, chaperones, etc.). As our focus was on developing a straightforward and 
ready-to-use system for biocatalysis, we opted for whole-cell catalysis which also eliminates 
additional catalyst purification steps. 
Table 2-4. Activity and selectivity of final protein variants as whole-cell, sonicated cell lysate, and 
purified protein for 3a product formation. The reactions were performed on analytical scale (10 
mM 2a, direct addition of 20 mM 1, 16-hour anaerobic reaction). Whole-cell catalyst loading was 
OD600= 5 (ApePgb AGW, RmaNOD Q52V) and OD600=20 (P411BM3-UA V87C, P411BM3-UA 
V87F). Cell lysates were diluted to the apparent OD600= 5 (ApePgb AGW, RmaNOD Q52V) and 
OD600=20 (P411BM3-UA V87C, P411BM3-UA V87F), corresponding to protein concentrations of 
0.9 – 2.1 µM. Catalyst loading in purified protein reactions was 5 µM. The diastereoselectivity 
ratio (dr) is given as cis:trans. 
 Whole cell Cell lysate Purified protein 
Protein TTN dr TTN dr TTN dr 
RmaNOD Q52V 100 ± 6 < 1 : 99 43 ± 2 < 1 : 99 53 ± 9 < 1 : 99 
ApePgb AGW 490 ± 20 89 : 11 190 ± 9 89 : 11 80 ± 10 87 : 13 
P411BM3-UA V87C 270 ± 30 95 : 5 56 ± 4 95 : 5 6.9 ± 0.9 95 : 5 






While biocatalysts often possess very high selectivity, this selectivity can be synthetically 
limiting. A single enzyme may make only a single isomer, but access to other isomers may 
be equally important; natural diversity can be leveraged effectively for this challenge. A 
combination of natural diversity and directed evolution enabled the stereodivergent 
cyclopropanation of unactivated and electron-deficient alkenes in mild, aqueous conditions 
with a fully genetically encoded heme protein expressed in bacteria. This set of biocatalysts 
can serve as starting points for green, sustainable synthesis of valuable cyclopropanated 
products.  
2.2 Structural characterization of engineered hemoproteins  
Following the engineering of a set of four heme proteins for stereodivergent 
cyclopropanation of unactivated and electron-deficient alkenes, we were interested in better 
understanding the structural and mechanistic determinants for their activity and 
stereoselectivity. One method to investigate structural determinants is through protein 
crystallography. We set out to obtain crystal structures for the four final biocatalysts, with 
the goal of seeing substrates, reactive intermediates, and products bound in the distal heme 
pocket.  
2.3.1 RmaNOD crystallography 
There were no previous structures for RmaNOD, so we started our search for crystallization 
conditions with sparse-matrix screening.49 These sparse-matrix screens are sets of 96 diverse 
conditions which have been designed to find initial crystallization conditions for most 
proteins of interest. During sparse-matrix screening for RmaNOD WT and RmaNOD Q52V 
crystallization, we found two conditions which gave good initial crystallization (0.5 M 
ammonium sulfate, 0.1 M sodium citrate tribasic dihydrate pH 5.6, 1.0 M lithium sulfate 
monohydrate and 0.2 M lithium sulfate, 0.1 M phosphate-citrate pH 4.2, 20 %(w/v) PEG 
1000). Seeing that both conditions had high concentrations of lithium sulfate and acidic pH 
as primary components, a refinement tray was set up across which citrate buffer pH and 
lithium sulfate concentration were varied. Under these conditions, the initial RmaNOD WT 




crystals attached to the plastic surface within the sitting drop crystal trays. As the crystals 
formed readily, instead of removing crystals from the surface, the subset of crystals which 
formed in solution were selected for cryoprotection and data collection on the Stanford 
Synchrotron Radiation Lightsource beamline 12-2 (SSRL 12-2). These crystals for 
RmaNOD WT and Q52V consistently diffracted with low-to-medium resolution (3–3.5 Å). 
Methods such as seeding, hanging drop (of sitting drop) trays, overlaying sitting drops on 
Fluorinert (to prevent adsorption to the well surface), and modifying cryoprotectant 
conditions were used to attempt to generate protein crystals with improved diffraction, but 
in each case the diffraction was the same or worse.  
The presence of the C-terminal polyhistidine tag can have an effect on the packing and 
crystallization of a target protein, particularly in small proteins or when the tagged terminus 
would form a crystal contact.50 Within the Arnold lab it was shown that even a few mutations 
to the small protein Rma cyt c led to a variant which was only found to crystallize after 
changing the location of the His expression tag. I therefore prepared a crystallization 
construct for RmaNOD Q52V where the protein was expressed with an N-terminal His6-
SUMO tag. The SUMO protein tag is commonly used as an expression tag and, using the 
Ulp1 protease to cleave the SUMO tag after immobilized metal affinity chromatography 
(IMAC), the protein of interest is left with a single serine as an N-terminal scar.51 The His-
tagged SUMO protein and Ulp1 protease can then be removed through a second IMAC 
purification.  
The tagless RmaNOD Q52V construct did not crystallize under the same conditions in which 
the C-terminally His-tagged crystallized, but a round of sparse-matrix screening followed by 
iterative refinement (Supplementary Information) led to crystallization conditions which 
yielded single crystals. These new crystals formed over several days and remained in solution 
rather than adsorbed to the well’s surface. The diffraction of these proteins did improve 
relative to the His-tagged constructs, with crystals diffracting to approximately 2.5 Å.  
Since no previous structure had been reported for RmaNOD, experimental phasing was 




identity for molecular replacement. With the heme cofactor containing an iron atom, the 
structure could be solved using experimental phasing of diffraction data with anomalous 
signal. The data were therefore collected using single-wavelength anomalous dispersion 
(SAD) at the iron K edge (1.74 Å). Details on the software used for phase solution and 
structure refinement are given in the supporting information. The resulting crystal structure 
(PDB ID 6WK3) has a resolution of 2.45 Å and displays C 1 2 1 symmetry with four 
monomers in the asymmetric unit. 
Initially, water was modeled at iron’s sixth coordination site, but through further refinement, 
it was found that acetate fit the density better. Acetate has been found to bind to heme in 
crystallization conditions previously,52 and the concentration of sodium acetate, the primary 
precipitant, is over 1.2 M in all of the refinement screening conditions used to crystallize 
RmaNOD Q52V. There were also copper ions modeled into the structure; these copper ions 
are likely crystallographic artifacts, as they form intermolecular contacts and all 
crystallization conditions for the tagless RmaNOD Q52V included a divalent metal ion. 
With an experimental protein crystal structure in hand, we were interested in comparing the 
structure to the homology model. While the homology model originally used for RmaNOD 
is moderately accurate globally (1.568-Å RMSD), the structure of the heme distal pocket is 
dramatically different (Figure 2-10). The B-helix, which includes residues 21 – 38, is shifted 
more than 1.5 Å closer to the heme, reducing the active-site volume. Even more striking is 
the structure for the E helix; while the homology model predicted a short E-helix followed 
by a 9-residue random coil before the CD helix, the random coil between the E-helix is only 
two amino acids long. The longer E helix forms a side of the distal heme pocket, with 
multiple residues (including Q52V, the key mutation to enhance cyclopropanation activity 
and selectivity in RmaNOD) pointing directly into the active site. The residues which were 
incorrectly predicted to be part of a random coil in the homology model are highly likely to 
interact with substrates either as they enter the active site or during catalysis. Position Q52 
was targeted based on sequence alignment with the mutated residue H64V in the sperm 




unlikely to be chosen when guided by only the homology model. This deviation between 
predicted and experimental structures highlights the importance of accurate structural models 
when selecting residues for site-saturation mutagenesis. 
  
   
Figure 2-10. Differences in structure between the prepared homology model and the solved crystal 
structure. The homology model is shown in gray and the crystal structure is shown in red. The 
foreground displays the differing lengths of the E helix in the homology model and crystal structure. 
One of the clearest methods to learn the origin of an enzyme’s stereoselectivity is through 
observing the substrate or product bound within the active site. Getting structures of 
substrate- or product-bound proteins is done by either soaking, in which the protein is 
crystallized before being exposed to the substrate (e.g. put in a solution containing the small 
molecule of interest before cryoprotecting and freezing), or co-crystallization, in which the 
crystallization condition is prepared including the small molecule of interest. Soaking has the 
advantage that many different small molecules can be soaked into crystals with known 
structure and diffraction quality.53 Soaking experiments are also necessary when the 
compound to be soaked into the crystal or a resultant intermediate compound are not stable 
over the time span required for the protein of interest to crystallize. However, if binding the 




formed protein crystal might not capture that biochemically relevant conformational 
change.54 Tight crystal packing or crystal contacts at an active-site entrance tunnel can also 
prevent small molecules from accessing the protein’s active site. In contrast, co-
crystallization can capture larger conformational changes and provide a snapshot which is 
more likely to be biochemically accurate, with the caveats that a protein with small-molecule 
induced conformational changes might not crystallize under the same conditions and that the 
addition of the small molecule (and solvents used to solubilize it) can disrupt protein 
crystallization.55 
The degree of conformational change upon substrate binding to RmaNOD Q52V is unknown 
and the RmaNOD Q52V construct crystallized in large quantities without issue; co-
crystallization was therefore chosen as the method of choice when attempting to observe 
substrate-bound RmaNOD Q52V. Co-crystallization trays for RmaNOD Q52V were 
prepared with added benzyl acrylate, a model substrate against which RmaNOD Q52V 
displayed 3700 TTN with >99% ee and dr. Benzyl acrylate is also more soluble in aqueous 
solution than 1-octene and 4-phenyl-1-butene, requiring the addition of less organic 
cosolvent to remain dissolved in the well solution. RmaNOD Q52V readily crystallized in 
the presence of benzyl acrylate, but data collected on these structures consistently showed an 
active site with no substrate bound.  
The orientation in the active site of the ester moiety in the iron-carbenoid reactive 
intermediate, together with the alkene’s angle-of-attack and substrate-binding mode, would 
dictate the stereoselectivity observed in the reaction. Iron-porphyrin carbenes (IPCs) have 
been studied experimentally and computationally,56,57 and in 2018 there were two reported 
protein crystal structures containing IPCs. Hilvert and coworkers reported a long-lived 
reactive IPC derived from EDA using myoglobin with the non-canonical amino acid N-
methyl-histidine as the heme axial ligand.58 Arnold and coworkers reported an IPC derived 
from ethyl 2-diazopropanoate (Me-EDA) in an engineered Rma cyt c protein variant used in 




Given the precedent of IPCs in protein crystal structures, we attempted to obtain a carbene-
bound structure of RmaNOD Q52V. As EDA and the resultant IPC would not be stable for 
a week-long co-crystallization experiment, soaking experiments were used to add EDA to 
the crystals. Even at 4 °C, the addition of EDA and sodium dithionite to RmaNOD Q52V 
crystals resulted in the rapid formation of bubbles and the protein crystals were destroyed 
faster than they could be looped and flash frozen. While the enzyme activity is inhibited 
under aerobic conditions, sodium dithionite can act as an oxygen scavenger and reduce the 
dissolved oxygen content.60 RmaNOD Q52V will also readily form EDA dimers (diethyl 
fumarate and diethyl maleate), consuming the iron-carbenoid intermediate. The carbene 
formation (and ostensibly EDA dimerization) in the presence of sodium dithionite was 
enough to preclude the use of this system to trap the EDA carbene intermediate; similar 
results were observed by Dr. Rusty Lewis when attempting to capture EDA in Rma cyt c 
variants (personal communication).  
As a surrogate substrate, crystal soaking with Me-EDA was attempted in place of EDA. Me-
EDA did not display activity for cyclopropanation with RmaNOD Q52V, but RmaNOD WT 
and variants have been reported to form carbon–silicon bonds with Me-EDA as the carbene 
precursor.61 Me-EDA dimerization has not been observed in our hands, and the resultant 
iron-carbenoid species was stable for over an hour in the Rma cyt c enzyme system in which 
it was studied.59 Although a structure with Me-EDA-derived carbene is not guaranteed to 
orient in the active site similar to the EDA-derived IPC would, a well-defined ester binding 
mode would be a strong indication of the EDA binding modality and provide insight into the 
origin of alkene cyclopropanation stereoselectivity. RmaNOD Q52V crystals were soaked 
with Me-EDA and sodium dithionite; unlike the EDA-soaked crystals, these crystals did not 
rapidly break down. There was no noticeable nitrogen evolution, but the lack of Me-EDA 
dimerization would make nitrogen evolution stoichiometric and limited by the protein 
concentration (compared to the catalytic EDA dimer formation). Unfortunately, as with 
RmaNOD Q52V crystals co-crystallized with benzyl acrylate, there was no electron density 




2.3.2 ApePgb AGW crystallography 
ApePgb AGW had by far the broadest substrate scope of the four enzymes used in the 
stereodivergent cyclopropanation of unactivated alkenes (Table 2-10), and multiple variants 
of ApePgb have been found to be starting points for additional new-to-nature directed 
evolution projects in the lab. It was therefore of substantial interest to obtain a crystal 
structure for this scaffold to inform the design and construction of further ApePgb 
mutagenesis libraries. Like RmaNOD, no structures for ApePgb had been reported before, 
although ApePgb WT was previously heterologously expressed in E. coli and functionally 
characterized.62 Only one member of the protoglobin family, Methanosarcina acetivorans 
protoglobin (MacPgb), has been crystallized.48,63 
To begin the search for crystallization conditions of ApePgb, sparse-matrix screens were set 
up for C-terminally polyhistidine-tagged ApePgb WT and ApePgb AGW. These screens 
resulted in a small number of conditions in which phase separation or oil droplets were 
observed; the distinct red coloration of the heme-bound protein made these distinct from 
precipitant phase separation and protein precipitation. Following multiple refinement screens 
with no improvement to the crystallization, the crystallization construct was revisited. When 
reviewing the homology model based on MacPgb, we noted that the C-terminus of the 
protein is in the dimer interface; if ApePgb would crystallize with similar crystal packing, the 
C-terminal polyhistidine tag would disrupt that crystal contact (Figure 2-11). A 
crystallization construct of ApePgb AGW was prepared with the N-terminal polyhistidine-





Figure 2-11. Homology model of ApePgb based on MacPgb. The two monomers in the crystallized 
dimer are colored as chainbows, with blue signifying the N-terminus and red signifying the C-
terminus. The two C termini are in crystal contacts near the dimer interface; C-terminal expression 
tags are therefore likely to affect the protein’s crystallization. 
In sparse-matrix screens with the tagless ApePgb AGW construct, a set of what were 
potentially “sea urchin” crystals formed in a condition (Figure 2-12a; condition: 2.8 M 1,6-
hexanediol, 0.1 M Tris pH 8.5, 0.2 M MgCl2). Refinement screening around these conditions 
had some effect on the urchin number, size, and rate of formation, but the quality of the 
crystals did not improve with variations in protein concentration, buffer pH, or precipitant 
concentration. Substrates (4-phenyl-1-butene and benzyl acrylate), substrate mimics (glycine 




to determine whether co-crystallization could improve the crystal quality. In each of these 
cases there was no improvement in the crystal morphology.  
A complementary technique to refinement screening which can be used to find improved 
protein crystallization conditions is random microseed matrix screening (rMMS).64,65 In 
random microseed matrix  experiments, like other seeding experiments, a seed stock is 
prepared by finely crushing crystals, which are then added to new crystallization experiments 
to provide nucleation sites for crystals to grow. In rMMS, the seed stocks are added to sparse-
matrix screens, providing a very different chemical space from the space in which the initial 
crystals grew. When sparse-matrix screens were set up with ApePgb AGW purified protein 
and seed stock, microcrystals and small needles formed in 0.1 M sodium cacodylate 
trihydrate pH 6.5, 1.4 M sodium acetate trihydrate (Figure 2-12b).  
 
Figure 2-12. Results of random matrix microseeding in ApePgb AGW. (a) “sea urchin”-like initial 
protein crystals found during sparse-matrix screening and refinement. (b) small needles formed in 
0.1 M sodium cacodylate trihydrate pH 6.5, 1.4 M sodium acetate trihydrate when microseeded 
with a crystal seed stock from the sea urchin crystals. 
Varying seed stock concentrations, buffer pH, and precipitant concentrations did not lead to 
improvement in the crystal size or morphology. The Hampton additive screen was also tested 
under these conditions without observable improvement in crystal size or quality. One 




the termini to remove flexible regions, introducing mutations at positions on the surface to 
improve the probability of crystallization, or using limited proteolysis techniques to remove 
flexible regions of the protein.66,67 As the goal is to investigate structural determinants for the 
selectivity of particular ApePgb variants, truncating or mutating the protein in order to 
crystallize it would interfere with this investigation. The work on crystallizing ApePgb AGW 
was therefore halted; further attempts to crystallize other protein variants based on the 
ApePgb scaffold are ongoing in the Arnold lab. 
2.3.3 P411BM3-UA crystallography 
Although many have attempted to crystallize the full-length P450BM3, the closest X-ray 
crystallographic structure has been of the heme and FMN domain,68 with the FAD domain 
crystallized separately.69 Only recently has cryo-EM enabled the solution of the full-length 
P450BM3 structure at low resolution (7.6 Å).
70,71 For structural insight into the effect of 
mutations on enzyme activity and selectivity, the P450BM3 variant of interest is typically 
expressed and purified as a heme-domain only crystallization construct. These heme-domain 
crystallographic constructs were prepared for P411BM3-UA V87C and P411BM3-UA V87F. 
The heme-domain constructs were prepared with the N-terminal polyhistidine-SUMO 
cleavable tag, and the proteins were expressed and purified as N-His6-SUMO-P411BM3 
constructs, the SUMO tag was cleaved with Ulp1 protease to yield purified protein for tagless 
P411BM3-UA V87C and P411BM3-UA V87F. 
A “superscreen” of conditions commonly found to crystallize P450BM3 heme domain 
constructs had been developed by previous lab members (Supplementary Information, Table 
2-13); this screen was used to find initial crystallization conditions for the two P411BM3-UA 
variants. Both proteins crystallized as pale green, thin, single needles surrounded by 
precipitate in 0.1 M Bis-Tris pH 5.5, 20% PEG 3350, 0.2 M Na(HCOO). Varying protein 
concentration, Bis-Tris buffer pH and PEG 3350 concentration decreased the level of 
precipitation and increased the crystal formation. Crystals of both P411BM3-UA variants were 
cryoprotected, flash frozen, and sent to SSRL for X-ray diffraction. While crystals from both 




2.4 Expanding enzymatic substrate scope to transfer trifluoromethyl-
carbenes to activated, unactivated, and electron-deficient alkenes  
The stereodivergent cyclopropanation of unactivated alkenes described in this chapter, like 
the majority of enzymatic cyclopropanation via carbene transfer,11–13,36 was limited to the 
use of α-diazoester carbene precursors. The use of carbene precursors without α-ester 
substitutions would increase the scope of chiral cyclopropanes accessible through these 
engineered biocatalytic platforms. One alternative acceptor-only diazo compound class are 
α-diazoperfluoroalkanes such as 2-diazo-1,1,1-trifluoroethane (DTFE), which can generate 
trifluoromethyl-substituted cyclopropanes through carbene-transfer reactions. 
Trifluoromethyl-substituted cyclopropanes have been used extensively in medicinal 
chemistry applications owing to the conformational rigidity conferred by the cyclopropane 
ring and the metabolic stability conferred by the trifluoromethyl substituent.72 
Biocatalytic trifluoromethyl-substituted cyclopropane synthesis has been previously 
reported: Fasan and coworkers reported an elegant biocatalytic method to prepare 
trifluoromethyl-substituted cyclopropanes from vinylarenes and ex situ-generated DTFE 
with high enantio- and diastereoselectivity.20 This example was limited to vinylarenes, 
however, and only trans-substituted cyclopropanes were synthesized. Diastereodivergent 
synthetic approaches to α-trifluoromethylcarbene transfer of unactivated and electron-
deficient alkenes would be useful for pharmaceutical and agrochemical compound 
development. 
In parallel to my work on the cyclopropanation of unactivated and electron-deficient alkenes 
with EDA, a postdoctoral fellow in the laboratory, Dr. Xiongyi Huang, was investigating the 
use of DTFE in enzymatic carbene-transfer reactions as part of his work on α-
trifluoromethylcarbene-transfer reactions.40,41 In his initial screening, he found that the 
lineage of ApePgb protein variants I had engineered displayed initial activity for 
cyclopropanation via DTFE carbene transfer and came to me for help with engineering the 
protein. We worked together on the construction and screening of additional single site-




(ApePgb “LQ”) and ApePgb Y60G F73W (ApePgb “GW”) which were active against both 
styrenyl and electron-deficient alkenes (Figure 2-13). Notably, the ApePgb LQ variant 
formed the cis diastereomer with electron-deficient alkenes in moderate to good 
stereoselectivity; these cis-trifluoromethyl-substituted cyclopropanes are difficult to access 
with reported synthetic methods. Cyclopropanation of unactivated alkenes was also tested, 
but ApePgb LQ and GW only show trace activity for the previous model unactivated alkenes, 
1-octene and 4-phenyl-1-butene.  
 
Figure 2-13. Substrate scope of ApePgb LQ (red) and GW (blue) variants against activated and 
electron-deficient alkenes. GC-MS data reported were collected by Dr. Xiongyi Huang and Lucas 
Schaus. 
Dr. Huang transferred the mutations from ApePgb to the protoglobin from the mesophilic 
methanogen Methanosarcina acetivorans (MacPgb), as MacPgb has been structurally 
characterized previously,48 as he intended to perform molecular dynamics simulations that 
required an accurate crystal structure. When that initial transfer of mutations to MacPgb 
yielded variants with comparable activity and selectivity to the ApePgb variants, I became 
interested in how general the effect on carbene transfer activity and selectivity is when 
transferring these mutations to other proteins in the protoglobin fold class. Transferring 




well as new-to-nature74 reactions – though there is certainly a positive bias in the literature 
toward successful transfers of mutations. I hypothesized that the carbene-transfer activity 
observed in ApePgb and MacPgb protein variants would be seen in protoglobin homologs 
and that the homologous proteins would provide additional starting points for directed 
evolution of carbene transferases. 
To build a set of homologous proteins, I used Protein-BLAST to search by protein sequence 
identity to assemble a set of representative proteins from the protoglobin fold class, which 
has been identified in archaea and bacteria. Of this list, proteins from thermophilic organisms 
were selected; proteins from thermophilic origins are (usually) more stable than their 
mesophilic orthologs, and this stability helps counteract the destabilizing nature of most 
mutations.75 The amino-acid residues mutated for DTFE cyclopropanation (W59, Y60, and 
F73) were conserved in all homologous protoglobins found, as were most first-shell active-
site residues which would be prime targets for site-saturation mutagenesis. I will refer to 
these homologous protoglobins in general as XxxPgb.  I ordered nine additional protoglobin 
sequences as linear DNA fragments (gBlocks, IDT) codon-optimized for E. coli and 
containing the LQ mutations (Table 2-5), and the oligonucleotides required to generate the 
GW variants using XxxPgb LQ genes as templatesThese XxxPgbs have between 51% and 





Table 2-5. List of protoglobin proteins selected for the transfer of mutation experiment. The table 
lists the protoglobin names, the originating organism, and Uniprot ID or NCBI accession number. 
ApePgb, MacPgb, and PfePgb were ordered and cloned prior to this gene acquisition. 
Protein Organism UniProt ID 
AauPgb Acetothermus autotrophicum H5SUA1 
CthPgb Crenotalea thermophila A0A1I7NC60 
ParPgb Pyrobaculum arsenaticum A4WIC7 
PmePgb Pyrinomonas methylaliphatogenes A0A0B6WXB4 
TamPgb Thermus amyloliquefaciens WP_038057460.1 (NCBI) 
TarPgb Thermus arciformis A0A1G7GW55 
TdaPgb Thermanaerothrix daxensis A0A0P6XZU8 
ThuPgb Thermoflexus hugenholtzii A0A212QV80 
TpePgb Thermorudis peleae A0A1E5BNX2 
ApePgb Aeropyrum pernix Q9YFF4 
MacPgb Methanosarcina acetivorans Q8TLY9 





Figure 2-14. Protein identity matrix showing the amino-acid sequence identity correlations for the 
various XxxPgbs. The lowest and highest sequence identities are CthPgb – ApePgb (51.8%) and 
PfePgb – ParPgb (82.7%). 
Together with a Master’s student mentee, Lucas Schaus, I subcloned these new genes into 
the pET22b protein expression vector. The resulting XxxPgb LQ variant plasmids were used 
as PCR templates to generate the XxxPgb GW variants. E. coli competent cells were then 
transformed with the plasmids encoding both sets of protein variants to produce the proteins 
of interest. The biocatalysts were tested for their activity with DTFE against an array of 




protein variant displayed carbene-transfer activity for most of the alkenyl substrates tested. 
While ApePgb variants showed only trace activity the vinyl Weinreb amide substrate N-
methoxy-N-methylacrylamide, variants of TarPgb and TdaPgb had high activity and 
diastereoselectivity against this substrate (Table 2-6). Weinreb amides are useful substrates 
as the corresponding products can be easily derivatized to generate myriad ketone-substituted 
cyclopropane products. These TarPgb and TdaPgb variants are therefore excellent starting 
points for directed evolution for biocatalytic synthesis and derivatizations to synthesize 
diverse trifluoromethyl-cyclopropylketones. Expansion of this reaction scope to include 2-
substituted N-methoxy-N-methylacrylamides would enable the synthesis of trifluoromethyl-
substituted cyclopropylketones with stereogenic quaternary carbons (Figure 2-15). 
Following his Master’s thesis work, Lucas joined the Arnold laboratory as a graduate student 
and has continued this work.  
Table 2-6. Activity and diastereoselectivity of TarPgb and TdaPgb wild type and variants in the 
synthesis of N-methoxy-N-methyl-2-(trifluoromethyl)cyclopropane-1-carboxamide. Activities 
were determined via NMR, using fluorobenzene as an internal standard. NMR data were collected 
by Lucas Schaus. 
Protoglobin Yield TTN dr 
TarPgb WT 21.5 % 600 36.3 % 
TarPgb GW 21.8 % 2000 96.0 % 
TdaPgb WT 17.6 % 1200 38.4 % 




Figure 2-15. Synthesis of Weinreb amide-substituted cyclopropanes. Carbene transfer to 
substituted N-methoxy-N-methylacrylamide forms a cyclopropane with a stereogenic quaternary 
carbon center. This compound can be further derivatized with Weinreb ketone synthesis to generate 





Prior to the work described in this Chapter, cyclopropanation via carbene transfer using iron-
porphyrin-binding proteins had been limited to styrenyl alkenes. Scientists demonstrated that 
heme proteins that bound a noble-metal substituted porphyrin in place of heme could transfer 
carbenes to unactivated alkenes,27 and an iron porphyrin catalyst had been shown to perform 
the reaction in organic solvent.26 I found that heme proteins could catalyze the 
cyclopropanation of unactivated and electron-deficient alkenes, and that their activity and 
selectivity could be improved through just 1–3 rounds of site-saturation mutagenesis of 
active-site residues. The four engineered protein variants enabled access to all four 
stereoisomers of unactivated and electron-deficient alkenes. I solved the crystal structure of 
one of these variants, RmaNOD Q52V; I used this structure to guide library design for 
RmaNOD variants engineered in Chapter 3.  The ApePgb scaffold was found to catalyze 
trifluoromethylcarbene transfer to activated and electron-deficient alkenes, and the activating 
mutations could be successfully transferred into homologous protoglobins. This work and 
other recent research on enzymatic carbene- and nitrene-transfer reactions showcase the 
breadth of reactions that iron-porphryin proteins can catalyze, and I anticipate that the heme 
protein biocatalytic platform will continue to expand in the near future. 
2.6 Supplementary information for Chapter 2 
Nomenclature for compound labeling 
Alkenyl substrates are named 2x (where x is a-m). The corresponding cyclopropyl esters 
(from reaction with ethyl diazoacetate 1) are named 3x. Single diastereomer compounds are 
named cis-3x or trans-3x. The 1-octene cyclopropane products, whose absolute 
configuration is known (see Compound chiral separation conditions and representative 
traces), are labeled (1(R/S), 2(R/S))-3a. Alkenyl substrates with functional groups protected 
(e.g. 7-octen-1-ol, 7-octen-1-oic acid) are named 2xa, and their corresponding cyclopropane 





Figure 2-16. Compound nomenclature used in this work. 
Materials and Methods 
Solvents and reagents were ordered from Sigma Aldrich, TCI, CombiBlocks, or Alfa Aesar 
and used without further purification. GC-FID data were collected on a Shimadzu GC-17A, 
Agilent 6850 GC system, and Agilent 7820A GC system. GC-MS data were collected on a 
Shimadzu GCMS-QP2010 SE. Screening HLPC-UV data were taken on an Agilent 1200 
series HPLC. Normal-phase chiral HPLC data were taken on an Agilent 1100 series HPLC. 
NMR spectra were recorded on a Bruker Prodigy 400 MHz instrument or Varian 300 MHz 
instrument with CDCl3 as solvent. 
1H NMR spectra were recorded at 400 MHz and 13C NMR 
spectra were recorded at 100 MHz. Chemical shifts were normalized to the chloroform 
solvent’s protio impurity (1H NMR 7.26 ppm, 13C NMR 77.16 ppm). Optical rotation data 
were collected on a JASCO P-2000 Polarimeter.  
Proteins tested in enzyme discovery 
Genes encoding eleven heme-binding proteins were ordered as codon-optimized gBlocks 
(Integrated DNA Technologies, Coralville, Iowa) and assembled into pET22b(+) with the 
pelB leader sequence removed and a C-terminal 6xHis tag. As the putative distal ligand could 
interfere with the initially low substrate binding affinities, the proteins were ordered with the 




vinylarene cyclopropanation in myoglobin24. Some gBlocks were also ordered with a 
mutation in a putative entrance tunnel residue previously found to enhance styrene 
cyclopropanation activity in myoglobin.24 These heme proteins were first tested for 
cyclopropanation activity using 1,7-octadiene and EDA as substrates (1,7-octadiene was 
chosen for its higher effective concentration of terminal olefin). The most active and selective 
proteins identified from these experiments, protoglobin from Aeropyrum pernix (ApePgb) 
and nitric oxide dioxygenase from Rhodothermus marinus (RmaNOD), were subsequently 
tested as wild-type proteins against 1-octene 2a, a commonly used model substrate for 
unactivated alkene cyclopropanation studies.  
Table 2-7. Heme-binding proteins tested for unactivated alkene cyclopropanation activity using 















Y42V F69A No 






Y29V Q50A No 








Hemoglobin IV H71V L93A Yes 




Protoglobin Y58V Yes 
Q9YFF4 Aeropyrum pernix Protoglobin Y60V Yes 






Screening previously engineered cytochromes P411BM3 for cyclopropanation activity 
A composite plate of 36 P411BM3-CIS proteins from lineages engineered for non-natural 
reactions such as aziridination, sulfimidation, amination, and non-styrenyl, activated alkene 
cyclopropanation14 was screened for activity and selectivity in 3a product formation. Most 
reactions showed trace activity and moderate diastereoselectivity, but the highest activities 
by a large margin were found in the lineage engineered for N-vinyl amide 
cyclopropanation.36 Screening this lineage for stereoselectivity showed that P411BM3-CIS 
L437F T438Q L75Y L181I, referred to in this study as P411BM3-UA, had the highest activity 
and enantioselectivity. It was therefore used as a starting point in unactivated alkene 
cyclopropanation. 
Homology models 
ApePgb was modeled with the Methanosarcina acetivorans protoglobin (PDB ID: 3ZJL) and 
RmaNOD was modeled with Alcaligenes eutrophus flavohemoglobin (PDB ID: 1CQX) 
using SWISS-MODEL.76 A homology model of P411BM3-UA was generated through side-
chain mutations to the P411BM3-CIS crystal structure (PDB ID: 4H23). Figures generated 
from protein homology models and crystal structures were made with PyMOL (Schrödinger, 
Inc.).  
Subcloning and transformation of genes 
Genes for Aeropyrum pernix protoglobin (ApePgb) and Rhodothermus marinus nitric oxide 
dioxygenase (RmaNOD) were ordered as codon-optimized gBlocks (Integrated DNA 
Technologies, Coralville, Iowa). The gBlocks were amplified via polymerase chain reaction 
(PCR), and the PCR products were gel extracted and purified with Zymoclean Gel DNA 
Recovery Kit (Zymo Research Corp, Irvine, CA). The PCR product was subcloned into 
pET22b(+) via Gibson assembly.77 Electrocompetent E. cloni EXPRESS BL21(DE3) cells 
(Lucigen, Middleton, WI) were transformed with Gibson assembly products using a Gene 
Pulser Xcell (Bio-Rad, Hercules, CA). Aliquots of SOC medium (750 µL) were added, and 
the cells were incubated at 37 °C and 230 rpm for 45 minutes before being plated on LB-




were grown at 37 °C and 230 rpm for 12–18 hours. Overnight cultures were used to inoculate 
flask cultures, prepare glycerol stocks, and isolate plasmids. Plasmids were isolated with 
Qiagen Miniprep kits, and the genes were sequence verified (T7 promoter/terminator 
sequencing primers, Laragen, Inc.).  
Medium-scale protein expression 
Cultures of Hyperbroth (HB, AthenaES) with 100 µg mL−1 ampicillin in unbaffled 
Erlenmeyer flasks were inoculated 1% (v/v) with stationary-phase overnight cultures and 
shaken in an Innova 42 shaker at 230 rpm, 37 °C. At OD600 = 0.8, cultures were chilled on 
ice for 20 minutes. Protein expression was induced with 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and heme production was enhanced with supplementation of 
1 mM 5-aminolevulinic acid (5-ALA). The cultures were shaken at 180 rpm and 22 °C 
overnight (18–24 hours). Cells were pelleted via centrifugation at 4000×g for 10 minutes at 
4 °C. The supernate was decanted, and the cells were resuspended in M9-N buffer 
supplemented with 25 mM glucose.  
Site-saturation library construction 
Site-saturation mutagenesis was performed using the 22-codon method.78 Briefly, 
oligonucleotides were ordered with NDT, VHG, and TGG codons in the coding strand at the 
amino acid position to be saturated. A reverse primer complementary to all three forward 
primers was also ordered. Two PCRs were performed for each library, the first containing a 
mixture of forward primers (12:9:1 NDT:VHG:TGG) and a pET22b(+) internal reverse 
primer and the second containing the complementary reverse primer and a pET22b(+) 
internal forward primer. The two PCR products were gel-purified with Zymoclean Gel DNA 
Recovery Kit (Zymo Research Corp, Irvine, CA) and ligated via Gibson assembly. 
Electrocompetent E. cloni EXPRESS BL21(DE3) cells (Lucigen, Middleton, WI) were 
transformed with the Gibson assembly product. Aliquots of SOC medium (750 μL) were 
added, and the cells were incubated at 37 °C for 45 minutes before being plated on LB-




Site-saturation library expression 
Single colonies from the LB-ampicillin agar plates were picked using sterile toothpicks and 
grown in 300 µL LB-ampicillin in 2-mL 96-well deep-well plates at 37 °C, 250 rpm, 80% 
humidity overnight (12–18 hours). Multichannel pipettes were used to transfer 30 µL of 
starter culture into deep-well plates containing 1 mL HB-amp per well. Glycerol stocks of 
these plates were prepared in parallel by adding starter culture (100 µL) and 50% (v/v) sterile 
glycerol (100 µL) to a 96-well microplate, which was then stored at −80°C. The deep-well 
expression culture plate was incubated at 37 °C, 250 rpm, 80% humidity for 2.5 hours. The 
plate was then chilled on ice for 30 minutes. The cultures were induced with 0.5 mM IPTG 
and supplemented with 1 mM 5-ALA to increase cellular heme production. The plate was 
incubated at 22 °C and 250 rpm overnight. The plate was centrifuged at 4000×g for 10 
minutes at 4 °C.  
Site-saturation library reactions and screening  
The pellets in the site-saturation library deep-well plates were resuspended in nitrogen-free 
M9 minimal medium (47.7 mM Na2HPO4, 22.0 mM KH2PO4, 8.6 mM NaCl, 2.0 mM 
MgSO4, and 0.1 mM CaCl2, abbreviated as M9-N, 400 µL). In an anaerobic chamber, 50 µL 
reactant mixture in ethanol (final concentrations in a 450 µL reaction: 20 mM EDA 1, 20 
mM 4-phenyl-1-butene 2b) were added to the reaction plate. The reaction plate was covered 
with a pierceable foil cover (USA Scientific) and shaken at 500 rpm for 3 hours. To quench 
the reaction and extract the substrates, 400 µL of a mixture of acetonitrile (49 mL) and 3 M 
HCl (1 mL) were added to each well. The reaction plate was shaken for an additional 30 
minutes, followed by centrifugation (4000×g, 10 minutes, 4 °C). The supernate was filtered 
through a 0.2 µm PTFE 96-well filter plate into a 96-well microplate (4000×g, 1 minute, 
RT). The microplate was sealed with a pierceable foil cover. The wells were screened for 
activity and diastereoselectivity of 3b formation via HPLC using a Kromasil 100-5-C18 
column, 4.6x50 mm with a 71% acetonitrile isocratic method (3 minutes). In later screening 
with higher enzymatic activity, the separation of cis- and trans-isomers of 3b was improved 
with the use of an Eclipse XDB-C18 column, 5 µm particle size, 4.6×150 mm and a 6-minute 




were streaked out from the glycerol stock onto LB-amp plates. A single colony was picked 
and grown in 5 mL LB-amp overnight (230 rpm, 37 °C). These overnight cultures were used 
in flask protein expression and small-scale biocatalytic reactions to verify enhanced activity 
and/or selectivity relative to the parent sequence.  
Sonicated lysate preparation and hemochrome assay 
An aliquot of cells for protein concentration determination was sonicated (QSonica Q500 
Sonicator, 1/8 in tip) for 2 minutes, 1 second on, 1 second off at 25% amplitude. Cells 
expressing ApePgb or RmaNOD variants had 0.1 volume equivalents Bugbuster 10X protein 
extraction reagent (EMD Millipore) added prior to sonication. The sonicated lysate was 
clarified via centrifugation at 4500×g and 4 °C for 10 minutes. The concentration of heme-
loaded protein was determined with the pyridine hemochromagen (hemochrome) assay.79 
Briefly, sonicated and clarified lysate (500 μL) was sterile filtered and added to a cuvette. 
Solution I (500 μL, 0.2 M NaOH, 40% (v/v) pyridine, 500 μM potassium ferricyanide) was 
added, and the spectrum of this oxidized sample was taken from 350–600 nm. Sodium 
dithionite (10 μL of 0.5 M solution in 0.5 M NaOH) was added, and the reduced spectrum 
was taken from 350–600 nm. The pyridine hemochromagen concentration was determined 
using its Q bands, with extinction coefficient 23.98 mM−1 cm−1 for (557 nmreduced – 540 
nmoxidized).
79 
Small-scale, whole-cell biocatalytic reaction preparation and work-up 
Small-scale reactions were set up in 2-mL GC crimp vials. E. coli expressing the appropriate 
heme protein catalyst (380 µL, adjusted to the appropriate optical density or protein 
concentration) were added to the vials, and they were brought into a Coy anaerobic chamber 
(~ 0-10 ppm O2). To each vial was added alkene (final concentration 10 mM) followed by 
EDA 1 (final concentration 20 mM) with 5% ethanol as a cosolvent. Directly following 
addition of EDA, the reaction vial was crimped and shaken at 500 rpm at RT for 16 hours. 
Reactions were worked up by the addition of HCl (16 µL, 3 M stock) and internal standard 
(16 µL of 40 mM acetophenone in cyclohexane). Cyclohexane (700 µL) was added and the 




carried out with a Retsch MM 301 mixing mill (1 minute, 30 Hz / 1800 rpm). Samples were 
centrifuged at 20000×g for 5 minutes at RT, and the organic layer was used for 
chromatographic analysis. 
Table 2-8. Activity and selectivity of hemin controls, wild-type protein, and engineering lineage 
intermediate proteins in 3a product formation. Mean and standard deviation were determined from 
two biological replicates of technical duplicates. The reactions were performed on analytical scale 
(10 mM 2a, direct addition of 20 mM 1, 16-hour anaerobic reaction). n.d.: not determined. The 
diastereoselectivity ratio (dr) is given as cis:trans and the enantiomeric excess (ee) is given for the 
major diastereomer. 
Catalyst TTN dr ee (major) 
Hemin 0.39 ± 0.04 25 : 75 n.d. 
Hemin + BSA 0.41 ± 0.03 23 : 77 n.d. 
RmaNOD WT 27 ± 9 3 : 97 89% 
ApePgb WT 18 ± 2 81 : 19 69% 
ApePgb Y60G 140 ± 40 82 : 18 96% 
ApePgb W59A Y60G 360 ± 90 85 : 15 96% 
P411BM3-UA 500 ± 130 89 : 11 94% 
 
Table 2-9. Activity and selectivity of wild-type and engineering lineage intermediate proteins in 3b 
product formation. Mean and standard deviation were determined from two biological replicates of 
technical duplicates. The reactions were performed on analytical scale (10 mM 2b, direct addition 
of 20 mM 1, 16-hour anaerobic reaction). The diastereoselectivity ratio (dr) is given as cis:trans 
and the enantiomeric excess (ee) is given for the major diastereomer. 
Protein TTN dr ee (major) 
RmaNOD WT 34 ± 4 17 : 83 71% 
ApePgb WT 85 ± 3 88 : 12 81% 
ApePgb Y60G 125 ± 3 83 : 17 94% 
ApePgb W59A Y60G 570 ± 50 80 : 20 94% 






Table 2-10. Substrate scope and diastereoselectivity of the four final variants. Activities were 
confirmed via GC-MS. +: activity against the substrate. *: trace activity detected. –: no detectable 
activity. n.d.: not determined. Diastereoselectivity ratio is given as cis:trans. Variants with high 
activity were characterized further in analytical-scale (Figure 2-8) and preparative-scale (Figure 2-








1-octene (3a) +, 95:5 d.r. +, 89:11 d.r. +, 4:96 d.r. +, <1:99 d.r. 
4-phenyl-1-butene (3b) +, 96:4 d.r. +, 84:16 d.r. +, <1:99 d.r. +, 3:97 d.r. 
benzyl acrylate (3c) +, 91:9 d.r. +, 71:29 d.r. +, 2:98 d.r. +, <1:99 d.r. 
6-bromo-1-hexene (3d) +, 92:8 d.r. +, 92:8 d.r. +, 4:96 d.r. +, <1:99 d.r. 
vinyl cyclohexane (3e) * +, 76:24 d.r. * * 
methylenecyclohexane (3f) * + + * 
1-penten-3-one (3g) * +, 89:11 d.r. * +, <1:99 d.r. 
2-vinylpyridine (3h) * * * +, <1:99 d.r. 
7-octen-1-ol (3i) + +, 91:9 d.r. * * 
7-octen-1-oic acid (3j) n.d. +, 83:17 d.r. n.d. n.d. 
(E)-penta-1,3-diene (3k) +, 96:4 d.r. +, 91:9 d.r. +, 31:69 d.r. +, 4:96 d.r. 
(Z)-penta-1,3-diene (3l) +, 55:45 d.r. +, 93:7 d.r. +, 35:65 d.r. +, 35:65 d.r. 
5-hexen-2-one (3m) – +, 94:6 d.r. – * 
 
Preparative-scale, whole-cell biocatalytic reaction setup and product purification 
Whole cells resuspended in M9-N supplemented with 25 mM glucose were brought into a 
Coy anaerobic chamber. Whole-cell catalyst was added to unbaffled Erlenmeyer flasks, 
followed by alkene (5 mM, 1.0 eq.) and EDA (10 mM, 2.0 eq.) diluted in ethanol (5% final 
ethanol cosolvent). The reactions were sealed and shaken at room temperature at 180 rpm 
for 16 hours. The product was extracted three times from the aqueous reaction mixture with 
1 volume eq. of 2:1 pentane:diethyl ether. The organic layer was dried with sodium sulfate 
and concentrated via rotary evaporation. The concentrated reaction mixture was then purified 
via flash chromatography (Biotage, Inc.). Pentane:diethyl ether gradients were generally 
more effective at separating the cyclopropane products from the EDA dimer byproducts. 





Table 2-11. Conditions for the preparative-scale reactions reported in the chapter. 3k and 3l were 
run at higher reaction volume due to the lower molecular weight of the substrates (and 
corresponding products). 
Product Protein variant used Reaction volume (mL) Whole-cell OD600 
3i ApePgb AGW 40 8 
3j ApePgb AGW 40 8 
3k RmaNOD Q52V 80 10 
3l ApePgb AGW 80 10 
3m ApePgb AGW 40 8 
 
Large-scale protein expression and purification 
HB-amp (1 L in 2.8 L unbaffled flask) was inoculated with 1% (v/v) overnight culture and 
shaken at 37 °C and 160 rpm. At OD600 = 1.3–1.5 the flasks were chilled on ice for 20 
minutes. Protein expression was then induced with a final concentration of 0.5 mM IPTG 
and 1 mM 5-ALA, and the cultures were grown for 24 hours at 22 °C and 140 rpm. The 
cultures were pelleted (4000×g, 5 minutes, 4 °C) and frozen at -20 °C. The cells were 
resuspended in binding buffer (25 mM Tris HCl pH 7.5, 100 mM NaCl, 25 mM imidazole). 
Hemin (1 mg gwet cells–1) was added to increase heme loading of the protein, and DNase I 
(0.1 mg mL–1) was added to reduce lysate viscosity. The cells were sonicated, the lysate was 
clarified via centrifugation (20000×g, 20 minutes, 4 °C), and the clarified lysate was filtered 
(0.45 µm sterile filter). The protein was purified via HisTrap (1 mL column) on an 
ÄktaPurifier (GE Healthcare Life Sciences), using a 25–300 mM imidazole gradient over 10 
column volumes. Fractions containing the protein of interest were pooled and buffer 
exchanged via centrifugal concentration to a 25 mM Tris HCl pH 7.5, 25 mM NaCl. The 
buffer-exchanged protein was flash-frozen and stored in 25 µL aliquots at -80 °C. The 
purified protein concentration was determined using the bicinchoninic acid assay (BCA 
assay, Thermo Scientific) using the standard protocol provided. 
Cloning, expression, and purification for crystallography 
DNA encoding RmaNOD Q52V, ApePgb AGW, P411BM3-UA V87C, and P411BM3-UA 
V87F were subcloned into a pET22b vector encoding an N-terminally His-tagged SUMO 
fusion through PCR amplification and Gibson assembly77 to generate “pSUMO” constructs 
of each variant. The P411BM3-UA variants were cloned into pSUMO as the heme domain 




transformed with the pSUMO constructs. Each was then expressed using the following 
method. A single colony was used to start an overnight culture in LB-amp, which was grown 
at 37 °C and 230 rpm. HB-amp (1 L in an unbaffled 2.8-L flask) was inoculated with 1% 
(v/v) overnight culture and shaken at 37 °C and 160 rpm (NFors shaker). At OD600 = 1.0, the 
flask was put on ice for 30 minutes, induced with final concentration of 0.5 mM IPTG, and 
supplemented with a final concentration of 1 mM 5-ALA. The culture was shaken overnight 
at 22 °C and 160 rpm. Following expression, the culture was centrifuged at 4000 × g for 10 
minutes at 4 °C and frozen at -20 °C. 
The pellet was thawed on ice and resuspended in resuspension buffer (25 mM Tris pH 7, 100 
mM NaCl). The cells were lysed via sonication (QSonica Q500 Sonicator). The lysate was 
clarified via centrifugation (15 minutes, 20817 × g) and filtered through 0.22-µm filters. The 
protein was purified on an Äkta purifier (GE Healthcare) with a 1-mL HisTrap column 
running a linear gradient between resuspension buffer (25 mM Tris pH 7, 100 mM NaCl, 20 
mM imidazole) and elution buffer (25 mM Tris pH 7, 100 mM NaCl, 500 mM imidazole). 
Fractions containing protein of interest were pooled and buffer exchanged into 25 mM Tris 
pH 7, 25 mM NaCl, 5 mM DTT. His-tagged Ulp1 protease (a gift from Christopher Bley, 
Hoelz lab Caltech) was added, and the proteolysis was allowed to proceed overnight. 
Following proteolysis, the sample was passed through two hand columns with Nickel-NTA 
agarose bulk resin (Qiagen) to remove the cleaved His-tagged SUMO and His-tagged Ulp1 
protease. The flow-through solution containing the protein of interest was buffer exchanged 
and concentrated in 25 mM Tris pH 7, 25 mM NaCl buffer, and flash-frozen in aliquots. 
Crystallization of tagless RmaNOD Q52V 
Sparse-matrix screens were set up using 0.2 µL protein and 0.2 µL well solution with a 
Gryphon robotic platform (Art Robbins Instruments). Quasicrystals were found in Crystal 
HT G10 (Hampton Research, 50 mM Cd(II)SO4, 0.1 M HEPES pH 7.5, 1.0 M sodium acetate 
trihydrate). Testing other divalent metal salts resulted in Cu(II)SO4 as an equivalent 
replacement for the cadmium salt. Refining from this condition using 24-well sitting-drop 




crystals in approximately one week in 40 mM Cu(II)SO4, 0.1M HEPES pH 7.6, 1.2 M 
sodium acetate trihydrate. These crystals were cryoprotected with well solution 
supplemented with glycerol (increased by steps of 5% sequentially up to 25% final 
concentration glycerol) and flash-frozen in liquid nitrogen. 
Data collection and refinement 
Diffraction data were collected on the Stanford Synchrotron Radiation Laboratory Beamline 
12-2. As there are no previously reported structures for the RmaNOD scaffold, the data were 
collected as single anomalous diffraction using the iron K edge (1.74 Å). Data were 
processed using XDS80, and three data sets were merged to increase anomalous signal 
redundancy. The data were used with AutoSol81 for experimental phasing and model 
building. Following model building and initial refinements in PHENIX,82 chain A of this 
model was used as a search model. The highest quality data set was determined in 
AIMLESS83 to have a high-resolution shell limit of 2.45 Å. Molecular replacement was 
performed using Phaser-MR84 with the merged data set model as the search model. The 
model was iteratively refined using PHENIX refine and COOT85 and validated with 







Table 2-12. Crystal data and refinement statistics for RmaNOD Q52V. 
Structure name 
Engineered carbene transferase RmaNOD 
Q52V, putative nitric oxide dioxygenase from 
Rhodothermus marinus 
PDB ID 6WK3 
Wavelength 1.74 Å 
Resolution range 43.65 – 2.45 (2.538 – 2.45) 
Space group C 1 2 1 
Unit cell 
a = 124.269, b = 102.472, c = 84.273 
α = 90, β = 98.529, γ = 90 
Total reflections 248224 (25486) 
Unique reflections 36943 (3600) 
Multiplicity 6.7 (7.1) 
Completeness (%) 95.98 (94.17) 
Mean I/sigma(I) 13.34 (1.53) 
Wilson B-factor 58.05 
R-merge 0.09393 (1.464) 
R-meas 0.1022 (1.581) 
R-pim 0.03949 (0.5911) 
CC1/2 0.997 (0.647) 
Reflections used in refinement 36927 (3600) 
Reflections used for R-free 1816 (177) 
R-work 0.2077 (0.2991) 
R-free 0.2467 (0.3343) 
CC(work) 0.966 (0.785) 
CC(free) 0.959 (0.723) 
Number of non-hydrogen atoms 4680 
  macromolecules 4481 
  Ligands 198 
  Solvent 1 
Protein residues 578 
RMS(bonds) 0.004 
RMS(angles) 0.74 
Ramachandran favored (%) 99.30 
Ramachandran allowed (%) 0.70 
Ramachandran outliers (%) 0.00 
Rotamer outliers (%) 0.00 
Clashscore 4.49 
Average B-factor 60.86 
  macromolecules 61.08 
  Ligands 55.85 
  Solvent 55.94 





Table 2-13. P450BM3 “superscreen” crystallographic conditions. Buffers are added at 0.2 M 
concentration unless otherwise noted. 
Well Condition 
A1 pH 5.5 Bis-Tris, 20% PEG 3350 
A2 pH 5.5 Bis-Tris, 10% PEG 4000, 0.2 M MgCl2 
A3 pH 5.5 Bis-Tris, 14% PEG 4000, 0.2 M MgCl2 
A4 pH 7.0 HEPES, 1.3 M (NH4)2SO4, 0.2 M MgCl2 
A5 pH 7.0 HEPES, 1.6 M (NH4)2SO4, 0.2 M MgCl2 
A6 pH 8.5 Tris, 2 M (NH4)2SO4 
B1 pH 5.5 Bis-Tris, 20% PEG3350, 0.2 M Na(HCOO) 
B2 pH 6.5 Bis-Tris, 10% PEG4000, 0.2 M MgCl2 
B3 pH 6.5 Bis-Tris, 14% PEG4000, 0.2 M MgCl2 
B4 3 M Na(HCOO) 
B5 3.25 M Na(HCOO) 
B6 3.5 M Na(HCOO) 
C1 pH 8.5 Tris, 25% PEG3350, 0.2 M KNO3 
C2 pH 7.5 Tris, 10% PEG 4000, 0.2 M MgCl2 
C3 pH 7.5 Tris, 14% PEG 4000, 0.2 M MgCl2 
C4 pH 6.5 Bis-Tris, 1.5 M (NH4)2SO4, 0.1 M NaCl 
C5 pH 8.5 Tris, 20% PEG 8000 
C6 pH 7.5 HEPES, 15% PEG 20000 
D1 pH 8.5 Tris, 25% PEG 3350, 0.2 M MgCl2 
D2 pH 8.5 Tris, 10% PEG 4000, 0.2 M MgCl2 
D3 pH 8.5 Tris, 14% PEG 4000, 0.2 M MgCl2 
D4 pH 7.5 HEPES, 20% PEG 550MME, 0.05 M CaCl2 
D5 pH 6 Cacodylate, 13% PEG3350, 0.14 M MgCl2 
D6 pH 6 Cacodylate, 18% PEG3350, 0.14 M MgCl2 
 
 
Small-scale lysate and purified protein reactions 
Small-scale reactions were set up in 2-mL GC crimp vials. Lysate or purified protein was 
diluted to the desired concentration with M9-N buffer (no glucose added), added to the vials, 




dithionite (final concentration 2 mM), alkene (final concentration 10 mM), and EDA 1 (final 
concentration 20 mM) with 5% ethanol as a cosolvent. Directly following addition of EDA, 
the reaction vial was crimped and shaken at 500 rpm at RT. Reactions were worked up by 
the addition of HCl (16 µL, 3 M stock) and internal standard (16 µL of 40 mM acetophenone 
in cyclohexane). Cyclohexane (700 µL) was added, and the reaction was transferred into 1.7-
mL Eppendorf tubes for extraction. The extraction was carried out with a Retsch MM 301 
mixing mill (1 minute, 30 Hz/1800 rpm). Samples were centrifuged at 20000×g for 5 minutes 
at RT, and the organic layer was used for chromatographic analysis. 
Determination of hemin-catalyzed cyclopropanation activity 
Hemin-catalyzed cyclopropanation reactions were set up as small-scale reactions above; 
hemin (50 µM final concentration) in M9-N buffer, with or without 1 mg mL–1 bovine serum 
albumin (BSA), was brought into the Coy anaerobic chamber in 2-mL glass crimp vials. To 
each vial were added sodium dithionite (final concentration 2 mM), alkene (final 
concentration 10 mM), and EDA 1 (final concentration 20 mM) with 5% ethanol as a 
cosolvent. Directly following addition of EDA, the reaction vial was crimped and shaken at 
500 rpm at room temperature for 16 hours.  
Compound synthesis and characterization  
General procedure A: 
Rhodium acetate dimer (10 µmol, 4.4 mg) and a stir bar were added to a 5-mL dram vial, 
and it was sealed with a septum. The sealed vial was purged with three cycles of vacuum and 
argon. Neat olefin (8 mmol) was added to the vial. EDA (2 mmol) was added in a 2-hour 
slow addition on ice and reacted overnight at room temperature. The crude reaction mixture 
was concentrated in vacuo and loaded on a SNAP Ultra silica flash cartridge. The reaction 
mix was separated on an Isolera flash purification system (Biotage, Charlotte, NC) with a 
hexane/ethyl acetate gradient. Fractions containing the desired product were pooled and 
concentrated in vacuo. Yields were approximately 5–30%, due in part to both significant 




General procedure B: 
Rhodium acetate dimer (40 µmol, 17 mg) and a stir bar were added to a scintillation vial and 
sealed with a septum. The sealed vial was purged with three cycles of vacuum and argon. 
The vial was charged with alkene (5 mmol) and dichloromethane (5 mL). EDA 1 (2.0 eq. 
diluted in 4 mL dichloromethane) was added at room temperature by slow addition over 2 
hours and reacted overnight at room temperature. The crude reaction mixture was 
concentrated in vacuo and loaded on a SNAP Ultra silica flash cartridge. Using 
pentane/diethyl ether as eluents, the reaction mix was separated on an Isolera flash 
purification system (Biotage, Charlotte, NC). Fractions containing the desired product were 
pooled and concentrated in vacuo. Yields of pure fractions were approximately 5–30%, due 
in part to both significant EDA dimer formation and low conversion of the unactivated 
alkenes. This method is preferable for more volatile alkenes, and the pentane/diethyl ether 
gradients appeared to give better separation from the EDA dimer byproducts compared to 
the hexanes/ethyl acetate gradient. 
Determination of absolute configurations of the cyclopropane products 
Absolute configurations of 3a were confirmed by comparison to literature chiral GC.15 
Cyclosil-B column, 90 °C isothermal, absolute configuration of products elute in order: cis 
(1S, 2R)–3a, (1R, 2S)–3a, trans: (1R, 2R)–3a, (1S, 2S)–3a. The absolute configurations of 
other compounds in this study were not determined, but one could infer them by analogy, 
assuming the facial selectivity of the diazo reagents and olefins from which these products 
were made remains the same for each protein variant. The inferred absolute configurations 
provided here should be used with caution, understanding that substrate effects could have 
inverted the absolute stereochemistry. The chiral separation conditions for all cyclopropane 
products are detailed below and can be utilized to compare the enzymatic products to an 
absolute configuration authentic standard in future studies. The optical rotations of some 




Ethyl 2-hexylcyclopropane-1-carboxylate (3a) 
 
3a was synthesized with procedure B from 1-octene 2a and 1 to give 3a as a 58:42 mixture 
of trans/cis-isomers. Both trans- and cis-3a are known compounds.15,16 
Cis-3a: 1H NMR (300 MHz, Chloroform-d) δ 4.13 (q, J = 7.1 Hz, 2H), 1.66 (ddd, J = 8.9, 
7.8, 5.5 Hz, 1H), 1.56 – 1.43 (m, 2H), 1.38 – 1.22 (m, 12H), 1.03 – 0.90 (m, 2H), 0.90 – 0.82 
(m, 3H). 
Trans-3a: 1H NMR (300 MHz, Chloroform-d) δ 4.11 (q, J = 7.1 Hz, 2H), 1.36 – 1.22 (m, 
15H), 1.14 (dt, J = 8.7, 4.5 Hz, 1H), 0.90 – 0.84 (m, 3H), 0.68 (ddd, J = 7.9, 6.1, 4.0 Hz, 1H). 
HR-MS (FAB+): fragment ion, loss of ethoxy group [M ‒ CH3CH2O]
+ C10H17O calculated 
153.1279, found 153.127. 
Ethyl 2-phenethylcyclopropane-1-carboxylate (3b) 
 
3b was synthesized with procedure B from 4-phenyl-1-butene 2b and 1 to give 3b as a 57:43 
mixture of trans/cis-isomers. Cis-3b is a known compound.14 
Cis-3b: 1H NMR (300 MHz, Chloroform-d) δ 7.37 – 7.22 (m, 5H), 4.20 (q, J = 7.1 Hz, 2H), 
2.70 (t, J = 7.3 Hz, 2H), 1.93 (tq, J = 14.1, 6.7 Hz, 2H), 1.80 – 1.66 (m, 1H), 1.34 (td, J = 7.1, 
0.7 Hz, 4H), 1.14 – 0.96 (m, 2H). 13C NMR (75 MHz, Chloroform-d) δ 173.2, 142.1, 128.6, 
128.4, 125.9, 60.5, 36.0, 29.0, 21.5, 18.4, 14.5, 13.6. 
Trans-3b 1H NMR (400 MHz, Chloroform-d) δ 7.32 – 7.23 (m, 2H), 7.24 – 7.13 (m, 3H), 
4.11 (q, J = 7.1 Hz, 2H), 2.72 (t, J = 7.7 Hz, 2H), 1.71 – 1.54 (m, 2H), 1.45 – 1.31 (m, 2H), 
1.26 (t, J = 7.1 Hz, 3H), 1.16 (ddd, J = 8.8, 4.8, 4.1 Hz, 1H), 0.69 (ddd, J = 8.2, 6.3, 4.1 Hz, 




35.2, 22.6, 20.4, 15.6, 14.4. HR-MS (FAB+): [M+H]+ C14H19O2, calculated 219.1385, found 
219.1382. 
1-Benzyl 2-ethyl cyclopropane-1,2-dicarboxylate (3c) 
 
 
General procedure A only produced trace amounts of the cyclopropane product 3c. As each 
final protein variant produced 3c with high activity, preparative-scale reactions were carried 
out for each protein. The purified products were confirmed via NMR and used for chiral 
separation method development and analytical-scale calibration curves. 
Cis-3c (prepared from P411-UA V87C) 1H NMR (400 MHz, Chloroform-d) δ 7.42 – 7.28 
(m, 5H), 5.15 (d, J = 12.3 Hz, 1H), 5.10 (d, J = 12.3 Hz, 1H), 4.08 (qd, J = 7.1, 1.0 Hz, 2H), 
2.16 – 1.99 (m, 2H), 1.71 (td, J = 6.7, 5.0 Hz, 1H), 1.28 – 1.23 (m, 1H), 1.20 (t, J = 7.2 Hz, 
3H). 13C NMR (101 MHz, Chloroform-d) δ 169.9, 169.9, 135.9, 128.7, 128.5, 128.4, 67.0, 
61.2, 21.9, 21.7, 14.3, 11.9. HR-MS: [M+H]+ C14H17O4,calculated 249.1127, found 
249.1125. Cis-3c optical rotation from ApePgb AGW product: [α]D
22 = −17.0 ° (c 0.1, 
EtOAc). Cis-3c optical rotation from P411BM3-UA V87C product: [α]D
22 = +9.8 ° (c 0.1, 
EtOAc). 
Trans-3c (prepared from P411-UA V87F) 1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.29 
(m, 5H), 5.13 (s, 2H), 4.14 (q, J = 7.1 Hz, 2H), 2.27 – 2.15 (m, 2H), 1.46 (ddd, J = 8.3, 6.2, 
1.8 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 171.8, 171.8, 
135.6, 128.8, 128.5, 128.5, 67.0, 61.3, 22.7, 22.5, 15.7, 14.3. HR-MS : [M+H] + C14H17O4, 
calculated 249.1127, found 249.1123. Trans-3c optical rotation from P411BM3-UA V87F 
product: [α]D





Ethyl 2-(4-bromobutyl)cyclopropane-1-carboxylate (3d) 
 
 
Both cis- and trans-3d are known compounds.37 3d was synthesized with Procedure A from 
6-bromo-1-hexene 2d and EDA 1 to give 3d. The crude cis:trans ratio of this reaction was 
not determined. 
Cis-3d 1H NMR (400 MHz, Chloroform-d) δ 4.14 (q, J = 7.1 Hz, 2H), 3.40 (t, J = 6.8 Hz, 
2H), 1.93 – 1.80 (m, 2H), 1.74 – 1.38 (m, 4H), 1.56 (s, 1H), 1.33 – 1.15 (m, 4H), 1.02 (td, J 
= 8.0, 4.5 Hz, 1H), 0.92 (ddd, J = 7.2, 5.4, 4.5 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) 
δ 173.1, 60.5, 34.0, 32.6, 28.4, 26.3, 21.7, 18.3, 14.5, 13.5. HR-MS (FAB+): Fragment ion, 
loss of ethoxy group [M - CH3CH2O]
+ C8H12
79BrO,calculated 203.0072, found 203.0026. 
3d fraction containing 71:29 trans/cis diastereomeric mixture, reporting shifts characterized 
as trans-3d.  1H NMR (400 MHz, Chloroform-d) δ 4.21 – 4.04 (m, 2H), 3.40 (td, J = 6.8, 3.6 
Hz, 2H), 1.94 – 1.79 (m, 2H), 1.72 – 1.46 (m, 3H), 1.39 – 1.31 (m, 2H), 1.31 – 1.19 (m, 4H), 
1.22 – 1.12 (m, 1H), 0.74 – 0.64 (m, 1H). 13C NMR (101 MHz, Chloroform-d) δ 174.5, 60.5, 
33.8, 32.5, 32.3, 27.8, 22.6, 20.3, 15.6, 14.4.  
Ethyl 2-cyclohexylcyclopropane-1-carboxylate (3e) 
 
 
Synthesized with general procedure A from vinylcyclohexane 2e and EDA 1 to give 3e. The 
crude trans:cis ratio of this reaction was not determined. Cis-3e is a known compound.14 
Cis-3e: 1H NMR (300 MHz, Chloroform-d) δ 4.18 – 4.04 (m, 1H), 1.85 – 1.51 (m, 6H), 1.29 
– 0.92 (m, 2H). 13C NMR (75 MHz, Chloroform-d) δ 173.2, 60.2, 35.8, 33.3, 33.2, 28.6, 





Ethyl spiro[2.5]octane-1-carboxylate (3f) 
 
Synthesized with general procedure A from methylenecyclohexane 2f and EDA 1. 3f is a 
known compound.38 
1H NMR (400 MHz, Chloroform-d) δ 4.11 (qd, J = 7.1, 1.0 Hz, 2H), 1.62 – 1.27 (m, 11H), 
1.24 (t, J = 7.1 Hz, 3H), 1.06 (dd, J = 5.4, 4.3 Hz, 1H), 0.79 (dd, J = 7.8, 4.3 Hz, 1H). 13C 
NMR (101 MHz, Chloroform-d) δ 173.1, 60.2, 37.4, 30.7, 28.8, 26.2 (2 overlapping 
carbons), 25.7, 25.7, 20.6, 14.4. HR-MS (FAB+): [M]+ C11H18O2, calculated 182.1307, 
found 182.1282. 
Ethyl 2-propionylcyclopropane-1-carboxylate (3g) 
 
Running general procedure B with 1-penten-3-one 2h produced no detectable cyclopropane 
product 3g; the primary products were diethyl fumarate, diethyl maleate, and an apparent 
1,3-dipolar [2+3] cycloaddition product (ethyl 3-propionyl-4,5-dihydro-1H-pyrazole-5-
carboxylate). Trans-3g was synthesized on a 5-mmol scale with a racemic strategy adapted 
from the chiral synthesis previously reported.39 Co(II) tetraphenylporphyrin (5 mol%, 168 
mg) and 1,1,-dimethylaminopyridine (DMAP, 305 mg, 2.5 mmol) were added to a 40-mL 
scintillation vial with stir bar. The vial was sealed with a septum and placed under an Argon 
atmosphere. Dichloromethane (18 mL) was added, followed by 1-penten-3-one 2g (510 µL, 
5 mmol). EDA 1 (725 µL, 6 mmol) was added via syringe pump over 2 hours. The crude 
reaction mixture was concentrated in vacuo and separated via flash chromatography with a 
SNAP Ultra 25g column using a gradient of 0-20% diethyl ether in pentane. Fractions 
containing trans-3g were concentrated in vacuo to give the desired product. 
Trans-3g 1H NMR (400 MHz, Chloroform-d) δ 4.14 (q, J = 7.2 Hz, 2H), 2.63 (q, J = 7.3 Hz, 




1.08 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 208.2, 172.3, 61.2, 37.3, 28.9, 
24.1, 17.2, 14.3, 7.8. HR-MS (ESI+): [M+Na]+ C9H14O3Na, calculated 193.0841 found 
193.0819. 
Cis-3g was synthesized based on a modified literature procedure of the methyl ketone 
analog.40 3-Oxabicyclo[3.1.0]hexane-2,4-dione (10 mmol) was added to anhydrous diethyl 
ether under Argon. Ethylmagnesium bromide (9 mL of 1 M in diethyl ether, diluted from 3 
M solution in diethyl ether, 9 mmol) was added dropwise over 20 min at -78 °C. The reaction 
mixture was allowed to warm to room temperature over 2 hours and stirred for 18 hours. The 
reaction was then quenched with aqueous ammonium chloride and extracted by diethyl ether 
(4 x 40 mL), dried over sodium sulfate and concentrated in vacuo. The crude product was 
used for the esterification step without further purification. Half of the crude product was 
dissolved in ethanol (20 mL), thionyl chloride (1 mL) was added, and the reaction proceeded 
at room temperature for 12 hours. The reaction was then quenched with aqueous sodium 
bicarbonate and diluted with water and extracted with diethyl ether. The crude mixture was 
purified via flash chromatography using a gradient of 0–50% diethyl ether in pentane. 
Fractions containing cis-3g were concentrated in vacuo to give the desired product.  
Cis-3g 1H NMR (400 MHz, Chloroform-d) δ 4.20 – 4.04 (m, 2H), 2.69 – 2.47 (m, 2H), 2.22 
(ddd, J = 9.3, 8.2, 6.7 Hz, 1H), 2.08 (ddd, J = 9.2, 8.4, 6.6 Hz, 1H), 1.70 (tdd, J = 6.7, 4.7, 
0.6 Hz, 1H), 1.23 (t, J = 7.2 Hz, 3H), 1.22 – 1.15 (m, 1H), 1.07 (td, J = 7.3, 0.5 Hz, 3H). 13C 
NMR (101 MHz, Chloroform-d) δ 206.6, 170.1, 61.1, 36.9, 27.9, 23.4, 14.3, 12.2, 7.9.  
Ethyl 2-(pyridin-2-yl)cyclopropane-1-carboxylate (3h) 
 
 
Both trans- and cis-3h are known compounds.41 Cis- and trans-3h were produced by 
refluxing 2-vinylpyridine 2h (10 mmol) with EDA 1 (10 mmol) in toluene (20 mL) 
overnight. The reaction yielded a 65:35 trans/cis mixture of diastereomers. The crude 




with a SNAP Ultra 10g Biotage column, 0–100% hexane:EtOAc gradient. Fractions 
containing pure trans-3h and cis-3h were separable and concentrated in vacuo to give the 
desired products (391.7 mg trans-3h, 290.7 mg cis-3h, 36% yield). 
Cis-3h: 1H NMR (400 MHz, Chloroform-d) δ 8.49 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.58 (td, 
J = 7.7, 1.8 Hz, 1H), 7.32 – 7.22 (m, 1H), 7.10 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 3.90 (qd, J = 
7.2, 1.5 Hz, 2H), 2.72 (td, J = 9.0, 7.6 Hz, 1H), 2.22 – 2.11 (m, 1H), 1.87 – 1.77 (m, 1H), 
1.47 – 1.36 (m, 1H), 1.02 (td, J = 7.1, 0.9 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 
171.1, 156.7, 148.9, 135.9, 123.6, 121.6, 60.3, 27.2, 21.7, 14.0, 11.7. 
Trans-3h 1H NMR (400 MHz, Chloroform-d) δ 8.43 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.54 (td, 
J = 7.7, 1.8 Hz, 1H), 7.21 (dt, J = 7.8, 1.1 Hz, 1H), 7.07 (ddd, J = 7.5, 4.9, 1.2 Hz, 1H), 4.15 
(q, J = 7.2 Hz, 2H), 2.56 (ddd, J = 8.9, 6.1, 3.9 Hz, 1H), 2.23 (ddd, J = 8.4, 5.5, 3.9 Hz, 1H), 
1.59 (dddd, J = 13.8, 9.0, 5.8, 3.8 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 173.4, 158.9, 149.4, 136.0, 122.5, 121.3, 60.7, 27.2, 24.4, 17.3, 14.3. HR-
MS (FAB+): [M]+ C11H13NO2, calculated 191.0946, found 191.092.  
Cis Ethyl 2-(6-hydroxyhexyl)cyclopropane-1-carboxylate (cis-3i) 
  
Cyclopropanation of the free alcohol 2i was performed via preparative-scale enzymatic 
reaction (ApePgb AGW) to give cis-3i.  
cis -3i 1H NMR (400 MHz, Chloroform-d) δ 4.12 (q, J = 7.1 Hz, 2H), 3.62 (t, J = 6.6 Hz, 
2H), 1.78 – 1.61 (broad m, 1H), 1.66 (ddd, J = 8.9, 7.8, 5.5 Hz, 1H), 1.60 – 1.43 (m, 4H), 
1.41 – 1.29 (m, 6H), 1.26 (t, J = 7.1 Hz, 3H), 1.25 – 1.16 (m, 1H), 1.05 – 0.95 (m, 1H), 0.91 
(ddd, J = 7.2, 5.5, 4.4 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) δ 173.3, 63.1, 60.4, 32.8, 
29.7, 29.2, 27.0, 25.8, 22.1, 18.3, 14.5, 13.5. HR-MS (FAB+): [M+H]+ C12H23O3, calculated 




Cis 6-(2-(ethoxycarbonyl)cyclopropyl)hexanoic acid (cis-3j) 
  
Cyclopropanation of the free carboxylic acid 2j was performed via preparative-scale 
enzymatic reaction (ApePgb AGW) to give cis-3j. 
Cis-3j 1H NMR (400 MHz, Chloroform-d) δ 12.00 – 9.50 (broad, 1H), 4.13 (q, J = 7.1 Hz, 
2H), 2.38 – 2.29 (m, 2H), 1.71 – 1.58 (m, 3H), 1.58 – 1.40 (m, 2H), 1.40 – 1.30 (m, 4H), 
1.29 – 1.16 (m, 1H), 1.26 (t, 3H), 0.99 (td, J = 8.1, 4.4 Hz, 1H), 0.91 (ddd, J = 7.2, 5.4, 4.5 
Hz, 1H). Trans-3j cyclopropane isomers (minor product in cis-3j 1H NMR): 1.14 (tdd, J = 
7.1, 4.8, 2.5 Hz), 0.68 (ddd, J = 7.8, 5.9, 4.0 Hz). 13C NMR (101 MHz, Chloroform-d) δ 
179.4, 173.3, 60.4, 34.0, 29.4, 28.8, 26.9, 24.8, 21.9, 18.3, 14.5, 13.5. HR-MS (FAB+): 
[M+H] + C12H21O4, calculated 229.1440, found 229.1448. 
Ethyl (E)-2-(prop-1-en-1-yl)cyclopropane-1-carboxylate (3k) 
 
Both trans- and cis-3k are known compounds.42 Terminal alkene cyclopropanation of (E)-
penta-1,3-diene 2k and EDA 1 accomplished via preparative-scale enzymatic reaction gave 
cis-3k (ApePgb AGW) and trans-3k (RmaNOD Q52V). 
Cis-3k 1H NMR (400 MHz, Chloroform-d) δ 5.66 (dq, J = 15.4, 6.5 Hz, 1H), 5.41 (ddq, J = 
15.3, 8.6, 1.7 Hz, 1H), 4.22 – 4.03 (m, 2H), 1.89 – 1.78 (m, 2H), 1.67 (dd, J = 6.5, 1.7 Hz, 
3H), 1.26 (t, 3H), 1.23 – 1.10 (m, 2H).  
Trans-3k 1H NMR (400 MHz, Chloroform-d) δ 5.60 (dqd, J = 15.1, 6.5, 0.8 Hz, 1H), 5.03 
(ddq, J = 15.2, 8.3, 1.7 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 1.95 (dddd, J = 9.4, 8.5, 6.3, 4.0 
Hz, 1H), 1.65 (dd, J = 6.5, 1.7 Hz, 3H), 1.57 – 1.53 (m, 1H), 1.31 (ddd, J = 9.2, 5.1, 4.3 Hz, 
1H), 1.26 (t, J = 7.1 Hz, 3H), 0.91 (ddd, J = 8.3, 6.3, 4.3 Hz, 1H). 13C NMR (101 MHz, 




C9H14O2, calculated 154.0994, found 154.0974. Trans-3k optical rotation from RmaNOD 
Q52V product: [α]D
23 = +164 ° (c 0.1, EtOAc). 
Ethyl (Z)-2-(prop-1-en-1-yl)cyclopropane-1-carboxylate (3l) 
 
Both trans- and cis-3l are known compounds.42 General procedure A was used to produce a 
mixture of 8 possible cyclopropanes (internal and terminal) for chiral GC standard from (Z)-
penta-1,3-diene 2l and EDA 1. Stereoselective, terminal alkene cyclopropanation 
accomplished via preparative-scale enzymatic reaction (ApePgb AGW). 
Cis-3l 1H NMR (400 MHz, Chloroform-d) δ 5.56 (dqd, J = 10.9, 6.9, 1.1 Hz, 1H), 5.34 (ddq, 
J = 11.0, 9.3, 1.8 Hz, 1H), 4.21 – 4.04 (m, 2H), 2.16 – 2.03 (m, 1H), 1.92 (ddd, J = 8.8, 7.8, 
6.0 Hz, 1H), 1.72 (dd, J = 6.8, 1.8 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H), 1.23 – 1.17 (m, 2H). 13C 
NMR (101 MHz, Chloroform-d) δ 172.3, 127.2, 126.3, 60.5, 21.0, 19.2, 14.5, 14.5, 13.3. 
Cis-3l optical rotation from ApePgb AGW product: [α]D
23 = −260 ° (c 0.1, EtOAc). 
Ethyl 2-(3-oxobutyl)cyclopropane-1-carboxylate (3m) 
 
Cis-3m is a known compound.16 General procedure B was used to produce a mixture of 
55:45 trans/cis 3m, and a preparative-scale enzymatic reaction (ApePgb AGW) produced 
cis-3m. 
Cis-3m 1H NMR (400 MHz, Chloroform-d) δ 4.13 (q, J = 7.1 Hz, 2H), 2.46 (td, J = 7.3, 2.3 
Hz, 2H), 2.13 (s, 3H), 1.94 – 1.62 (m, 3H), 1.26 (t, J = 7.1 Hz, 4H), 1.06 – 0.86 (m, 2H). 13C 
NMR (101 MHz, Chloroform-d) δ 208.9, 173.2, 60.7, 43.7, 30.2, 21.8, 21.3, 18.6, 14.7, 13.8. 
HR-MS (FAB+): [M+H]+ C10H17O3, calculated 185.1178, found 185.1171. Cis-3m optical 
rotation from ApePgb AGW product: [α]D




Compound chiral separation conditions 
Table 2-14. Chromatographic separation conditions. Column dimensions: Cyclosil-B 30 m length 
x 0.32 mm ID x 0.25 µm film thickness; Chiraldex G-TA 30 m length x 0.25 mm ID x 0.12 µm 
film thickness; DB-WAXETR (15/30 m) length x 0.32 mm ID x 0.25 µm film thickness; Chiralpak 
IC 4.6 mm x 250 mm x 5 µm; Chiralpak IA 4.6 mm x 250 mm x 5 µm. 
Compound Instrument / column Method Retention times 
3a GC-FID, Cyclosil-B 90 °C isothermal 
Cis 67.9 min, 69.5 min; trans 
81.7 min, 83.5 min 
3b 
GC-FID, Cyclosil-B 
80 °C hold 2 min, 30 °C 
min–1 to 140 °C hold 40 
min 
cis 30.2 min, 30.9 min; trans 
35.7 min (unresolved) 
HPLC, Chiralpak IC 
Hexane: 0.8% 
isopropanol isocratic 
cis 7.1 min, 7.3 min 




80 °C hold 2 min, 30 °C 
min–1 to 170 °C hold 30 
min 
Trans 24.5 min (unresolved); 
cis 26.4 min, 26.8 min 
HPLC, Chiralpak IC 
Hexane:16% 
isopropanol isocratic 
Cis 4.6 min (unresolved; trans 
6.4 min, 7.2 min 
3d GC-FID, Chiraldex G-TA 
100 °C, 2 °C min–1 to 
170 °C 
Cis 25.1 min, 25.3 min; trans 
27.1 min, 27.2 min 
3e GC-FID, Cyclosil-B 
80 °C hold 2 min, 30 °C 
min–1 to 100 °C hold 80 
min 
Cis 44.7 min, 46.8 min; trans 
76.6 min, 78.2 min 
3f GC-FID, Chiraldex G-TA 80 °C isothermal 50.05 min, 51.0 min 
3g 
HPLC, Chiralpak IC 
Hexane: 9% 
isopropanol isocratic 
Trans 8.7 min, 9.7 min (second 
peak coelution with EDA 
dimer) 
GC-FID, Cyclosil-B 
80 °C hold 2 min, 30 °C 
min–1 to 125 °C hold 12 
min 
Cis 12.5 min, 12.7 min 
3h GC-FID, Cyclosil-B 
80 °C hold 2 min, 20 °C 
min–1 to 120 °C, 6 °C 
min–1 to 180 °C 




80 °C hold 2 min, 10 °C 
min–1 to 170 °C 
2i 8.4 min; EDA dimer 
(byproducts) 8.9 min, 10.1 min; 
cis-3i 14.5 min, trans-3i 14.6 
min 
3ia HPLC, Chiralpak IA 
Hexane: 0.5% 
isopropanol isocratic 




90 °C hold 2 min, 10 °C 
min–1 to 250 °C 
EDA dimer (byproducts) 5.0 
min, 6.2 min, 2j 9.7 min, cis-3j 
16.6 min, trans-3j 16.7 min 
3ja HPLC, Chiralpak IC 
Hexane: 1% 
isopropanol isocratic 




Compound Instrument / column Method Retention times 
3k GC-FID, Cyclosil-B 
80 °C hold 2 min, 5 °C 
min–1 to 140 °C 
Terminal cyclopropane 
products: cis 9.5 min, 9.6 min; 
trans 9.9 min, 10.1 min 
3l GC-FID, Cyclosil-B 
80 °C hold 2 min, 10 °C 
min–1 to 85 °C hold 20 
min 
Terminal cyclopropane 
products: cis 15.8 min, 16.3 
min; trans 17.6 min, 20.4 min 
3m GC-FID, Chiraldex G-TA 90 °C isothermal Cis 112.7 min, 114.6 min 
 
Calibration curves for analytical-scale TTN determination 
Calibration curves were prepared with analogous conditions to the analytical scale reactions. 
Cyclopropane product standards were diluted in ethanol and added (20 µL) to M9-N buffer 
(380 µL), with final concentrations of product ranging from 0–20 mM (with two to three 
technical replicates). The samples were worked up the same as analytical-scale reactions, by 
the addition of HCl (16 µL, 3 M stock) and internal standard (16 µL of 40 mM acetophenone 
in cyclohexane). Cyclohexane (700 µL) was added, and the samples were transferred into 
1.7-mL Eppendorf tubes for extraction. The extraction was carried out with a Retsch MM 
301 mixing mill (1 minute, 30 Hz/1800 rpm). Samples were centrifuged at 20000×g for 5 
minutes at RT and the organic layer was used for chromatographic analysis. Cyclopropane 
products for methylenecyclohexane 3g and 2-vinylpyridine 3h were set up in the same way, 
with the exception of running ten single replicates over the 0–20 mM product range.  
The ratio of the product area and internal standard (P/S ratio) was determined for each 
sample, and a linear regression was performed for the P/S ratio versus the known 
concentration in each reaction, with the y–intercept set to 0. The resulting slopes were used 
to determine the concentration of product in the analytical-scale reactions, which is in turn 








Table 2-15. Information on engineered proteins in the chapter. All variants for biocatalytic reactions 
were in pET22b(+) vectors lacking the pelB signal peptide sequence and expressed in the E. cloni 
EXPRESS BL21(DE3) E. coli cell strain. DNA and amino-acid sequence information are deposited 
on CaltechDATA (DOI: 10.22002/D1.1437). 
Protein Original organism Mutation(s) with respect to WT 
ApePgb WT Aeropyrum pernix  
ApePgb Y60G Aeropyrum pernix Y60G 
ApePgb W59A Y60G Aeropyrum pernix W59A Y60G 
ApePgb W59A Y60G F145W 
("AGW") 









P411BM3-CIS Bacillus megaterium 
V78A, F87V, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
T268A, A290V, L353V, I366V, 
C400S, E442K 
P411BM3-UA Bacillus megaterium 
P411-CIS, L75Y, L181I, L437F, 
T438Q 
P411BM3-UA-V87C Bacillus megaterium 
P411-CIS, L75Y, V87C, L181I, 
L437F, T438Q 
P411BM3-UA-V87F Bacillus megaterium 
P411-CIS, L75Y, V87F, L181I, 
L437F, T438Q 
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While biocatalysis is increasingly incorporated into drug development pipelines, most 
biocatalysts in pharmaceutical production were engineered after drug development was 
completed. Incorporating biocatalysts into early stages of drug discovery requires the ability 
to rapidly build molecular diversity. By engineering proteins to produce chiral motifs with 
derivatizable functional handles, biocatalysts can be used to help generate diverse building 
blocks for drug discovery. Here we show the engineering of the heme protein Rhodothermus 
marinus nitric oxide dioxygenase (RmaNOD) for the diastereodivergent formation of a 
pinacolboronate-substituted cyclopropane, which can be derivatized using cross-coupling 
reactions to generate diverse stereopure cyclopropane building blocks. These 
cyclopropylboronates can be prepared at gram scale using lyophilized biocatalysts and 






3.1 Leveraging biocatalysis in the drug development pipeline 
Since the beginning of the second wave of biocatalysis,1 enzymes have been engineered for 
and applied to the synthesis of myriad molecules of industrial interest, from low-value, high-
volume fuels2,3 and specialty chemicals4 to value-added fine chemicals such as flavors and 
fragrances.5 One application where the advantages of biocatalysis have truly shone is the 
synthesis of pharmaceutical compounds. The chemo-, regio-, and stereoselectivity required 
in the synthesis of complex pharmaceuticals can be met by a single enzyme engineered for 
this specific function. The high value of pharmaceutical compounds offsets the substantial 
cost of protein engineering and biocatalyst production. It is therefore unsurprising that 
intensive academic and industrial research and development have gone into the discovery 
and engineering of enzymes to synthesize pharmaceutical compounds.6–8 
The early stages of a drug discovery and development pipeline require the ability to rapidly 
generate tens to hundreds of grams of a candidate drug for further studies.9 For biocatalysts 
to outperform the competing chemical processes, the speed at which they can carry a project  
from initial activity determination to industrial production is crucial.8–10 The field of protein 
engineering has made great strides toward faster and more efficient biocatalyst development, 
which has begun to bring biocatalysis into the drug development pipeline, albeit after the 
drug candidate has been identified and is in clinical trials. Integrating biocatalysis even earlier 
in the drug development pipeline requires examining and overcoming current limitations of 
biocatalysts, namely their narrow substrate scope and the time required to engineer them for 
the desired activity. To determine where biocatalysts can fit earlier in the drug discovery 
pipeline, we must look at the workflow of the drug discovery pipeline and examine what is 
needed at each stage (Figure 3-1). The drug discovery development pipeline starts with 
identifying a target for treatment, typically a key protein for which an inhibitor could be 
developed. Following this, a screen to assay fitness (e.g. protein inhibition) is developed, and 
large libraries of small molecules are tested. Molecules identified at this stage (lead 
fragments) are used as a core motif for further derivatization and optimization. When a 
molecule has been optimized and has met the features required for its function, it will move 





Figure 3-1. Drug development pipeline. Target identification: determination of which biomolecule 
of interest will be targeted for the therapeutic effect. Compound screening and hit validation: screen 
small-molecule libraries and determine which have the desired therapeutic effect. Lead 
identification and optimization: lead fragments are derivatized and decorated to improve their 
therapeutic effect. Clinical trials: drug candidates are tested for their efficacy and safety to be 
approved by regulatory bodies (e.g. FDA). 
The lead identification and optimization stage of drug discovery, in which lead fragments are 
diversified to improve their efficacy, is a highly attractive stage for the incorporation of 
biocatalysts. At this stage, a lead fragment might already require several synthetic steps to 
produce and generating decorated analogs requires either selective functionalization of the 
lead fragment or modifying the synthetic route to incorporate diverse functional groups. 
Enzymes have been shown to excel at selective late-stage functionalization in natural product 
and pharmaceutical syntheses, installing functional groups with high selectivity.9,11 
Developing a set of enzymes to selectively produce dozens or hundreds of decorated analogs 
of the lead fragment will take a long time – at a stage of drug development in which speed is 
a crucial factor. Instead, employing an enzyme to produce a single analog of the complex 
chiral lead fragment with high selectivity, which is readily derivatized by commonly used 
methods in diversity-oriented synthesis, would then allow for the use of standard medicinal 
chemistry diversification libraries and pipelines which have been developed and optimized 














Figure 3-2. Expanding cyclopropane diversity through selective installation of derivatizable 
functional groups. (a) Enzymes can catalyze reactions with high specificity and selectivity, but 
often suffer from a narrow substrate scope. (b) Combinatorial chemistry approaches can be used to 
install diverse functional groups, but can lack the stereoselectivity control needed to generate the 
target compound. (c) Enzymes with high activity and selectivity for a single transformation can be 
coupled with combinatorial chemistry approaches to generate a diverse array of substituted 
cyclopropanes. 
Combining traditional synthesis and enzymatic synthesis has been a cornerstone of the 
biocatalysis field for decades; these chemoenzymatic approaches use the specificity and 
selectivity of enzymes together with well-established synthetic steps, where the optimal 
catalyst for each step is used. In many cases, a key synthetic step which sets one or more 
stereocenters is performed enzymatically, preceded or followed by chemical synthetic 
steps.13–15 Coupling enzymes with combinatorial chemistry has precedent as well; 
researchers have shown the use of chemoenzymatic approaches to diversify small molecules, 
with decarboxylases generating substrates for olefin metathesis,16 halogenases generating 
substrates for cross-coupling reactions,17,18 and carbene transferases installing nitrile 





Substituted cyclopropanes are prevalent in pharmaceutical and agrochemical    
compounds.20–22 The ability to rapidly produce derivatives of a stereopure cyclopropane 
could be used in lead fragment optimization to assist future drug discovery and development 
efforts. Boronate ester moieties are ubiquitous in medicinal chemistry due to their robust 
activity in the presence of a wide range of functional groups and their efficacy in convergent 
synthesis of complex molecules.12 Therefore, I envisioned that an enzymatically produced 
pinacolboronate (Bpin)-substituted chiral cyclopropane could be used as a substrate for 
Suzuki-Miyaura cross-coupling reactions to generate a diverse array of substituted 
cyclopropanes. In light of our previous studies that showed that heme proteins can be 
engineered to generate the cyclopropane-containing pharmaceuticals,23-26 I chose to develop 
a chemoenzymatic strategy to produce a cyclopropane motif with a functional handle, which 
could then be derivatized to form substituted chiral cyclopropanes. To realize this approach, 
I set out to engineer heme proteins to catalyze the stereoselective cyclopropanation via 
carbene transfer of ethyl diazoacetate (EDA) and vinylboronic acid pinacol ester, generating 




 Figure 3-3. Proposed enzymatic reaction of vinylboronic acid pinacol ester (1) and ethyl 
diazoacetate (2) to form the cyclopropylboronate ester (3). 
3.2 Initial activity determination and enhancement via directed evolution 
The first step in a directed evolution campaign is the identification of parent-protein 
candidates with promiscuous activity for the reaction of interest. The initial-activity screen 
for the reaction of 1 and 2 was carried out using a panel of heme-binding proteins which had 
been engineered for a variety of heme-catalyzed, new-to-nature reactions.27 This collection 




cytochromes c, and globins (Supplementary Information, Table 3-1). The activity was 
determined by GC-MS, with mass fragmentation and retention time of the 
cyclopropylboronate compared to the authentic product standard. The best initial activities 
for the formation of cis- and trans- cyclopropylboronate were shown by Aeropyrum pernix 
protoglobin W59A Y60G F145W (ApePgb AGW) and Rhodothermus marinus nitric oxide 
dioxygenase Q52A (RmaNOD Q52A), respectively. Both variants were developed during 
the engineering for the cyclopropanation of linear, aliphatic alkenes.28 These proteins were 
also tested for their ability to use alternative commercially available boronate esters such as 
MIDA ester and dibutyl ester, but only the pinacol ester showed detectable cyclopropanation 
activity. The initial stereoselectivity was good, with ApePgb AGW catalyzing the formation 
of the cyclopropylboronate ester with 96:4 diastereomeric ratio (dr) and 96% enantiomeric 
excess (ee, determined by chiral GC-FID). 
Single site-saturation libraries were generated for ApePgb AGW at amino-acid residues 63, 
86, and 90. Hits were identified in screening, but subsequent validation of protein variants 
identified as hits in screening failed to verify improved variants. In parallel, screening 
RmaNOD Q52A for enhanced trans-cyclopropylboronate activity yielded variant RmaNOD 
Y32T Q52A, with 420 TTN and an inversion of diastereoselectivity from 17:83 cis:trans to 
90:10 cis:trans (Figure 3-4). RmaNOD Y32T Q52A produced the same major cis-
enantiomer as ApePgb AGW with 99% ee, but with higher activity. We therefore used the 





Figure 3-4. Location of residues 32 and 52 in the RmaNOD scaffold, based on the RmaNOD Q52V 
crystal structure (PDB ID: 6WK3). Residues Y32 and A52 are shown in blue. The heme-bound 
acetate is omitted for clarity. 
As we had thus far only targeted a small subset of the active-site residues, we expanded the 
search to include several more active-site residues. In order to screen a larger sequence space 
without increasing the overall screening time with a medium-throughput GC-based screening 
method, we opted to reduce redundancy by screening 44 clones per library rather than the 
usual 88. Screening only 44 clones for a 22-member library still has an 86% library coverage 
(compared to 98% coverage for 88 clones per library) while allowing for higher sequence-
space coverage (Supplementary Information, Figure 3-11).  
Using RmaNOD Y32T Q52A as parent, in a second round of site-saturation mutagenesis, we 
targeted residues M31, F36, Y39, F46, L48, P49, I53, L56, R79, R86, V89, and L101, 
screening 44 colonies per library (Figure 3-5).  This round of engineering yielded beneficial 
mutations at positions 39, 48, 79, and 86. Residues 39 and 48 are in the distal heme pocket, 
but R79 and R86 coordinate with the heme carboxylate; the underlying cause for the activity 
enhancement at these positions is unclear. It is noteworthy that the mutations at R79 
enhanced activity at the cost of diastereoselectivity, while mutation of residues 39 and 48 




combination of mutations Y32T, Y39H, L48R, Q52A, and R79W was found under screening 
conditions to both improve activity and stereoselectivity. This variant, RmaNOD THRAW, 
displays 1300 total turnovers (TTN) while maintaining high dr (94:6 cis:trans) and greater 
than 99% ee (Figure 3-6a). 
 
Figure 3-5. RmaNOD scaffold (PDB ID: 6WK3) displaying residues targeted in the cis-selective 
lineage. Residues targeted for mutagenesis are shown as α-carbon spheres. Positions at which the 
final variant contained a mutation relative to RmaNOD WT are shown in blue; other targeted 





Figure 3-6. Activity and diastereoselectivity of the cis- and trans- specific lineages for the 
formation of 3. Variant names are listed as parent protein plus new amino-acid substitution(s). Data 
points are from biological duplicates of technical triplicates. 
In parallel to the engineering which generated the cis-selective variant RmaNOD THRAW, 
we targeted the RmaNOD scaffold to engineer a trans-selective protein variant. The trans-
selective lineage evolution was led by my collaborator, Bruce Wittmann. Site-saturation 




RmaNOD Q52A as the parent (Figure 3-7). We screened 44 colonies per library and 
identified mutation L101N, which improved diastereoselectivity for the trans-product 
without significantly affecting enzyme activity (Figure 3-6b). In the second generation, site-
saturation mutagenesis libraries were generated at positions 35, 42, 53, 56, 60, 79, 96, 97, 
and 125, using RmaNOD Q52A L101N as the parent. Here, we identified beneficial 
mutations at positions 56 and 60, with L60H as the most beneficial one (defined as enhancing 
activity the most while retaining diastereoselectivity).  
 
Figure 3-7. RmaNOD scaffold (PDB ID: 6WK3) displaying residues targeted in the trans-selective 
lineage. Residues targeted for mutagenesis are shown as α-carbon spheres. Positions at which the 
final variant contained a mutation relative to RmaNOD WT are shown in blue; other targeted 
positions are shown in green. 
Because the activity of RmaNOD Q52A L60H L101N was still low, we continued with two 
further rounds of site-saturation mutagenesis. Using RmaNOD Q52A L60H L101N as the 
parent, in the first round, we targeted positions 27, 28, 43, 47, 48, 55, 59, 94, 105, 111, and 




most beneficial. In the final round of site-saturation mutagenesis, we increased the coverage 
of the first- and second-shell residues by targeting positions 16, 19, 20, 23, 24, 27, 28, 31, 
36, 46, 49, 56, 79, 98, 100, 108, 109, 112, 117, and 118, now using RmaNOD Q52A L60H 
L101N I105M as the parent. From these libraries, we discovered the beneficial mutations 
L20W, M31F, L56A, and L56I. In a recombination library of these four mutations, we 
identified RmaNOD L20W Q52A L56I L60H L101N I105M as the combination with the 
greatest enhancement in activity with 2300 TTN, while maintaining greater than 99:1 
trans:cis dr and 99% ee (Figure 3-6b).  
3.3 Derivatization of cyclopropylboronates via cross-coupling reactions 
We successfully engineered heme proteins to catalyze the formation of one cis enantiomer 
and one trans enantiomer of the cyclopropylboronate, but we still lacked enzymes for the 
other two stereoisomers. We then looked for a chemoenzymatic solution to achieve 
stereodivergence. We hypothesized that a combination of stereoretentive and stereoinvertive 
cross-coupling reactions could be used to access each of the four stereoisomers of the 
derivatized cyclopropyl ester (Figure 3-8). This would require the stereocenter adjacent to 
the ester to have inverted to form the opposite diastereomer. In contrast, inversion at the 
stereocenter adjacent to the Bpin moiety would not lead to all four stereoisomers through 
stereoretentive and stereoinvertive cross-coupling reactions. Using chiral GC, we determined 
that RmaNOD Y32T Q52A and ApePgb AGW formed the same stereoisomer of the 
cyclopropylboronate product. As ApePgb AGW and RmaNOD Q52V were known to 
catalyze the cyclopropanation of 1-octene and EDA to form stereoisomers differing at the 
ester stereocenter, we hypothesized that the cis- and trans- RmaNOD variants also had 






Figure 3-8. Proposed access to all four stereoisomers of derivatized cyclopropane esters. Accessing 
all four stereoisomers requires the ability to either enzymatically generate all cyclopropylboronate 
stereoisomers or generate cyclopropylboronate esters with an inverted stereocenter at the ester and 
access to stereoretentive and stereoinvertive cross-coupling reactions. 
Biscoe and coworkers reported reaction conditions for the enantiodivergent cross-coupling 
of diverse trifluoroborates.29 As the interconversion between pinacolborane and 
trifluoroborate functional groups is a well-established single-step synthesis,30 we 
hypothesized that applying these cross-coupling conditions to trifluoroborated derivatives of 
our cyclopropylboronates would enable access to all four stereoisomers without requiring 
the discovery of two more enzymes with complementary stereoselectivity. To this end, we 
began a collaboration with Julie Hofstra, a graduate student studying cross-coupling 
reactions in the Reisman lab at Caltech. To test the trifluoroborate-based cross-coupling 
reactions, she prepared the trifluoroborate-substituted cyclopropane from the RmaNOD 
THRAW enzymatic product (Figure 3-9a). Unlike the cyclopropylboronate, which was an 
oil, the trifluoroborated product was solid; we hypothesized that this product could be 
crystallized to confirm the absolute configuration of our product. Indeed, the trifluoroborate-




via X-ray crystallography; the absolute configuration determination of (1R,2S) is in 
agreement with the configuration proposed by analogy to the cyclopropanation of 1-octene 
and EDA28 and lends further evidence toward the hypothesis that the stereocenter inverted 
between the cis- and trans- RmaNOD biocatalysts is adjacent to the ester. We attempted to 
crystallize the trans-trifluoroborated cyclopropane product to confirm this, but crystallization 
attempts were unsuccessful. 
With trifluoroborate-substituted cyclopropanes in hand, the stereodivergent cross-coupling 
reaction conditions were tested. While the stereoretentive cross-coupling reactions proceeded 
well, the cross-coupling reaction conditions reported by Biscoe and coworkers to be 
stereoinvertive resulted in either stereoretentive cross-coupling or no reaction. Discussions 
with the authors revealed that the steric hindrance of small carbocycles prevented 
stereoinvertive cross-coupling; as such only the stereoretentive cross-coupling reactions 
would demonstrate activity. Despite the challenges encountered in performing the 
stereoinvertive cross-coupling reactions, both trifluoroborate- and Bpin-substituted 
cyclopropanes can be used in stereoretentive cross-coupling reactions to generate substituted 
cyclopropanes (Figure 3-9b). A potential future application of enzymatic diversity-oriented 
synthesis would be the installation of trifluoroborate moieties on molecules other than 






Figure 3-9. Derivatizations of 3. (a) 3 can be reacted with potassium bifluoride to form the 
trifluoroborated salt 4. (b) Cyclopropylboronate 3 was converted to multiple arylboronates through 
Pd-catalyzed cross-coupling reactions while retaining high enantioselectivity. The yields reported 








3.4 Reaction engineering for preparative-scale production of 
cyclopropylboronates 
The efficient production and purification of large quantities of a compound are crucial for a 
diversity-oriented synthesis approach with the goal to generate derivatives of a lead fragment. 
I therefore investigated potential improvements to both the reaction engineering and 
downstream processing of the enzymatic product. 
3.4.1 Buffer optimization 
During directed evolution for cyclopropylboronate production, we noticed a nonlinearity in 
our calibration curves, with decreased rate of response at low product concentrations. In 
preparative-scale reactions, we observed the hydrolysis of the pinacolboronate to the free 
boronic acid, and thus attributed the nonlinearity of our calibration curves to this loss in 
product formation. As M9-N buffer has a high concentration of magnesium (which could 
promote hydrolysis), I hypothesized that buffer optimization could remove the undesired 
hydrolysis. Using MOPS buffer in place of M9-N did slightly decrease the nonlinearity 
(Figure 3-10), but the hydrolyzed cyclopropylboronic acid was still observed in preparative-
scale reactions. Instead of furthering buffer optimization efforts, we focused on approaches 
to reprotect the cyclopropylboronic acid. A mixture of cyclopropylboronate ester and 
cyclopropylboronic acid can be efficiently reprotected in organic solvent with the addition 





Figure 3-10. Nonlinear response behavior of the cyclopropylboronate compounds. 
3.4.2 Lyophilized biocatalyst formulation 
To enable access to these engineered biocatalysts for chemists without cell culture 
experience, I tested the formulation of the enzymes as lyophilized whole cells. Proteins have 
long been lyophilized to improve their shelf life and storage,31 and many commercially 
available enzymes sold today are formulated as lyophilized powders. Rather than preparing 
biocatalysts as fresh cells each time a reaction is required, the biocatalyst is produced in a 
large-scale fermentation, which eliminates batch-to-batch variability in specific expression 
and activity levels and allows for robust process optimization. Lyophilizing biocatalysts as 
whole Escherichia coli cells rather than cell lysate or purified protein decreases cost by 
removing additional lysis and purification steps, removes the requirement to exogenously 
add expensive redox cofactors, and in some cases provides enhanced stability to the 
biocatalyst relative to purified lyophilisate.32,33 I therefore prepared large-scale cultures (1 L) 
of RmaNOD THRAW and RmaNOD WAIHNM and lyophilized the whole-cell pellets. The 
resultant lyophilisate was ground into a fine powder with a mortar and pestle to facilitate 
weighing and adding catalyst to reaction vessels. The lyophilized cell powder could be 




Lyophilized biocatalysts allow for reactions being performed in the presence of minimal 
amounts of water. While water is viewed as a green solvent, starting the reaction in it simply 
adds a second waste stream if the downstream processing requires extracting the compounds 
into organic solvent. Biocatalysts have been used extensively in organic solvent systems.  
Lipase reactions are a great example, as their reaction equilibrium is dependent on the ratio 
of water and substrate. Performing reactions directly in organic solvent is also beneficial in 
cases where the substrate is poorly soluble or unstable in water. Rother and others have 
shown multiple examples of the efficacy of biocatalytic reactions run in organic solvent and 
1-5% water using lyophilized whole cells, either directly in solution32 or within “teabag” 
membranes for easy catalyst removal.34 Analytical-scale experiments with lyophilized 
RmaNOD THRAW and RmaNOD WAIHNM cells in methyl tert-butyl ether with 1-5% 
aqueous buffer added showed that the biocatalysts were still active under micro-aqueous 
conditions, though the drastically different reaction conditions prevent product extraction 
and comparison to the product standard calibration curves generated from aqueous samples. 
Further work on micro-aqueous preparative-scale reaction optimization could enable an 
alternative biocatalytic synthesis and product isolation workflow; this could be particularly 
promising for cyclopropylboronate formation, as performing the reaction under low water 
content has the potential to decrease pinacolboronate hydrolysis. 
3.4.3 EDA addition optimization 
In scale-up reactions, whether with fresh or lyophilized whole cells, a pad of cell debris 
would form at the surface where the EDA was being added dropwise. Switching to a long 
needle that inserted into the solution instead of dropping EDA on top of it prevented the 
formation of this cell debris pad. I noted the distinct formation of gas bubbles at the point the 
needle tip inserted into solution, which indicated that the EDA was rapidly consumed at the 
point of addition, evolving nitrogen at that point to form a bubble. I hypothesized that the 
local concentration of EDA at the needle tip (and thus the concentration of the EDA solution 
added via slow addition) was a crucial parameter. Previously, the concentration of EDA in 
the syringe was 800 mM, the same as we used in our screening assay. After testing the 




via slow addition to 163 mM (increasing the water content of the EDA solution) while 
maintaining the same final reaction volume. The resultant RmaNOD THRAW preparative-
scale reaction had decreased EDA dimer formation and was used in the trifluoroboration 
product isolation described below to yield the trifluoroborated enzymatic product in 52% 
isolated yield. 
3.4.4. Efficient product isolation 
Downstream processing is a crucial consideration for any product synthesized in large scale; 
an efficient process to separate and purify the product from the catalyst and byproducts needs 
to be developed. At laboratory scale, this is typically performed with some combination of 
acid-base extractions, solvent extractions, and silica column chromatography.  
In the case of cyclopropylboronate synthesis, the final reaction mixture contains whole-cell 
biocatalysts, cyclopropylboronate product, the EDA dimer byproducts diethyl maleate and 
diethyl fumarate, and unreacted starting material. Due to the product’s partial hydrolysis to 
the cyclopropylboronic acid, silica column chromatography resulted in poor isolated yields. 
We examined alternative methods to efficiently isolate the cyclopropylboronate product. One 
option was distillation; the vinylboronate starting material, EDA dimers, and 
cyclopropylboronate product have different boiling points. Using rotary evaporation to 
remove starting material and a Vigreux distillation column to remove EDA dimers, 3.7 g of 
cyclopropylboronate were purified from a crude reaction extract in a column free approach 
(36% isolated yield, 41% isolated yield based on recovered starting material, 95:5 dr, 99% 
ee). Further iterative optimization of the reaction and downstream processing will improve 
the yields, while decreased starting material and byproducts in the final reaction mixture will 
make downstream processing more efficient. 
A second option explored was the trifluoroboration of the cyclopropylboronate to the 
trifluoroborate-substituted cyclopropane. Previously, the trifluoroboration was carried out on 
purified cyclopropylboronate, but by performing the trifluoroboration on a crude reaction 
mixture, both the cyclopropylboronate and the free boronic acid can be converted to the 




product. First, organic solvent is used to extract the cyclopropane, starting material, and EDA 
dimer byproducts from the aqueous reaction. Concentrating this mixture in vacuo removes 
the organic solvent and the volatile starting material. This remaining crude mixture, 
consisting of primarily cyclopropylboronate, cyclopropylboronic acid, and EDA dimer 
byproducts, is used as the starting material for a well-established trifluoroboration reaction.30 
The reaction can then be lyophilized to remove the more volatile organic compounds, and 
the cyclopropane product can be separated from the fluoride salt with an acetone extraction. 
This technique minimizes loss of cyclopropane product from pinacol deprotection and 
provides a column-free and scalable approach to the trifluoroborate salt. Using this approach, 
lyophilized whole cells harboring RmaNOD THRAW were used in a 1-mmol scale reaction 
to produce the cyclopropylboronate; the cyclopropylboronate was purified as the 
trifluoroborate salt with a 52% isolated yield across both steps. The trifluoroboration and 
distillation approaches can both be performed at large scale with further optimization. 
3.4.5 Assessment of carbene precursor scope 
The ability to generate diverse cyclopropanes from the cyclopropylboronate is limited in part 
by the carbene precursor used; we were therefore interested in testing diazo compounds in 
addition to EDA. RmaNOD THRAW and RmaNOD WAIHNM were examined for their 
ability to form and transfer five additional diazo esters and ketones to vinyl Bpin to produce 
alternate cyclopropylboronates. In each case, however, there was no formation of the 
cyclopropylboronate detected. To expand the cyclopropylboronate repertoire, it appears that 
a substrate-walk engineering approach is needed, where one first screens for carbene-transfer 
activity on styrene and other model substrates. Once the enzyme has been evolved to accept 
alternative diazo compounds as carbene precursors, these variants can be assayed for their 
ability to accept vinylboronate substrates. A similar approach was required for organoborane 
synthesis, with a separate engineered lineage for each diazo compound.35 
3.5 Conclusions 
Chemoenzymatic approaches can couple the specificity of biocatalysts with the broad 




libraries. Variants of RmaNOD were engineered for diastereodivergent cyclopropanation, 
stereoselectively forming 3. We demonstrated that 3 could be further derivatized with 
standard Suzuki-Miyaura cross-coupling reactions. The reaction conditions and downstream 
processing protocol were modified to increase the isolated yield and improve the ease of 
isolation of 3. Further condition optimization could improve the yield and/or productivity of 
the process, generating 3 at large scale. 
3.6 Supplementary information for Chapter 3 
Materials and instrumentation 
Solvents and reagents were ordered from Sigma Aldrich, TCI, Aurum, or Alfa Aesar and 
used without further purification. GC-FID data were collected on Shimadzu GC-17A and 
Agilent 7820A GC systems. GC-MS data were collected on a Shimadzu GCMS-QP2010 SE 
and Agilent 7820A with 5977B MSD. 1H NMR, 11B NMR, and 13C NMR spectra were 
recorded on a Bruker Prodigy 400 MHz instrument; 1H NMR spectra were recorded at 400 
MHz, 11B NMR spectra were recorded at 128 MHz, and 13C NMR spectra were recorded at 
101 MHz. For 1H NMR and 13C NMR, chemical shifts were normalized to the deuterated 
solvent’s proto impurity (CHCl3: 
1H NMR 7.26 ppm, 13C NMR 77.16 ppm; DMSO-d5: 1H 
NMR 2.50 ppm, 13C NMR 39.52 ppm). 19F NMR were recorded on a Varian 300 MHz 
instrument; 19F NMR spectra were recorded at 282 MHz.  
Site-saturation library construction 
Site-saturation mutagenesis was performed using the 22-codon trick.36 Two methods were 
used for primer design and cloning: kinase-ligase-DpnI (KLD) (New England Biolabs) and 
Gibson assembly. In KLD cloning, primers were designed for blunt-end cloning with the 
KLD kit, where the degenerate codons were placed at the blunt end. The PCR product was 
then ligated via the KLD enzyme mix for 1 hour and used to transform electrocompetent 
cells. In the second approach, primers were designed for Gibson assembly, with the 
degenerate codons placed within either the forward or reverse primer. Two PCRs were 
performed for each library, the first containing a mixture of degenerate primers (12:9:1 




overhang to the degenerate primer. The second primer for each PCR is located in the 
ampicillin cassette to select against off-target PCR products. The two PCR products were 
gel-purified with the Zymoclean Gel DNA Recovery Kit (Zymo Research Corp, Irvine, CA) 
and ligated via Gibson assembly, followed by transformation.  
Transformation of genes 
Electrocompetent Escherichia coli (E. coli, E. cloni EXPRESS BL21(DE3) cells, Lucigen, 
Middleton, WI) were transformed with Gibson assembly products using a Gene Pulser Xcell 
(Bio-Rad, Hercules, CA). SOC medium (750 µL) was added, and the cells were plated on 
LB-ampicillin (100 µg mL−1) (LB-amp) agar plates. Overnight cultures (5 mL LB-amp in 
culture tubes) were grown at 37 °C and 230 rpm for 12–18 hours. Overnight cultures were 
used to inoculate flask cultures, prepare glycerol stocks, and isolate plasmids. Plasmids were 
isolated with Qiagen Miniprep kits, and the genes were sequence verified (T7 promoter / 
terminator sequencing primers, Laragen, Inc.). 
96-Well plate library expression 
Single colonies from the LB-amp agar plates were picked using sterile toothpicks and grown 
in 400 µL LB-amp in 2-mL 96-well deep-well plates at 37 °C, 250 rpm, 80% humidity 
overnight (12–18 hours). Libraries were screened at a depth of 44 colonies per library (Figure 
3-11). Multi-channel pipettes were used to transfer 50 µL of starter culture into deep-well 
plates containing 1 mL Hyperbroth (AthenaES) with 100 µg mL−1 ampicillin (HB-amp) per 
well. The deep-well expression culture plate was incubated at 37 °C, 250 rpm, 80% humidity 
for 2.5 hours. The plate was then chilled on ice for 30 minutes. Expression of the protein of 
interest was induced with isopropyl-β-D-thiogalactoside (IPTG), and cellular heme 
production was increased with 5-aminolevulinic acid (ALA); an induction mixture 
containing IPTG and ALA in HB-amp (50 µL) was added to each well for a final 
concentration of 0.5 mM IPTG and 1 mM ALA, 1.1 mL culture volume. The plate was 






Figure 3-11. Representative 96-well plate layout for screening two libraries per plate. Keeping four 
positive controls (parent protein) and four negative controls (sterile wells) allowed for 44 colonies 
per library to be screened. 
96-Well plate reactions and screening  
96-Well deep-well plates containing E. coli expressing a protein variant were centrifuged at 
4000 × g for 10 minutes at 4 °C. The supernatant was discarded, and pellets were resuspended 
in nitrogen-free M9 minimal media (M9-N, 380 µL) and brought into a Coy vinyl anaerobic 
chamber (0–20 ppm O2). To each well were added 4,4,5,5-tetramethyl-2-vinyl-1,3,2-
dioxaborolane (1) (10 µL, 400 or 800 mM in ethanol) and EDA (2) (10 µL, 400 or 800 mM 
in ethanol) and sealed with an adhesive foil cover. The reactions were shaken in the Coy 
chamber at room temperature for 16 hours. The plate was then removed from the Coy 
chamber, and the reactions were worked up: to each reaction, internal standard (20 mM 4-
methyl anisole in 1:1 hexane:ethyl acetate, 20 µL) and 1:1 hexane:ethyl acetate (480 µL) 
were added. A silicone plate sealing mat (AWSM1003S, ArcticWhite) was used to cover the 
plate, and the plate was vortexed. The plate was then centrifuged (4000 × g, 10 minutes) and 
the organic layer was transferred to GC vial inserts in GC vials. The samples were assayed 
for product formation via GC.  
Wells with improved activity relative to the parent protein were streaked out onto LB-amp 
agar plates. A single colony from the plate was picked and grown in 5 mL LB-amp overnight 
(230 rpm, 37 °C). These overnight cultures were used in flask protein expression and small-





Medium- and large-scale protein expression  
Cultures of 50 mL HB-amp  (50 mL in 250-mL unbaffled flasks or 1 L in 2.8-L unbaffled 
flasks) were inoculated 1% (v/v) with saturated overnight cultures and shaken in an Inova 42 
shaker at 230 rpm, 37 °C or an NFors shaker at 160 rpm, 37 °C. At an approximate OD600 of 
1.0 – 1.2, cultures were chilled on ice for 30 minutes. Protein expression was induced with 1 
M IPTG to a final concentration of 0.5 mM, and heme production was enhanced with 
supplementation of 1 M ALA to a final concentration of 1 mM. The cultures were shaken in 
an Innova 42 shaker at 230 rpm (160 rpm for Infors) at 22 °C overnight (18–24 hours). Cells 
were transferred to 50-mL Falcon tubes or 500-mL centrifuge buckets and pelleted via 
centrifugation at 4000 × g for 10 minutes at 4 °C.  
Lineage validation reactions 
Small-scale reactions were set up in 2-mL GC crimp vials. E. coli expressing the appropriate 
heme protein catalyst (380 µL, adjusted to the appropriate optical density with 20 mM MOPS 
buffer, pH=7) was added to the vials; the vials were then brought into a Coy anaerobic 
chamber (0 – 20 ppm O2). To each vial was added 1 (10 µL in ethanol, final concentration 
20 mM) followed by 2 (10 µL in ethanol final concentration 40 mM). Directly following 
addition of 2, the reaction vial was crimped and shaken at 500 rpm at room temperature. 
Reactions were worked up for GC analysis. For GC analysis, 20 µL 100% ethanol and an 
internal standard (20 µL 4-ethyl anisole, 20 mM in 1:1 hexane:ethyl acetate) were added to 
the vial. A 1:1 mixture of hexane:ethyl acetate (480 µL) was added, and the reaction was 
transferred into 1.7-mL Eppendorf tubes for extraction. The liquid-liquid extraction was 
carried out with a Retsch MM 301 mixing mill (1 minute, 30 Hz / 1800 rpm). Samples were 
centrifuged at 20817 × g for 5 minutes at RT, and the organic layer was used for 
chromatographic analysis.  
Sonicated lysate preparation and hemochrome assay 
An aliquot of cells adjusted to a density of OD600= 30 for protein concentration determination 
was sonicated (QSonica Q500 Sonicator, 1/8 in tip) for 4 minutes, 1 second on, 1 second off 




extraction reagent (EMD Millipore) was added; the lysate-Bugbuster mixture was incubated 
for 15 minutes at room temperature to improve cell lysis. The sonicated lysate was clarified 
via centrifugation at 20817 × g and 4 °C for 10 minutes. The concentration of heme-loaded 
protein was determined with the pyridine hemochromagen (hemochrome) assay.37 Briefly, 
sonicated and clarified lysate (500 µL) was added to a cuvette. Solution I (500 µL of 0.2 M 
NaOH, 40% (v/v) pyridine, 500 µM potassium ferricyanide) were added, and the spectrum 
of this oxidized sample was taken from 350 – 600 nm. Sodium dithionite (10 µL of 0.5 M 
solution in 0.5 M NaOH) was added, and the reduced spectrum was taken from 350 – 600 
nm. The pyridine hemochromagen concentration was determined using its Q bands, with the 
literature extinction coefficient of 23.98 mM−1 cm−1 for (557 nmreduced – 540 nmoxidized). 
Preparation of lyophilized whole-cell biocatalysts 
Cultures of 1 L HB-amp in unbaffled 2.8-L Erlenmeyer flasks were inoculated 1% (v/v) with 
saturated overnight cultures and shaken in an Infors shaker at 160 rpm, 37 °C. At an 
approximate OD600 of 1.0, cultures were chilled on ice for 30 minutes. Protein expression 
was induced with 1 M IPTG to a final concentration of 0.5 mM, and heme production was 
enhanced with supplementation of 1 M ALA to a final concentration of 1 mM. The cultures 
were shaken in an Infors shaker at 230 rpm and 22 °C overnight (18–24 hours). Cells were 
transferred to 500-mL centrifuge buckets and pelleted via centrifugation at 4000 × g for 10 
minutes at 4 °C. The pellet was transferred into a 50-mL Falcon tube and flash-frozen on 
powdered dry ice. The lid of the 50-mL Falcon tube was replaced by a Kimwipe held on with 
a rubber band and put in a lyophilization bottle. Pellets were lyophilized for at least 36 hours 
on a Labconco 4.5 plus freezone benchtop lyophilizer (Labconco, Kansas City, MO) to 
ensure complete lyophilization. Following lyophilization, the cells were transferred into a 
sealable plastic bag and ground into a fine powder using a mortar and pestle. The lyophilized 
cell powder was stored at -20°C until use. 
Preparative-scale biocatalytic reactions with lyophilized whole cells 
To a 250-mL round-bottom flask, lyophilized whole cells harboring RmaNOD THRAW 




buffer (KPi 50 mM pH 7.5, 37.6 mL) by stirring for 10 minutes. The round-bottom flask was 
sealed with a septum and cycled with Argon and vacuum three times. To the reconstituted 
catalysts 2 (174.8 µL neat substrate, 1 mmol, final concentration 20 mM) was added. Using 
a syringe pump, EDA solution (5 mL EtOH, 7 mL dH2O, 241.8 µL EDA, solution 
concentration 163 mM, final concentration 40 mM) was added over a period of 2 hours, using 
a long Luer lock needle such that the needle sat below the solution surface during addition. 
The reaction was stirred at room temperature overnight (16-hour total reaction time). Upon 
reaction completion, the reaction mixture was stored at -20 °C until workup.  
Procedure for column-free purification of trifluoroborated product (4) 
The trifluoroboration procedure was adapted from Bagutski et al.30 Following completion of 
the reaction, the product was extracted three times with 1:1 hexane:ethyl acetate (1 volume 
equivalent per extraction). Deprotected boronic acid was reprotected by stirring the organic 
layer with pinacol (236 mg, 2 mmol, 2.0 equivalents) in the presence of magnesium sulfate 
(1 g). The solution was filtered to remove magnesium sulfate and concentrated in vacuo to 
remove solvent and remaining unreacted starting material (1). The crude reaction mixture 
was then resuspended in 1:1 methanol:water (8 mL total). Potassium bifluoride solution (1.67 
mL of 3 M solution in water, 5.0 equivalents) was added dropwise, and the reaction was left 
to proceed overnight. The solution was concentrated in vacuo to remove methanol, flash-
frozen, and lyophilized to remove water. Acetone (20 mL) was added to the 40-mL 
scintillation vial containing the lyophilized crude product. The product was resuspended in 
the sealed scintillation vial via sonication bath. The solution was vacuum filtered, and the 
vial was washed three times with acetone (10 mL). The acetone was removed in vacuo, and 
the product was dried on high vacuum. 
Determination of initial cyclopropanation activity 
A panel of heme proteins previously engineered for carbene or nitrene transfer reactions27 
was tested for their activity in formation of 3; proteins included in these tests were expressed 
in 96-well plates (96-Well plate library expression). The cell pellets were resuspended with 




chamber. A substrate solution (50 µL of 180 mM 1 and 2, 20 mM final concentration of each 
substrate) was added to each well. The plates were sealed with an adhesive foil cover and 
shaken at 500 rpm and room temperature for 6 hours. The foil covers were removed, 500 µL 
cyclohexane were added to each well, and the plates were sealed with silicone sealing mats 
and vortexed for 1 minute. The organic layer was transferred to GC vial inserts in GC vials, 
and formation of 3 was analyzed via GC-MS.  
The highest initial activity for cis-selective cyclopropanation was exhibited by ApePgb 
W59A Y60G F145W and its intermediate variants. The highest initial activity for trans-
selective cyclopropanation was produced by RmaNOD Q52A, RmaNOD Q52V, and Mb 
H64V V68A; ApePgb W59A Y60G F145W and RmaNOD Q52V were variants engineered 
for unactivated alkene cyclopropanation.28 The myoglobin was engineered by the Fasan lab 
for styrenyl alkene cyclopropanation reactions.38 
Table 3-1. Protein scaffolds tested for formation of 3 in the initial-activity screening. 
UniProt ID of 
wild type Organism Annotation 
Number of 
variants tested Formation of 3 
B3FQS5 Rhodothermus 
marinus 
Cytochrome c 9 Trace detected 
P15452 Hydrogenobacter 
thermophilus 
Cytochrome c-552 2 n.d. 
P00080 Rhodopila 
globiformis 






P02185 Physeter catodon Myoglobin 1 Detected 
B3DUZ7 Methylacidiphilum 
infernorum 
Hell’s gate globin 2 Trace detected 
O66586 Aquifex aeolicus Thermoglobin 1 Trace detected 
G7VHJ7 Pyrobaculum 
ferrireducens 






Q9YFF4 Aeropyrum pernix Protoglobin 10 Detected 












Table 3-2. Activity of top variants from initial screening. Activity is given as integrated area for 
the target ions 182 m/z and 195 m/z. *Variant was found during protein engineering for the 
referenced project. n.d.: not detected in given ion channel. 
Variant Reference cis (182 m/z) trans (182 m/z) cis (195 m/z) trans (195 m/z) 
ApePgb WT 28 122 n.d. n.d. n.d. 
ApePgb Y60G 28 1865 n.d. n.d. n.d. 
ApePgb Y60G 
F145N 
28* 32478 896 2620 1314 
ApePgb W59A 
Y60G 
28 5375 n.d. 351 n.d. 
ApePgb W59A 
Y60G F145W 
28 30043 n.d. 2513 204 
Mb H64V V68A 38 423 1095 n.d. 1437 
RmaNOD WT 28 n.d. 576 n.d. 251 
RmaNOD Q52V 28 193 1039 n.d. 1074 
RmaNOD Q52A 28* n.d. 1417 n.d. 1767 
 
Calibration curves for analytical-scale concentration determinations 
To generate a calibration curve for analytical-scale reactions, solutions at varying 
concentrations of the cyclopropane authentic standard were prepared in E. coli cell 
resuspensions (20 mM MOPS, pH = 7.01, 4.8% ethanol, OD600 = 28 for cis-3, OD600 = 30 
for trans-3). Two 420-µL aliquots of each solution at each concentration were worked up 
following the protocols in small-scale, whole-cell biocatalytic reaction preparation and 
work-up, skipping the addition of 20 µL 100% EtOH, and the worked-up sample was 
analyzed by GC-MS. The y-axis of each calibration curve gives the product:internal standard 
ratio, calculated as total ion count (TIC) of the GC-MS peak corresponding to the target 
product divided by the TIC of the GC-MS peak corresponding to the internal standard. The 
x-axis of each calibration curve is the concentration corresponding to the product:internal 
standard ratio. The resulting calibration curves reproducibly display non-linearity, in which 
low concentrations of cyclopropane show a diminished response. While this indicates a 
product loss event, the standard curve reproducibility shows that it can be utilized to reliably 




Compound synthesis and characterization 
Racemic standards of cis-3 and trans-3 were prepared according to a three-step procedure by 
Bull and coworkers.39 I carried out the large-scale enzymatic syntheses with RmaNOD 
THRAW. Distillation and cross-coupling reactions were carried out by Julie Hofstra. 
Ethyl 2-(phenylthio)cyclopropane-1-carboxylate 
 
A round-bottom flask containing a racemic mixture of N,N'-bis(3,5-di-tert-
butylsalicylidene)-1,2-cyclohexanediaminocobalt(II) (0.043 equiv, 726 mg total, 363 mg of 
each enantiomer) was flushed with Ar for 15 minutes, and then 50 mL of degassed water 
were added (water was degassed by bubbling Ar gas through the liquid for 30 minutes). The 
ethyl diazoacetate (1.0 equiv, 2.9 mL) and phenyl vinyl sulfide (1.5 equiv, 4.7 mL) were 
added via syringe, and the reaction was stirred under a positive pressure of Ar (balloon) at 
40 °C for 24 hours. Upon completion, the reaction was cooled to room temperature and 12 
mL of isohexane was added. Air was bubbled through the reaction for 30 minutes to oxidize 
the Co catalyst. The crude mixture was then filtered through a pad of silica gel, which was 
subsequently washed with CH2Cl2. The solution was concentrated and purified by column 
chromatography (silica, 15:1 pentane:Et2O) to provide 2.05 g of cis-S1 (33% yield) and 2.28 
g of trans-S1 (37% yield). 
 
Each diastereomer of S1 was monooxidized with m-CPBA and subsequently converted to 





The cyclopropane trans-S1 (1.97 g) was added to a round-bottom flask, dissolved in 90 mL 
of CH2Cl2, and cooled to 0 °C. The m-CPBA (99%, 1.63 g) was added in three portions over 
30 minutes and then continued to stir for 2 hours at 0 °C. Aqueous KOH (3 M, 35 mL) was 
added, and the layers were separated. The aqueous layer was extracted with CH2Cl2 (5 × 35 
mL). The combined organic layers were dried with MgSO4, filtered, and concentrated. The 
crude material was purified by column chromatography (silica, 1:2 hexane:Et2O) to provide 
1.39 g of trans-S2 (66% yield). 
Ethyl (cis)-2-((S)-phenylsulfinyl)cyclopropane-1-carboxylate 
The cyclopropane cis-S1 (1.78 g) was added to a round-bottom flask, dissolved in 80 mL of 
CH2Cl2 and cooled to 0 °C. The m-CPBA (99%, 1.44 g) was added in three portions over 30 
minutes and then continued to stir for 2 hours at 0 °C. Aqueous KOH (3 M, 30 mL) was 
added, and the layers were separated. The aqueous layer was extracted with CH2Cl2 (5 × 30 
mL). The combined organic layers were dried with MgSO4, filtered, and concentrated. The 
crude material was purified by column chromatography (silica, 1:2 hexane: diethyl ether) to 
provide 1.20 g of cis-S2 (63% yield). 
Ethyl (cis)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-
carboxylate 
The cyclopropane trans-S2 (1.29 g) was added to a round-bottom flask and dissolved in 54 
mL of THF. The reaction was cooled to –78 °C, and then the iPrMgCl (2 M, 4.4 mL) was 
added dropwise. The reaction continued to stir for 10 minutes before the addition of 2-
isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.2 mL). The reaction was warmed to 
0 °C and continued to stir for 6 hours before being warmed to room temperature. Methanol 
(15 mL) was added to quench the reaction and stirred for 5 minutes. Then, 150 mL of diethyl 
ether were added, the mixture was filtered and concentrated. The crude mixture was purified 
by column chromatography (florisil, 10% to 50% diethyl ether : hexane) to provide 480 mg 
of trans-3 (37% yield). 1H NMR (400 MHz, chloroform-d) δ 4.19 – 3.98 (m, 2H), 1.83 – 




(m, 1H). 13C NMR (101 MHz, CDCl3) δ 174.5, 83.6, 60.6, 25.0, 25.0, 17.8, 14.4, 11.3.
 11B 
NMR (128 MHz, CDCl3) δ 32.1. 
Ethyl (cis)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-
carboxylate 
The cyclopropane cis-S2 (1.10 g) was added to a round-bottom flask and dissolved in 46 mL 
of THF. The reaction was cooled to –78 °C, and then the iPrMgCl (2 M, 3.5 mL) was added 
dropwise. The reaction continued to stir for 10 minutes before the addition of 2-isopropoxy-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.9 mL). The reaction was warmed to 0 °C and 
continued to stir for 6 hours before being warmed to room temperature. Methanol (15 mL) 
was added to quench the reaction and stirred for 5 minutes. Then, 150 mL of diethyl ether 
were added, the mixture was filtered and concentrated. The crude mixture was purified by 
column chromatography (florisil, 10% to 50% diethyl ether: hexane) to provide 440 mg of 
cis-3 (39% yield). 1H NMR (400 MHz, chloroform-d) δ 4.18 – 4.04 (m, 2H), 1.79 – 1.69 (m, 
1H), 1.21 (d, J = 1.7 Hz, 12H), 1.02 – 0.92 (m, 1H), 0.62 – 0.51 (m, 1H). 13C NMR (101 
MHz, CDCl3) δ 174.3, 83.5, 60.5, 24.8, 24.7, 18.6, 14.3, 13.0.





Whole E. coli cells were grown fresh as described above (Medium- and large-scale protein 
expression); two 1-L cultures in 2.8-L non-baffled flasks were grown for RmaNOD 
THRAW. The cells were resuspended in 1X M9-N buffer (OD600 = 30, 664 mL) and 




with a septum and attached to a Schlenk line; three cycles of Argon purging and vacuum 
evacuation were used to remove oxygen from the reaction flask. The mixture remained under 
argon flow throughout the entire reaction. Substrate (1) (neat stock, 7.5 mL, 60 mM final 
concentration) was added via syringe. EDA (2) (10.41 mL diluted in 35.9 mL ethanol 
cosolvent, 120 mM final concentration) was added over 2 hours via syringe pump slow 
addition. The reaction continued to stir overnight (16 hours) at room temperature. The 
reactions were then extracted three times with 1:1 hexane:ethyl acetate. The organic fractions 
were concentrated in vacuo and used in the subsequent protection step without purification. 
To the crude mixture of 3 and the deprotected cyclopropylboronic acid (6) were added 
pinacol (1.18 g), anhydrous magnesium sulfate (15 g), and anhydrous diethyl ether (100 mL). 
The reaction flask was sealed with a rubber septum and stirred for 2 hours at room 
temperature. After 2 hours, an aliquot was analyzed by 1H NMR spectroscopy to ensure 
complete consumption of 6. The reaction was filtered over a plug of anhydrous MgSO4, 
concentrated, and purified by distillation.  
The crude mixture was purified via fractional distillation using a short path distillation setup 
attached to a small Vigreux column under reduced pressure. The residual alkene starting 
material was isolated at 10 torr and 40 °C to obtain 820 mg of the reagent as a colorless oil. 
The Vigreux column was then removed and a mixture of the desired product 3, diethyl 
fumarate, and diethyl maleate were co-distilled at 5 torr and 70–100 °C. The obtained mixture 
was transferred to a round-bottom flask and vigorously stirred while heated under vacuum 
(40 °C at 1 torr for 24 hours, then 45 °C at 1 torr for 24 hours, then 50 °C at 1 torr for 3.5 
hours) to remove the undesired diethyl fumarate and diethyl maleate side products. Product 
3 was isolated as a colorless oil (3.7 g, 95% purity, 36% yield, 41% yield based on recovered 
starting material). 






To a dram vial equipped with a magnetic stir bar were added 3 (50 mg, 0.208 mmol, 1 equiv) 
and 1 mL of ethanol. A solution of KHF2 (78 mg, 1 mmol, 5 equiv) in 0.22 mL of water was 
added to the vial, then sealed with a screw cap, and stirred overnight at room temperature. 
Upon completion, the solvent was removed in vacuo and the BF3K salt was extracted with 
acetone (3 × 4 mL). The combined organic layers were filtered through a plug of cotton and 
concentrated to provide 35 mg of the desired cyclopropyl BF3K salt (76% yield). A small 
sample (~1 mg) was recrystallized from slow evaporation of acetone to provide crystals 
suitable for X-ray diffraction. 1H NMR (400 MHz, DMSO-d6) δ 3.92 (qd, J = 7.1, 1.2 Hz, 
2H), 1.32 – 1.22 (m, 1H), 1.12 (t, J = 7.1 Hz, 3H), 0.75 (ddd, J = 8.8, 4.9, 2.5 Hz, 1H), 0.56 
(dddt, J = 10.8, 8.2, 2.4, 1.1 Hz, 1H), -0.13 (dddt, J = 14.7, 10.3, 8.7, 4.3 Hz, 1H). 13C NMR 
(101 MHz, DMSO) δ 174.9, 59.1, 40.6, 40.4, 40.2, 40.0, 39.8, 39.6, 39.3, 17.3, 17.3, 17.3, 
17.3, 14.7, 10.3, 10.3, 10.2, 10.2.  11B NMR (128 MHz, DMSO-d6) δ 3.43, 3.00.
 19F NMR 
(282 MHz, DMSO-d6) δ -135.1, -135.2. 
Suzuki-Miyaura cross-coupling with 4 
 
In a glovebox under an inert atmosphere, 4 (4.4 mg, 0.02 mmol, 1 equiv) was dissolved in 
110  L of a mixture of 10:1 toluene:degassed water in a half dram vial equipped with a 
magnetic stir bar. The 4-bromoanisole (5.6 mg, 1.5 equiv), Pd(OAc)2 (0.09 mg, 0.02 equiv), 
n-BuPAd2 (0.22 mg, 0.03 equiv), and Cs2CO3 (17.6 mg, 2.7 equivalents) were added 
sequentially. The vial was sealed with a Teflon cap, wrapped with electrical tape, and stirred 
at 100 °C for 20 hours. The reaction was cooled to room temperature, loaded onto a packed 





General procedure: Suzuki-Miyaura cross-coupling with cis-3  
 
In a glovebox under an inert atmosphere, 3 (48 mg, 0.2 mmol, 1 equiv), aryl bromide (1.5 
equiv), Pd(OAc)2 (2.2 mg, 0.05 equiv), n-BuPAd2 (5 mg, 0.07 equiv), Cs2CO3 (3.0 equiv), 
and toluene (2 mL) were sequentially added to a 2-dram vial equipped with a magnetic stir 
bar. The vial was sealed with a Teflon cap, wrapped with electrical tape, and stirred at 100 
°C for 36 hours. The reaction was cooled to room temperature, loaded onto a packed silica 
column, and purified by column chromatography to afford the desired product. 
Ethyl (1R,2S)-2-(4-methoxyphenyl)cyclopropane-1-carboxylate (5a) 
Prepared from (1R,2S)-3 (48 mg, 1.0 equiv, 0.2 mmol) and 1-bromo-
4-methoxybenzene (56 mg, 1.5 equiv, 0.3 mmol). The crude residue 
was purified by column chromatography (silica, 10% Et2O/hexanes) 
to yield 40.4 mg of 5a (92% yield). The product was analyzed by chiral SFC and no minor 
enantiomer peak was detected, confirming the product is formed in >99% ee. This is a known 
compound, and the spectroscopic data are in agreement with the literature.38 Chiral SFC: 
(OJ-H, 2.5 mL/min, 5% IPA in CO2,  = 254 nm): tR (major) = 3.9 min, tR (minor) = 5.5 min.
 
1H NMR (400 MHz, chloroform-d) δ 7.21 – 7.15 (m, 2H), 6.80 (dt, J = 8.9, 2.5 Hz, 2H), 3.89 
(q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 2.52 (q, J = 8.7, 8.0 Hz, 1H), 2.03 (ddd, J = 9.2, 7.8, 5.6 
Hz, 1H), 1.70 – 1.61 (m, 1H), 1.30 (ddd, J = 8.7, 7.8, 5.0 Hz, 1H), 1.02 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.2, 158.4, 130.4, 128.7, 113.4, 60.3, 55.3, 25.0, 21.8, 14.2, 
11.4. HRMS (EI+, m/z): calculated for C13H16O3 [M]
+: 220.1100, found 220.1095. 
Ethyl (1R,2S)-2-(3,4-difluorophenyl)cyclopropane-1-carboxylate (5b) 
Prepared from (1R,2S)-3 (48 mg, 1.0 equiv, 0.2 mmol) and 4-bromo-
1,2-difluorobenzene (58 mg, 1.5 equiv, 0.3 mmol). The crude residue 
was purified by column chromatography (silica, 10% Et2O/hexanes) to yield 29.7 mg of 5b 




detected, confirming the product is formed in >99% ee. Chiral SFC: (OJ-H, 2.5 mL/min, 0% 
IPA in CO2,  = 210 nm): tR (major) = 2.9 min, tR (minor) = 3.4 min.
 1H NMR (400 MHz, 
chloroform-d) δ 7.13 – 6.93 (m, 3H), 3.92 (q, J = 7.1 Hz, 2H), 2.56 – 2.45 (m, 1H), 2.07 
(ddd, J = 9.3, 7.9, 5.7 Hz, 1H), 1.63 (ddd, J = 7.4, 5.6, 5.2 Hz, 1H), 1.34 (ddd, J = 8.7, 7.9, 
5.3 Hz, 1H), 1.05 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.8, 151.2, 151.1, 
150.7, 150.5, 148.7, 148.6, 148.2, 148.1, 133.9, 133.8, 133.8, 133.8, 133.8, 125.5, 125.4, 
125.4, 125.4, 118.4, 118.3, 116.8, 116.6, 60.6, 24.7, 24.7, 21.9, 14.2, 11.7. 19F NMR (282 
MHz, CDCl3) δ -138.7 (m), -140.7 (m). HRMS (EI+, m/z): calculated for C12H12F2O2 [M]
+: 
226.0805, measured 226.0805. 
Ethyl (1R,2S)-2-(anthracen-9-yl)cyclopropane-1-carboxylate (5c) 
Prepared from (1R,2S)-3 (48 mg, 1.0 equiv, 0.2 mmol) and 9-
bromoanthracene (77 mg, 1.5 equiv, 0.3 mmol). The crude residue was 
purified by column chromatography (silica, 5-15% Et2O/hexanes) to 
yield 25.5 mg of 5c (44% yield). The product was analyzed by chiral 
SFC and no minor enantiomer peak was detected, confirming the product is formed in >99% 
ee. Chiral SFC: (OJ-H, 2.5 mL/min, 15% IPA in CO2,  = 254 nm): tR (major) = 7.3 min, tR 
(minor) = 7.9 min. 1H NMR (400 MHz, Chloroform-d) δ 8.63 (d, J = 8.9 Hz, 1H), 8.50 (d, J 
= 8.7 Hz, 1H), 8.36 (s, 1H), 7.98 (t, J = 8.6 Hz, 2H), 7.51 – 7.42 (m, 4H), 3.55 – 3.34 (m, 
2H), 3.09 (q, J = 8.3, 7.9 Hz, 1H), 2.57 (td, J = 8.3, 5.6 Hz, 1H), 2.01 (ddd, J = 8.8, 8.1, 4.6 
Hz, 1H), 1.82 (ddd, J = 7.8, 5.6, 4.7 Hz, 1H), 0.54 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
CDCl3):  171.8, 131.9, 131.8, 131.2, 129.7, 129.4, 129.0, 127.0, 125.6, 125.5, 125.3, 125.1, 
125.0, 124.8, 60.1, 22.5, 20.9, 16.7, 13.6. 
Ethyl (1R,2S)-2-(6-chloropyridin-3-yl)cyclopropane-1-carboxylate (5d) 
Prepared from (1R,2S)-3 (48 mg, 1.0 equiv, 0.2 mmol) and 5-bromo-
2-chloropyridine (58 mg, 1.5 equiv, 0.3 mmol). The crude residue was 
purified by column chromatography (silica, 5-40% Et2O/hexanes) to 
yield 15 mg of 5d (33% yield) as a colorless oil. The product was analyzed by chiral SFC, 




CO2,  = 254 nm): tR (major) = 2.3 min, tR (minor) = 2.6 min. 
1H NMR (400 MHz, 
chloroform-d) δ 8.30 (dt, J = 2.5, 0.7 Hz, 1H), 7.53 (ddd, J = 8.2, 2.5, 0.7 Hz, 1H), 7.25 – 
7.19 (m, 1H), 3.94 (qt, J = 7.1, 3.6 Hz, 2H), 2.48 (q, 1H), 2.14 (ddd, J = 9.0, 7.9, 5.7 Hz, 1H), 
1.67 (dt, J = 7.5, 5.5 Hz, 1H), 1.42 (ddd, J = 8.7, 8.0, 5.2 Hz, 1H), 1.06 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.6, 150.9, 149.8, 139.5, 131.5, 123.5, 60.8, 22.2, 21.8, 
14.3, 11.4. HRMS (FAB, m/z): calculated for C11H12ClNO2 [M]
+: 225.0557, measured 
225.0706. 
General procedure: Suzuki-Miyaura cross-coupling of trans-4 
 
In a glovebox under an inert atmosphere, trans-3 (4.8 mg, 0.02 mmol, 1 equiv), aryl bromide 
(1.5 equiv), Pd(OAc)2 (0.22 mg, 0.005 equiv), n-BuPAd2 (0.5–0.8 mg, 0.07–0.11 equiv), 
Cs2CO3 (3.0 equiv), and toluene (0.2 mL) were sequentially added to a 1/2-dram vial 
equipped with a magnetic stir bar. The vial was sealed with a Teflon cap, wrapped with 
electrical tape, and stirred at 100 °C for 24 hours. The reaction was cooled to room 
temperature, flushed through a pipet over a short pad of silica gel, and concentrated in vacuo. 
The crude reaction was dissolved in deuterated chloroform and analyzed by NMR versus an 
added standard (2,3,5,6-tetrachloronitrobenzene) to obtain an NMR yield of the product.  
Ethyl trans-2-(4-methoxyphenyl)cyclopropane-1-carboxylate 
Prepared from trans-3 (4.8 mg, 1.0 equiv, 0.02 mmol) and 1-bromo-
4-methoxybenzene (5.6 mg, 1.5 equiv, 0.03 mmol). The crude residue 
was analyzed by NMR spectroscopy against an internal standard (2.0 
mg of 2,3,5,6-tetrachloronitrobenzene, singlet at 7.73 ppm) to afford the reaction yield 
(56%). 1H NMR (500 MHz, Chloroform-d) δ 7.06 – 7.01 (m, 2H), 6.84 – 6.80 (m, 2H), 4.17 
(q, J = 7.1 Hz, 2H), 3.79 (s, 5H), 2.49 (ddd, J = 9.2, 6.5, 4.2 Hz, 1H), 1.83 (ddd, J = 8.4, 5.2, 






Prepared from trans-3 (4.8 mg, 1.0 equiv, 0.02 mmol) and 4-bromo-1,2-
difluorobenzene (5.8 mg, 1.5 equiv, 0.03 mmol). The crude residue was 
analyzed by NMR spectroscopy against an internal standard (3.5 mg of 
2,3,5,6-tetrachloronitrobenzene, singlet at 7.73 ppm) to afford the reaction yield (61%). 1H 
NMR (500 MHz, Chloroform-d) δ 7.11 (dt, J = 10.2, 8.3 Hz, 1H), 6.94 (ddd, J = 11.4, 7.5, 
2.3 Hz, 1H), 6.89 (ddt, J = 8.2, 3.9, 1.8 Hz, 1H), 4.23 (qd, J = 7.2, 0.8 Hz, 2H), 2.53 (ddd, J 
= 9.3, 6.4, 4.1 Hz, 1H), 1.91 (ddd, J = 8.5, 5.3, 4.2 Hz, 1H), 1.70 – 1.62 (m, 1H), 1.37 – 1.33 
(m, 3H), 1.32 – 1.29 (m, 1H). 
Compound separation conditions 
Table 3-3. Achiral separation conditions for compound 3. 
Compound Instrument; 
column 
Method program Retention times 
3 GC-FID; 
HP-5  
90 °C isothermal 1 minute 
15 °C/min to 110 °C 
60 °C/min to 280 °C isothermal 
1 minute  
Internal standard: 2.9 minutes 
Cis-3: 4.6 min 
Trans-3: 4.7 min 
3 GC-MS; 
HP-5ms UI 
90 °C isothermal 1 minute 
75 °C/min to 325 °C isothermal 
1.5 minutes 
Internal standard: 2.3 min 
Cis-3: 3.55 min 
Trans-3: 3.76 min 
 
Table 3-4. Chiral separation conditions. Due to the worse separation conditions for trans-3 
enantiomers, a separate method was prepared when only cis-3 enantioselectivity was to be 
measured. 
Compound Instrument; column Method program Retention times 
Cis-3 GC-MS; CP-Chirasil 
Dex CB (25 m, 0.25 mm 
ID, 0.25 µm film 
thickness) 
80 °C isothermal 2 minutes 
10 °C/min to 130 °C, 
isothermal 15 minutes 
Cis minor: 14.3 min, 
major: 14.8 min 
(trans unresolved): 19.0 
min  
Trans-3  GC-MS; CP-Chirasil 
Dex CB (25 m, 0.25 mm 
ID, 0.25 µm film 
thickness) 
90 °C isothermal 180 
minutes 
Cis major (1R, 2S): 87.4 
min, minor: 98.9 min 
Trans major: 172.8 min, 
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C h a p t e r  4  
EXPANDING NEW-TO-NATURE REACTIONS BEYOND HEME 
PROTEINS 
 
Content in this chapter is adapted from published work: 
† denotes equal contribution  
Goldberg, N. W.;† Knight, A. M. ;†  Zhang, R. K.; Arnold, F. H. Nitrene Transfer Catalyzed 
by a Non-Heme Iron Enzyme and Enhanced by Non-Native Small-Molecule Ligands. J. Am. 
Chem. Soc. 2019, 141, 19585-19588. 
A.M.K. prepared a list of potential metalloproteins based on structural information, 
assembled biochemical information available for the top candidates, and designed codon-
optimized genes for order. A.M.K. and N.W.G. transformed all plasmids into an expression 
strain of Escherichia coli (E. coli). A.M.K. performed whole-cell expression tests of the 
library. A.M.K. and N.W.G. expressed and purified non-heme metalloproteins and assayed 
their hydrosilylation activity. N.W.G. and R.K.Z. found initial nitrene-transfer activity with 
Pseudomonas savastanoi ethylene-forming enzyme (PsEFE). A.M.K. and N.W.G. ran 
controls to confirm the activity to be enzymatic. A.M.K. carried out alternative ligand 
experiments. A.M.K. designed site-saturation mutagenesis libraries. A.M.K. and N.W.G. 
constructed and A.M.K. screened and analyzed these libraries, and N.W.G. performed shake-
flask validation of potentially improved variants. A.M.K. characterized evolved variants via 
thermostability assays, and time course experiments. A.M.K. generated crystallography 
constructs of C–H insertion variants and purified the constructs. A.M.K. and N.J.P. 







Proteins that use metal ion cofactors catalytically have been underutilized to explore new-to-
nature enzymatic reactions, despite the biocatalytic potential of these metalloproteins. To 
facilitate the use of this protein diversity, I have curated a collection of metalloproteins which 
bind redox-active metal ion cofactors, have solvent-accessible active sites, and have been 
shown to express heterologously in E. coli. One of these proteins, Pseudomonas savastanoi 
ethylene-forming enzyme (PsEFE), a non-heme iron enzyme, can catalyze olefin 
aziridination and nitrene C–H insertion reactions, and was improved by directed evolution. 
As this nitrene-transfer reaction does not require α-ketoglutarate (αKG) as a co-substrate, 







4.1 Expanding new-to-nature metalloprotein chemistry beyond heme 
proteins 
While enzymes from myriad functional classes have been engineered to enhance their 
stability and substrate scope in their native reaction classes, metalloproteins engineered for 
new-to-nature reactions have been almost exclusively dependent on metal complex 
cofactors, either native or nonnative. Carbene and nitrene transfer has been demonstrated 
with heme proteins binding their native cofactor, analogous iron cofactors such as chlorin,1 
or metal-substituted cofactors such as iridium,2 rhodium,3 and ruthenium porphyrins.4 
Beyond heme proteins, research groups have inserted non-native metal complexes into 
proteins using bioconjugations methods like biotin/streptavidin complexes. The Ward and 
Lewis groups have pioneered the use of bioconjugated rhodium complexes in protein 
scaffolds for new-to-nature reactions such as carbene transfer, hydrogenation, and olefin 
metathesis.5,6 In each of these cases, the majority of the metal’s primary coordination sphere 
is pre-formed as part of the cofactor. However, many metalloproteins in Nature consist of 
metal ions coordinated directly by the protein via side-chain and main-chain interactions. 
The nomenclature distinguishing metal cofactors which are single ions or part of 
coordination complexes is imprecise. For clarity, I will refer to metallocofactors with the 
metal tightly bound within a non-proteinaceous coordination complex as metal complex 
cofactors, and metallocofactors with the metal ion bound directly by the protein (via side-
chain or main-chain interactions) as metal ion cofactors. 
The ability to perform new-to-nature biocatalytic reactions with proteins that bind metal ion 
cofactors rather than metal complex cofactors would expand the degree to which the metal’s 
primary coordination sphere can be modulated. Whereas a heme protein’s coordination 
sphere can only be modified by mutating the single axial coordinating ligand or synthesizing 
and incorporating a non-native heme cofactor, the primary coordination sphere of a metal-
ion-bound metalloprotein can be modified through multiple coordinating residue mutations 
and loosely associated co-substrates (e.g. α-ketoglutarate (αKG), Figure 4-1). Heme also 
lacks a cis-coordination site, having only two open coordination sites distal to each other. As 




advantageous for preventing these side reactions and improving reaction selectivity. If the 
reaction of interest requires two adjacent coordination sites, however, heme or non-native 
metalloporphyrins will not be capable of performing the transformation. 
 
Figure 4-1. Potential primary coordination sphere plasticity in heme proteins and non-heme 
metalloproteins. In metal complex cofactor metalloproteins such as heme proteins, four metal 
coordination sites are occupied by the (natural or non-natural) porphyrin ring, requiring porphyrin 
synthesis and substitution to alter most of the primary coordination sphere. In metal ion cofactor 
metalloproteins such as αKG-dependent enzymes, multiple side-chain interactions can be modified 
with mutagenesis, and the metal and ligand can both be substituted through modified reaction 
conditions. 
One strategy which has been used successfully is modulating enzyme activity and selectivity 
using non-iron metalloporphyrins in heme proteins.2 Like hemoproteins, metalloproteins 
featuring a metal ion cofactor can be metallated with a non-native metal ion 
(xenometallation) to modulate their activity. Under physiological conditions, metalloproteins 
are either metallated through cellular metal delivery systems or are metallated based on local 
metal concentrations and the protein’s specificity.7–9 Generally, mismetallated proteins are 
simply inactive, but in some cases enzymes have been shown to have activity for their native 
reaction with multiple metals (cambialism). Ancestral nitrogenases have been predicted to 
be cambialistic,10 and several superoxide dismutases have been shown to be cambialistic, 
performing their native reactions with either iron or manganese.11 In biocatalytic reactions, 
where parameters such as metal ion concentrations can be easily adjusted, an apoenzyme of 
interest can be xenometallated by adding an excess of a different metal for which the enzyme 




decades, with native and engineered copper proteins shown to bind cobalt,12 iron,13 nickel,14 
and even noble metals.15  
The Arnold laboratory and others have developed many interesting and useful new-to-nature 
biocatalytic reactions,16,17 primarily through screening variants of a small set of heme protein 
scaffolds. The world of metalloprotein diversity is vast, with an estimated 30% of all proteins 
binding a metal; the potential for new-to-nature biotransformations using non-heme 
metalloproteins is likewise vast. We therefore set out to develop a collection of non-heme 
metalloproteins which could be tested for promiscuous activity for new-to-nature reactions 
of interest. 
4.2 Curating a collection of non-heme metalloproteins for discovering 
new-to-nature activities 
When selecting a starting protein for a protein engineering campaign, one generally chooses 
a protein with the desired catalytic activity on a substrate similar to the target substrate. 
Databases such as UniProt18 and BRENDA19 have sequence and functional information on 
(most if not) all known enzyme classes. Selecting proteins with reported function on 
compounds similar to the substrate of interest and testing those proteins for initial activity on 
this compound, while not guaranteed to work, is a tried-and-true method to find initial 
enzymatic activity which one can improve with directed evolution. 
For a desired new-to-nature activity, however, one cannot simply look in a functional 
database to find an enzyme with the catalytic activity on a similar substrate. When first 
reported, carbene and nitrene transfer using a heme protein would not appear in a functional 
database like BRENDA or UniProt; the only result matching the search term “carbene 
transfer” in UniProt  is Rma cytochrome c (UniProt ID B3FQS5), which was engineered in 
the Arnold laboratory for this new-to-nature activity.20 Inspiration to search for these novel 
biocatalytic activities came from the chemical catalysis literature. Chemists have been using 
metalloporphryins for C–H activation reactions for decades,21 having in turn been inspired 




and coworkers therefore took cytochrome P450BM3, the workhorse heme protein in the 
Arnold lab, and assayed its styrene cyclopropanation activity, a model reaction for carbene 
transfer. The activity and selectivity of the protein are modulated by the heme’s axial ligand 
and the surrounding protein environment, but the coordination geometry and the primary 
electronic contribution is fixed by the porphyrin ring of the heme cofactor. Indeed, heme 
itself will catalyze styrene cyclopropanation and many more reported transformations, albeit 
at low levels. 
The difficulty of selecting a suitable protein scaffold increases when the primary 
coordination sphere of the metal is composed entirely of protein interactions and labile 
interactions with water or small molecules. A reaction of interest might have a known catalyst 
in the chemistry literature, but designing a catalyst’s primary coordination sphere into a 
protein active site is computationally expensive and infeasible in most cases currently, 
though researchers have made some progress in the field of de novo enzyme design.23 Rather 
than attempting to computationally design a new catalytic active site into a protein structure, 
we instead decided to rely on the prevalence of enzyme catalytic promiscuity24 and looked 
to Nature’s diversity of metal-binding proteins for candidate protein scaffolds for new-to-
nature reactions. We initially purchased, subcloned, and successfully expressed the genes 
encoding 14 copper-binding proteins to use in testing non-heme metalloprotein reactions. 
These were selected because copper complexes are well known in the synthetic literature and 
the mononuclear cupredoxins have been extensively studied by bioinorganic chemists. We 
also requested and received plasmids encoding non-heme metalloproteins of interest from 
other research groups; these were primarily non-heme iron and copper-binding proteins from 
Professors Hans Renata (Scripps Research) and Harry Gray (California Institute of 
Technology). We quickly realized that the collection should be expanded to cover more 
protein classes and sequence diversity and set out to take a more systematic approach in the 




4.2.1 Criteria selection and bioinformatic analysis of the Protein Data Bank 
To ensure we were looking at as large of a pool of potential proteins as possible, I expanded 
our search for any protein binding redox-active metal ions of interest. When protein 
engineers look for a starting point, they can usually turn to databases where protein activities 
are annotated. As we are looking for non-natural activities, we cannot rely on functional 
annotations, but rather must hypothesize based on active-site structures and geometries. We 
therefore opted to narrow the search by looking at proteins with a reported crystal structure, 
as this was the easiest way to see if the (putative) active site might accommodate our 
substrates of interest. I used the Protein Data Bank (PDB), a collection of over 140,000 
crystal structures,25 and the MetalPDB, a database with annotated coordination geometries 
of metals within proteins in the PDB.26 To narrow the structures in the PDB and MetalPDB 
databases down to potentially interesting proteins, I used several search criteria. First, 
structures were required to contain a redox-active metal ion; cobalt, copper, iron, nickel, and 
manganese were included. Zinc, while bound broadly by metalloproteins, was omitted as it 
is redox inactive and only used in enzymes as a Lewis acid.27 I composed a list of all PDB 
ligand IDs for these metal ion cofactors while omitting metal complex cofactors which 
contain these metals, ensuring that only metal ion cofactors were included as results. 
MetalPDB metal ion cofactor search queries were similar and included specifying 
coordination geometries. The proteins selected were also kept to fewer than 580 amino acids 
in length; while there is a slight trend of larger proteins exhibiting lower stability,28 this cutoff 
was a practical choice due to the price and turn-around time increasing above sequences 
longer than 1800 nucleotides for the chosen gene synthesis service. The search was also 
limited to proteins reported to have been expressed in E. coli for crystallization; this would 
ensure that the protein of interest had been successfully expressed in our preferred expression 
host. Finally, sequence identity for representative structures was set to 95%, preventing 
engineered protein variants or commonly studied proteins from being overrepresented in the 
results.  
Combining the results from the MetalPDB and PDB searches yielded a collection of 2572 




the best approach was visual inspection of the proteins rather than relying on any further 
annotated information. I also wanted a diverse array of protein structures and as such did not 
want to further narrow down the candidate proteins solely via structural criteria beyond the 
initial criteria listed above. To make the visual inspection of large numbers of protein 
structures more efficient, I generated structure viewing files (PyMOL sessions) with settings 
to make it easy and clear to see the geometry of the active site, its solvent exposure and 
accessibility, and other factors which could be beneficial or detrimental. Candidate proteins 
were chosen based on the solvent accessibility of the metal site and interesting features of 
the active-site region. This analysis resulted in a list of 179 candidate proteins.  
I then reviewed the literature on the proteins on this short list to determine if there are any 
which should be ruled out based on previous reported results (toxicity, poor expression, 
unstable, etc.). For many proteins submitted, this information was not available. A lack of 
information on poor protein stability or poor expression did not preclude a given protein, but 
literature documentation of instability or toxicity would remove a given candidate. Many 
proteins of interest were from structural genomics projects for which there are expression 
and purification methods, but no peer-reviewed research associated. Proteins from 
thermophilic organisms were preferred as they are generally thermostable, and 
thermostability has been shown to be a key trait when choosing a starting point for 
evolution.29 65 sequences were codon-optimized for E. coli and sent for gene synthesis, of 
which 62 were successfully synthesized and cloned into pET expression vectors. Overall, the 
proteins selected represent substantial diversity in the metalloprotein sequence space; the 
highest pairwise sequence identity was only 49%, with a mean sequence identity of 10%.  
4.2.2 Construct preparation and initial expression tests 
To efficiently turn a list of candidate metalloproteins into expressed proteins ready for 
testing, we decided to order the collection of genes already inserted into an E. coli expression 
vector. As Twist Biosciences did not have an in-house protein expression vector which used 
our standard T7lac promoter expression system, a custom pET expression vector was on-




Biosciences into this expression vector. For proteins which were predicted to natively require 
a signal peptide to form the holoprotein in vivo (based on UniProt annotations and the SignalP 
server),30 the gene was synthesized with the nucleotides to encode an N-terminal pelB signal 
peptide. This is particularly important for genes such as lytic polysaccharide monooxygenase 
(Uniprot ID D6EWM4), for which the amino group and side chain of the N-terminal His 
residue is part of the primary coordination sphere.31 
As Twist Biosciences did not have an in-house strain of E. coli with the λDE3 lysogen 
(necessary for expression with the T7lac promoter in our vector), E. coli BL21(DE3) 
electrocompetent cells were transformed with the plasmids from Twist Biosciences. Each 
protein had been previously reported to express heterologously in E. coli, but it was important 
to confirm that the proteins would express in our plasmid construct under standard expression 
conditions. E. coli harboring each plasmid were grown at small (5 mL) scale and expression 
of the protein of interest was assayed with protein gel electrophoresis (Supplementary 
Information, Figure 4-29). Under standard expression conditions, 40 of the 62 proteins were 
strongly overexpressed, and only seven had no detectable expression. Of these seven, four 
are pelB-tagged proteins, which in our experience have enhanced expression at reduced 
IPTG induction concentrations. 
The names, bound metals, and UniProt IDs for 86 non-heme metalloproteins (including the 
initial cupredoxins ordered and cloned in house, the clonal genes acquired from other 
research groups, and the clonal genes ordered from Twist Biosciences) are in the 
Supplementary Information (Table 4-4 and Table 4-5). The DNA and amino-acid sequences 
are deposited as a supplemental worksheet through CaltechDATA (DOI: 
10.22002/D1.1437).  
This collection of non-heme metalloproteins is available to the biocatalysis community.  
4.3 Toward enzymatic hydrosilylation with non-heme metalloproteins 
One class of catalytic mechanisms in which we were interested are reactions which go 




elementary steps in the synthetic catalytic repertoire, enzymatic mechanisms using these 
steps are limited to complex systems such as nitrogenases.32 Key examples include the 
Suzuki-Miyaura cross-coupling reactions discussed in Chapter 3, hydroamination, 
hydroboration, and hydrosilylation. These reactions generally require cis-coordination sites 
inaccessible to heme-protein catalyzed reactions. While the Arnold laboratory reported the 
first enzyme known to form a carbon–silicon bond by using an engineered heme protein, 
many of the organosilicon compounds ubiquitous to the modern world are generated through 
industrial-scale hydrosilylation reactions. To this end, we set out with the intention of 
engineering metalloproteins as catalysts for hydrosilylation, in collaboration with Dow, Inc. 
In many initial discovery experiments, a large set of proteins, either variants developed from 
previous directed evolution campaigns or newly cloned constructs, is used to screen for one 
specific desired reaction. Our goal was to find promiscuous activity for any hydrosilylation 
reaction in a large and diverse enzyme library (curated as described in Section 4.2); once 
activity was found for a hydrosilylation reaction, we reasoned that substrate walking could 
expand to diverse hydrosilylation reactions utilizing the same catalytic mechanism. We 
assembled a set of model substrates, including activated, unactivated, and electron-deficient 
alkenes (Figure 4-2). The silanes used were limited by the fact that alkoxysilanes and silanes 
with fewer substituents will hydrolyze under aqueous conditions. 
 
Figure 4-2. Initial hydrosilylation reaction tests. Each pairwise combination of alkene and silane 
was tested individually. Reaction conditions: anaerobic, RT, 10 mM silane, 10 mM alkene, whole 




The first group of enzymes we expressed and used in whole E. coli cells were copper 
enzymes (Table 4-4). As phosphate buffers rapidly precipitated copper from solution, 
alternative buffers were tested to minimize metal salt precipitation. MOPS buffer displayed 
less copper precipitation and was used for non-heme metalloprotein reactions for the 
remainder of the project. We determined by UV-visible spectroscopy that these proteins were 
metallated in vivo when expressed in the periplasm (Figure 4-3). E. coli cells expressing these 
copper proteins would turn vivid shades of blue following addition of copper sulfate. These 
proteins were tested against the initial set of four alkenes and two silanes as whole cells, 
lysate, and lysate with sodium dithionite added. 
 
Figure 4-3. Copper-binding protein metallation. (a) Example UV-visible spectra of the copper 
binding proteins azurin and amicyanin. Copper sulfate and dithionite-reduced holoprotein samples 
do not display the characteristic absorbance peaks from 600 – 620 nm. (b) Copper protein 
metallation in whole E. coli cells. From left to right: Pae azurin, Afe rusticyanin, Pde amicyanin, 
Ppu azurin, Rme pseudoazurin.  
Preliminary hydrosilylation reaction screening using whole cells and crude cell lysates 
containing the copper proteins did not yield detectable hydrosilylation activity. As there is 
literature precedent that the coordinating sidechains in azurins can be mutated without 
complete loss of copper binding,33,34 Nat Goldberg also explored mutants which would have 
an additional vacant coordination site (i.e. bound to water rather than an amino-acid side 
chain). These variants still had soluble expression and bound copper, but were also not found 




We therefore decided to pursue further screening using purified proteins. The use of purified 
proteins offers several advantages over whole cells or lysates: it allows for a known quantity 
of catalyst in each reaction and normalizing for variable expression. Purified protein 
reactions can also be run at higher catalyst loading, such that even single-digit enzyme 
turnover or stoichiometric activity would be detectable in sensitive GC-MS screening. The 
removal of the cellular milieu from the reactions also prevents any potential cellular 
background reactions from taking place and removes small-molecule cellular contaminants 
from the analysis, leading to cleaner GC-MS spectra. 
Since protein purification is both time and resource intensive, we wanted to maximize protein 
production and minimize the quantity of each protein of interest required. We first pursued 
a strategy to maximize the reaction space explored by pooling several substrates in each well 
(Figure 4-4). This allowed us to screen several potential hydrosilylation reactions using high 
catalyst loading, without requiring prohibitively large quantities of each protein of interest. 
We chose a set of olefins and carbonyls of varied electronic and geometric character, as well 
as a set of three different silanes that are stable under the reaction conditions. We tested 
reactions at three different pH values (pH 5, 7, and 9 by using MES, MOPS, and CHES 
buffers), as this can alter the protonation state of the coordinating residues, which affects how 
easily they can dissociate from the metal center and vacate substrate binding site(s) for 
hydrosilylation. We also examined the absence or presence of a reductant, sodium dithionite, 







Figure 4-4. Pooled substrate sets. Each substrate set was added as a mixture for a single biocatalytic 
reaction. GC-MS analytics allowed for mass-fragmentation-specific analysis; any potential activity 
could then be followed up on with reactions containing a single substrate-silane pair. 
These pooled substrate reactions were used in screening wild-type and ligand-mutated 
copper proteins. In each case that a potential hydrosilylation product peak was detected, 
follow-up controls showed that the peak was an artifact or non-enzymatic background (false 




substrate-silane pair in each reaction to reduce the sample complexity and potential for cross 
reactivity (Figure 4-5).  
 
Figure 4-5. Final hydrosilylation substrate matrix. The characteristic mass fragmentation pattern 
and retention times are given for the GC-MS method on an Agilent GC-MS (7820 GC oven, 5977B 
single-quadrupole MS) with a 30m × 0.25 mm ID × 0.25 µm film thickness DB-5ms column and 





At this time, the larger metalloprotein collection ordered through Twist Biosciences (Table 
4-5) arrived. While the copper-binding proteins have characteristic UV-visible spectra upon 
metallation, many of the other proteins in this new collection do not. We therefore 
investigated mass spectrometric techniques to determine protein metallation. Protein LC-MS 
and protein TOF were both tested using azurin holoprotein confirmed by UV-visible 
spectroscopy to be metallated. These native protein approaches invariably resulted in 
apoprotein detection; the protein’s instability to the analytical conditions appeared to result 
in demetallation. As an alternative metal detection route, we found that inductively coupled 
plasma-mass spectrometry (ICP-MS) is a reliable way of determining enrichment of the 
metal of interest in our protein samples. It should be noted that this will detect all metals in 
solution and not only those specifically bound to the protein. To determine background metal 
concentrations, we used a sample of the final flow through from each protein’s purification 
as negative control. The analysis from our first round of ICP-MS data collection showed that 
the deionized water used for the protein purification and storage buffers had high background 
in some metals, most notably iron. We have since then adapted our protein purification 
protocol to use distilled deionized water, which lowered this background substantially (an 
average of 19-fold lower 56Fe background). There was consistently high Ni content in the 
protein samples, which we attributed to the C-terminal polyhistidine tag and the Ni affinity 
chromatography used to purify the proteins. Using protein ICP-MS, we have confirmed the 
enrichment of the expected metal ligands in 13 of 17 proteins analyzed. The proteins which 
did not have enrichment were exclusively non-heme iron proteins which also use αKG as a 
coordinating ligand to the iron. In the absence of αKG, it is possible that the binding affinity 
for the metal is not strong enough to keep the metal bound throughout the purification 
process. Further reactions with αKG binding proteins should therefore be tested with αKG 
or an analogous small-molecule ligand added. 
To minimize chances of false positives due to cross contamination from other in-house 
reaction screening, we moved to using a GC-MS DB-5ms column dedicated to these 
reactions. The GC-MS methods were also optimized for minimal inlet split ratios, 




standards that Nat synthesized, we were able to confirm the retention time and mass 
fragmentation for each compound. I prepared separate GC-MS methods for each substrate 
pair, using single ion monitoring (SIM) mode to monitor the characteristic mass fragments 
expected in the hydrosilylation products (Figure 4-5). The reactions with this 3 × 5 substrate 
matrix were set up at only one pH (MOPS pH 7) in the presence and absence of sodium 
dithionite, resulting in 30 reactions per protein. Two proteins could therefore be set up in a 
single 96-well deep-well plate while leaving the outer wells empty, avoiding potential 
differences in assay conditions sometimes observed (edge effects). 
One key control was ensuring that hydrosilylation was possible under conditions typical for 
biocatalytic reactions (aqueous, room temperature, anaerobic) and that our substrates and 
potential products are not degraded under these conditions and can be detected by our 
methods. To this end, we performed hydrosilylation reactions of each of our model silanes 
and olefins/alkyne in aqueous buffer with Karstedt’s catalyst and Speier’s catalyst, both 
known platinum catalysts for hydrosilylation, for a total of 18 reactions. In all 18 reactions, 
we observed high consumption of the silane starting material (>50%). Reactions with 
triethylsilane and dimethyl(phenyl)silane with both olefins and alkyne were generally very 
clean, with at least 50% yield of the expected anti-Markovnikov hydrosilylation products. 
The corresponding silanol byproducts were not observed in significant quantities. Reactions 
with methyl(phenyl)silane also showed hydrosilylation products, but with more 
uncharacterized side products, including probable silanols. Silanol formation from 
methyl(phenyl)silane is not observed in the absence of a catalyst, suggesting that the catalysts 
are activating this silane rather than a background degradation.  
Control reactions were key to ensuring any hydrosilylation product detected was enzymatic. 
In most cases, a false positive was ruled out by comparing to negative control reactions or 
testing whether the peak area was proportional to the enzyme loading. In one case, the false 
positive came from an unexpected component of the screening workflow. The 
hydrosilylation of dimethyl(phenyl)silane and styrene was observed under screening 




difference was that screening reactions were prepared in 96-well deep-well plates and 
validation was run in 2-mL glass vials. Control reactions showed that otherwise identical 
reactions set up in the plates showed activity when the glass vial reactions did not. Through 
a process of elimination, we determined that the activity was coming from the plate seal 
applied during the solvent extraction post reaction; the plate seal, a PTFE-coated silicone 
plate-sealing mat material (ArcticWhite LLC, part number AWSM-1003S), was used such 
that the solvent extraction could be performed through vortexing. The silicone mat was 
presumably manufactured via industrial hydrosilylation and contained trace catalyst. The 
silicone mat was confirmed to catalyze the reaction by adding a piece of this plate sealing 
mat to a glass vial containing aqueous buffer, styrene, and dimethyl(phenyl)silane — only 
reactions containing the silicone sealing mat showed the hydrosilylation product (Figure 4-
6). This unexpected background reaction was removed by performing solvent extractions 
through pipette mixing rather than vortexing. This shows both the ubiquity of hydrosilylation 






Figure 4-6. Background reactivity caused by a silicone sealing mat. When the substrates 
dimethyl(phenyl)silane and styrene were added to aqueous buffer in the presence of PTFE-coated 
silicone plate-sealing mat material (ArcticWhite LLC, part number AWSM-1003S), a peak with 
the expected retention time and mass fragmentation pattern was present (green). The peak was not 
observed when an otherwise identical reaction vial was prepared in the absence of the plate-sealing 
mat material (white). 
With the 3 × 5 silane / substrate matrix (Figure 4-5) and updated GC-MS analytics, we 
screened an additional 36 purified proteins from the metalloprotein collection. In this 
screening, there were no reactions which displayed hydrosilylation product formation. Future 
work on enzymatic hydrosilylation could continue screening native metalloprotein diversity. 
One particular area of metalloprotein diversity that can be explored are proteins which 
include a metal-hydride intermediate as part of their native catalytic mechanism, such as 
nitrogenases32 and hydrogenases.35 The complexity of the cofactor synthesis pathways and 
holoprotein maturation for these proteins (as well as extreme oxygen sensitivity) makes them 




research groups are focused on improving the expression and stability of these proteins in 
model organisms, however, and these more robust expression platforms could be tested as 
potential starting points. As more non-heme metalloproteins are engineered for other new-
to-nature reactions on model substrates like those tested in this section, those variants can be 
screened for their activity on hydrosilylation and related reactions. Once initial activity is 
found, it has been shown countless times that directed evolution can improve that activity – 
all that is needed is a starting point and a good screen.36 
4.4 Nitrene-transfer activity with αKG enzymes 
In addition to the suite of reactions tested as part of the Dow collaboration, we were interested 
in testing non-heme metalloproteins for their ability to perform carbene- and nitrene-transfer 
reactions similar to the transformations for which heme proteins have been previously 
engineered.16 There are a few rationales for the decision to pursue reactions already catalyzed 
by engineered heme proteins: these new-to-nature reactions are known to be possible to 
perform enzymatically under physiological conditions, the starting materials are inexpensive 
and/or already available, and the analytical instrumentation and methods are established. 
The αKG-dependent enzymes in the curated collection natively catalyze oxene-transfer 
reactions via an iron-oxo intermediate to hydroxylate their substrates, consuming molecular 
oxygen and converting one equivalent of αKG to succinate in the process (Figure 4-7). As 
Coelho and coworkers hypothesized that the catalytic oxene-transfer machinery of P450BM3 
could also form iron-carbenoid and iron-nitrenoid species,37 we hypothesized that the 







Figure 4-7. Typical oxene-transfer reactions carried out by non-heme metalloenzymes.  
While testing our collection of αKG-dependent enzymes for nitrene-transfer activity, we 
found that one protein, wild-type ethylene-forming enzyme from Pseudomonas savastanoi 
(PsEFE WT), showed greater than background activity for the aziridination of styrene and 
tosyl azide (Figure 4-8,  
Table 4-1).  
 






Table 4-1. Activities of α-KG-dependent iron enzymes toward aziridination to form 3. 
Enzyme Relative activity 
P. savastanoi ethylene-forming enzyme 12.0 
Streptomyces sp. 2-aminobutyric acid chlorinase 0.93 
A. thaliana anthocyanidin synthase 0.54 
G. oxydans leucine dioxygenase 1.11 
E. coli taurine dioxygenase 0.61 
S. vinaceus arginine hydroxylase 0.57 
S. muensis leucine hydroxylase 0.61 
Bovine serum albumin (negative control) 1.00 
 
 
PsEFE WT has been studied both for the potential biotechnological application of efficient 
ethylene production38 as well as the fact that it has two native activities.39 In its first, more 
classical αKG-dependent enzyme activity, an equivalent of αKG is used to oxidize L-Arg to 
form pyrroline-5-carboxylic acid, an intermediate in proline synthesis (Figure 4-9a). Its 
second native reaction is the conversion of αKG into ethylene (Figure 4-9b). 
 
 
Figure 4-9. Reactions catalyzed natively by Pseudomonas savastanoi ethylene-forming enzyme 
(PsEFE). (a) An equivalent of αKG is used to oxidize L-Arg to form pyrroline-5-carboxylic acid, 
an intermediate in proline synthesis, with guanidine, succinate, carbon dioxide, and water as 





When testing new reactions, it is critical to ensure that product formation is enzyme catalyzed 
and not a background reaction. Several additional controls were carried out to ensure that the 
activity was due to PsEFE WT and not due to background activity. These controls include 
running the reaction in the absence of key reagents such as iron, ascorbate (reductant), and 
αKG (co-substrate). In addition, we generated a protein variant which lacked two of the 
coordinating amino-acid residues (PsEFE H189A D191A). This double mutant protein still 
solubly expressed and purified, but was expected to have a greatly disrupted metal-binding 
site. These control reactions showed that omission of iron or the use of the double mutant 
abolishes activity, indicating that the reaction is enzymatic and occurs in the iron-binding 
site (Table 4-2). The activity is also proportional to the catalyst loading, lending further 
evidence that it is enzymatic. Another test is whether the product is enantioenriched; while 
the enzyme might form racemic product, it is unlikely that a background reaction would form 
an enantioenriched product. Chiral HPLC analysis showed that PsEFE WT was (R)-
selective, with 25% enantiomeric excess (ee); the P411BM3 variant previously engineered for 
this nitrene-transfer reaction was (S)-selective. 
Table 4-2. Control and ligand-substitution reactions for PsEFE WT aziridination to form 3. 
Deviation from standard conditions Aziridine yield (%) 
H189A D191A mutant (disrupted iron binding) <0.01% 
No iron 0.01% 
No αKG or analog 0.04% 
None (standard conditions) 0.08% 
Succinate instead of αKG 0.11% 
Acetate instead of αKG  0.56% 
N-oxalylglycine instead of αKG 0.64% 
No ascorbate, acetate instead of αKG 0.50% 
 
Given the ability to catalyze the aziridination of tosyl azide and styrene, we investigated the 
scope of nitrene-transfer reactions that PsEFE WT could catalyze. The tests focused on the 
aziridination of unactivated alkenes, which had not been reported with the P411BM3 
aziridination platform.40 We also tested 4-ethyl anisole, a model substrate for benzylic C–H 




anisole or the aziridination of 1-octene, but the aziridination of allylbenzene and 4-phenyl-
1-butene were detected, with 1.5 to 2-fold higher signal than the background and negative 
control reactions (Figure 4-10). 
 
Figure 4-10. Aziridination of unactivated alkenes. Reaction conditions: 50 µM PsEFE WT purified 
protein, 1 mM ferrous ammonium sulfate, 1 mM αKG, 10 mM alkene, 10 mM tosyl azide, 5% 
ethanol cosolvent, 2 hours, room temperature. 
In addition to testing for further nitrene-transfer reactions, an array of carbene-transfer 
reactions were tested with PsEFE WT. The formation of the metal-carbenoid intermediate is 
a crucial prerequisite for the carbene-transfer reaction to occur, and its formation is heavily 
dependent on the catalyst and the specific diazo compound used as a carbene precursor. Four 
diazo compounds with varied steric and electronic properties were tested (Figure 4-11). 
Xenometallation of PsEFE was also attempted, adding first-row transition metals (Mn, Ni, 
Co, Cu) in place of Fe in reactions. To limit the combinatorial expansion of test reactions, 
styrene was used as the alkene in all carbene-transfer reaction attempts. GC-MS traces of 
organic extracts of these reactions were analyzed for mass spectra corresponding to both 
carbene transfer to styrene and for dimerization of the diazo molecules; no carbene transfer 
activity above the negative control background was observed, and no clear evidence of 






Figure 4-11. Attempted carbene transfer reactions. Reaction conditions: 50 µM purified PsEFE 
WT, 100 µM metal salt, 1 mM α-KG, 1 mM sodium dithionite, 10 mM styrene, 10 mM diazo 
reagent, 5% ethanol cosolvent. Reactions were analyzed via GC-MS.  
Following the initial evaluation of PsEFE WT’s new-to-nature reaction scope, we decided 
to focus on aziridination of styrene with tosyl azide as our model reaction in a directed 
evolution campaign to develop PsEFE as a new-to-nature biocatalytic platform. As has been 
observed countless times, mutations which are found to be beneficial when evolving for one 
function can also provide the starting activity for other reactions of interest;42 engineering 
PsEFE for this aziridination model reaction would likely enable access to additional new-to-
nature reactions. 
4.4.1 Analogs of α-ketoglutarate modulate PsEFE’s aziridination activity 
Ethylene-forming enzyme requires α-ketoglutarate for both of its native functions, but the 
nitrene-transfer reaction should not require an equivalent of the co-substrate to go through 
the catalytic cycle. I therefore hypothesized that α-ketoglutarate would not be strictly 
required and could potentially be replaced with other compounds to modulate the activity of 
PsEFE. This change would be analogous to the ability of cytochrome P411BM3 to catalyze 




as the heme domain only); while the native oxene transfer reaction required the electron 
transport chain to be intact, the new-to-nature reaction does not have this strict requirement. 
Total activity was improved for both indole alkylation43 and C-H functionalization44 by 
removing a section of the “unnecessary” domains. There is literature precedent that PsEFE 
can accept a co-substrate other than αKG: Hausinger and coworkers demonstrated that 2-
oxoadipate could be used in place of αKG in the formation of pyrroline-5-carboxylic acid, 
albeit at a 500-fold loss in activity, and other keto-acids were reported to display no 
detectable P5C formation.39 I tested PsEFE WT aziridination reactions with αKG substituted 
with several other carboxylate-containing compounds (Figure 4-12). Most resulted in activity 
equal to or worse than αKG, but acetate and N-oxalylglycine (NOG) both enhanced 
aziridination activity greater than five-fold (Table 4-2). 
 
Figure 4-12. αKG and analogs tested for their effect on PsEFE aziridination activity. Acetate and 
N-oxalylglycine display enhanced activity relative to αKG. 
There are several potential advantages for replacing αKG in the reaction. αKG is inexpensive 
(approximately $1/g from Sigma-Aldrich), but replacing αKG with an even cheaper ligand 
(e.g. acetate at $0.14/g from Sigma-Aldrich) could decrease reaction costs. More 




should prevent the competing native oxene transfer from occurring, even under aerobic 
conditions. The ability to substitute the ligand by simply changing the reaction conditions 
and without requiring the synthesis of a non-native metal complex cofactor enables the facile 
modulation of the primary coordination sphere.  
4.5 Evolution of enzymes with enhanced nitrene-transfer activity 
The initial activity found for the PsEFE-catalyzed aziridination of styrene provided a starting 
point for evolving a non-heme metalloprotein into a platform for non-native activity; the next 
step was enhancing this activity through directed evolution. 
When designing our protein engineering strategy, I considered our expected screening 
throughput (maximum number of samples screened per day) and what factors might affect 
PsEFE’s aziridination activity. As the primary screen would be via LC-MS, the screen would 
be approximately 3–4 minutes per sample (approximately 400 clones per day at maximum). 
With this medium-throughput screening capability, I opted for site-saturation mutagenesis at 
positions which might reasonably modulate enzymatic activity. As the nitrene-transfer 
reaction putatively proceeds within the arginine substrate binding pocket, I primarily focused 
on mutations within that region of the protein. This scaffold had not previously been 
engineered for nitrene-transfer activity and the effects of mutations throughout the active site 
were unknown. I therefore ordered primers for 24 site-saturation libraries targeting residues 
in the first shell of the arginine and α-ketoglutarate binding sites (amino acid positions 84, 
86, 87, 91, 171, 173, 175, 186, 189, 191, 192, 198, 206, 228, 268, 270, 277, 279, 281, 283, 
314, 316, 317, 318, highlighted in Figure 4-13). Out of these 24 libraries, 15 were 
successfully cloned, expressed, and screened on the first pass (84, 86, 87, 91, 171, 173, 186, 
189, 191, 192, 277, 283, 314, 316, 317, highlighted in Figure 4-14). Libraries which were 






Figure 4-13. Amino-acid residues targeted for site-saturation mutagenesis in the first round of 
PsEFE engineering. Structural representation of PsEFE complexed with α-ketoglutarate 
(represented in sticks) and Mn (the metal with which the protein was crystallized, purple sphere) 
(PDB ID: 5VKB). 24 positions are displayed for which primers for site-saturation mutagenesis 





Figure 4-14. Amino-acid residues targeted for site-saturation mutagenesis and screened via LC-MS 
in the first round of PsEFE engineering. Structural representation of PsEFE complexed with α-
ketoglutarate (represented in sticks) and Mn (the metal with which the protein was crystallized, 
purple sphere) (PDB ID: 5VKB). 15 positions are displayed for which site-saturation mutagenesis 
libraries were cloned, expressed, and screened for aziridination activity; side chains are represented 
as sticks and shown in light blue.  
Site-saturation mutagenesis libraries were screened at a rate of 80 clones per library, as well 
as eight clones of the parent and eight sterile controls. The screening was performed on the 
LC-MS using the mass selective detector (MSD) signal at m/z = +274 ([M+H]+) to quantify 
aziridine product formation. The high number of parent and sterile controls and screening 
depth is due to the high variability observed when testing the PsEFE WT activity; eight 
parent and eight sterile controls spread across the plate enabled us to monitor the variability 




In parallel to screening the libraries from round 1, I had determined that purified wild-type 
PsEFE has enhanced activity when adding acetate in place of α-ketoglutarate and that the 
reaction also works under aerobic conditions. Rather than modifying the screening 
conditions partway through a single round of directed evolution, the remaining libraries were 
screened under anaerobic conditions with α-ketoglutarate as the supplemented ligand. 
Variants with enhanced aziridination activity relative to the parent protein (PsEFE WT) were 
then sequenced and expressed at 40-mL scale. These validation reactions were performed 
with clarified cell lysate, testing the variants under anaerobic and aerobic conditions and 
supplementing with either acetate or αKG. While there were variants with modest 
enhancement from other site-saturation libraries, PsEFE C317M using acetate as the ligand 
was by far the variant with the highest enhancement in aziridination activity, including under 
acetate-supplemented conditions (Figure 4-15). We therefore fixed PsEFE C317M as the 
parent for the second round of site-saturation mutagenesis. 
 




In the second round of evolution, we targeted 10 positions for site-saturation mutagenesis 
(84, 86, 91, 171, 186, 192, 277, 283, 314, 316, highlighted in Figure 4-16). The amino-acid 
positions chosen for mutagenesis were ones which either failed in cloning or expression 
during round 1 or showed some variants with modest improvements in activity during round 
1 screening. Most of these positions could be targeted using the primers purchased in the first 
round of mutagenesis. For positions 314 and 316, new primers were purchased to include the 
C317M mutation (otherwise the mutation would be overwritten in PCR amplification). These 
libraries were screened under aerobic conditions and supplemented with acetate in place of 
α-ketoglutarate. Of these libraries, the largest enhancements in aziridination activity in the 
screening data were found at the libraries targeting positions 171, 277, and 314. In 
sequencing the variants with beneficial mutations, we also found a non-programmed single 
nucleotide substitution (C290T) which introduced the (serendipitously beneficial) amino-
acid substitution T97M. 
 
Figure 4-16. Amino-acid residues targeted in the second round of mutagenesis. Ten residues for 
which site-saturation mutagenesis libraries were cloned, expressed, and screened for aziridination 




As the second round of evolution had multiple modest improvements (1.5–2-fold activity 
enhancements) rather than one variant which was clearly the best, we prepared a 
recombination library of the mutations found in the best-performing variants in the round 2 
validation reactions. In preparing a recombination library, we introduced the mutations via 
PCR similar to the site-saturation mutagenesis cloning strategies. The mutations included in 
the recombination library were T97M, R171A, R171V, R171L, R277H, F314M, F314Q, 
F314L; at each position, the parent residue was also included in the library, resulting in 64 
possible variants. 
As the four amino-acid residues were spread out across the gene, we were able to generate 
three PCR fragments which included the programmed mutations at positions 97, 171, and 
314 (Figure 4-17). To introduce the mutation at position 277, we used an equimolar mixture 
of plasmids PsEFE C317M and PsEFE R277H C317M as the template for the PCR. These 
three PCR products were gel extracted and assembled via Gibson assembly.  
 
Figure 4-17. PsEFE recombination library primer design. The promoter (T7lac), gene (P32021, 
PsEFE), and primer binding sites are annotated. The plasmid map was generated via Benchling 
software (Benchling, San Francisco, CA). 
To get high coverage and redundancy of this recombination library, four 96-well plates of 
this recombination library were screened (320 clones). This resulted in PsEFE T97M R171L 




of the aziridine product with 120 TTN and 88% ee. The TTN is modest compared to values 
reported for cytochromes P411BM3, but the high expression of PsEFE WT and variants 
enables the facile preparation of large quantities of enzyme (Supplementary Information, 
Figure 4-32). 
A third round of site-saturation mutagenesis was carried out targeting eight additional 
positions (84, 95, 173, 175, 186, 192, 270, and 283), which resulted in the variant PsEFE 
MLLHMM with comparable activity in lysate and 90% ee, a slight enhancement over PsEFE 
MLHMM. During the validation of the variant’s activity as purified protein, however, the 
enhanced enantioselectivity was maintained, but the TTN decreased two-fold relative to 
PsEFE MLHMM. The increased enantioselectivity was insufficient to justify the loss in 
activity. Further evolution could be carried out on PsEFE MLHMM if there was an 
application for this specific aziridine production. However, as the goal here was the 
development of a biocatalytic platform using non-heme metalloproteins, PsEFE MLHMM 
was chosen as the final aziridination variant in this evolution campaign. 
The second round of site-saturation mutagenesis and subsequent recombination were both 
performed with acetate supplemented in place of αKG. One mutation identified, R277H, is 
at the amino-acid residue which coordinates the distal carboxylate of αKG, and therefore 
potentially disrupted the native ligand binding (Figure 4-18). Indeed, aziridination reactions 
prepared with PsEFE MLHMM and αKG or NOG had the same activity as reactions with 
no ligand added, while acetate enhanced the activity by an order of magnitude (Figure 4-19). 
This was a strong indication that the PsEFE MLHMM aziridination catalyst no longer 
productively binds the native ligand, αKG. The PsEFE variants catalyzing nitrene transfer 
are no longer αKG-dependent enzymes, but PsEFE MLHMM, along with other variants with 






Figure 4-18. Position of R277 relative to αKG. R277 interacts with the distal carboxylate of αKG 








4.5.1 Exploring engineered PsEFE sequence for other nitrene-transfer reactions 
The recombination plates generated using beneficial mutations in the second round of site-
saturation mutagenesis libraries represented a large amount of active-site residue sequence 
diversity which had been shown to be beneficial for nitrene-transfer reactions. As the active 
site has been remodeled since the initial reactions testing alternative nitrene-transfer 
reactions, we hypothesized that this recombination library might contain protein variants 
which could perform alternative nitrene-transfer reactions. In this screen, activity on the 
intramolecular C–H insertion of 2-ethylbenzenesulfonyl azide was found (Figure 4-20), with 
the best variant, PsEFE R171V F314M C317M (PsEFE VMM) catalyzing the reaction with 
310 TTN, but only 9.4% ee with the screening ligand (acetate). Its activity and selectivity 
were further increased by using NOG as a ligand, with up to 730 TTN and 47% ee. Not only 
does the activity and stereoselectivity vary drastically through ligand substitution, but also 
the chemoselectivity: PsEFE without a ligand slightly favors formation of the sulfonamide 
over the sultam, while the addition of NOG increases the ratio of sultam:sulfonamide to up 




Figure 4-20. Intramolecular C–H insertion reaction. 2-ethylbenzenesulfonyl azide can be converted 






Table 4-3. Intramolecular C–H insertion activity with ligand substitutions in PsEFE VMM. 
Reaction conditions: 20 µM purified PsEFE VMM, 10 mM 2-ethylbenzenesulfonyl azide, 
anaerobic, room temperature, 6 hours.  110 µM enzyme concentration. 
PsEFE variant Ligand TTN ee (%) Insertion / reduction 
VMM None 25 n.d. 0.9 
VMM αKG 130 61 9.0 
VMM Acetate 310 9.4 24 
VMM NOG 450 48 105 
VMM1  NOG 730 47 100 
 
A second variant in the recombination plate which was identified to have C–H insertion 
activity was PsEFE VHMM, with the only difference being the R277H mutation. As the 
aziridination variant PsEFE MLHMM contained this R77H mutation and had no activity 
enhancement from αKG nor NOG, I hypothesized that PsEFE VHMM would only be 
activated by acetate. Indeed, while PsEFE VMM exhibits enhanced activity with αKG and 
NOG, only acetate enhances PsEFE VHMM’s C–H insertion activity (Figure 4-21). The best 
variant for this reaction is still PsEFE VMM with NOG as a ligand, but the ability to 
modulate ligand binding through mutations at R277, including preventing the native ligand 
from productively binding, could be useful for further PsEFE protein engineering. 
 
 
Figure 4-21. Intramolecular C–H insertion with variants PsEFE VMM and PsEFE VHMM. PsEFE 
VMM is enhanced by αKG, NOG, and acetate, while PsEFE VHMM is only enhanced by acetate. 
Reaction conditions: 20 µM purified PsEFE variant, 10 mM 2-ethylbenzenesulfonyl azide, 




4.5.2 Analysis of evolved variants’ stability and lifetime 
A time course of the aziridination reaction was run with PsEFE WT and PsEFE MLLHMM 
to better understand the reaction kinetics and enzyme stability. Reactions containing purified 
protein were set up in triplicate both anaerobically and aerobically. Time points were taken 
at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours, at which point those 
reactions were quenched by addition of acetonitrile (350 μL) and the internal standard 
propiophenone (1 μL mL-1 in acetonitrile, 50 μL).  
As seen in Figure 4-22, the reaction with wild-type PsEFE is almost done by the 15-minute 
mark, while the yield with MLLHMM continues to increase for approximately 2 hours. The 
reaction appears to proceed for a longer time anaerobically than aerobically for PsEFE 
MLLHMM, but the low activity for the aerobic reaction makes such comparisons 
challenging. 
 
Figure 4-22. Aziridination time course. Time courses denoted “air” were set up aerobically; time 




This rapid enzyme inactivation could be indicative of enzyme instability. Indeed, in purified 
protein reactions, what is ostensibly protein precipitation is observed to increase over time. 
The thermostability of PsEFE WT has been measured with ITC;45 not surprisingly, the 
protein is reported to have increased stability in the presence of iron and α-ketoglutarate. I 
used a thermal shift assay46 using SYPRO orange (Thermo Fisher Scientific) to measure the 
effect iron, acetate, and αKG have on the stability of each protein variant. It is clear from the 
data that, even though beneficial mutations were only chosen based on activity and 
stereoselectivity, the protein’s stability improved from wild type to the final variants. There 
is also a significant enhancement in thermostability for early variants upon addition of αKG, 
which is not observed in the later evolved variants. This indicates that the mutations 
introduced, despite being within the active site, enhanced PsEFE’s thermostability, and that 
screening for higher TTN also likely exerted pressure for mutations to stabilize the protein. 
 
 
Figure 4-23. Thermostability of wild-type and evolved PsEFE variants for aziridination and 
intramolecular C-H insertion. The thermostability of the proteins was assayed anaerobically in the 
presence of Fe, in the presence of Fe, ascorbate, and αKG (noted as 2OG for 2-oxoglutarate), and 
in the presence of Fe, ascorbate, and acetate. 
4.6 Structural characterization of PsEFE variants 
To understand the effect of the mutations and non-native ligands in the PsEFE protein 




and analogs of both molecules have been reported by the Schofield and Hausinger groups 
using manganese in place of iron to allow for aerobic crystallography.47,48 In these structures, 
PsEFE is seen to adopt an open conformation with a highly solvent-accessible active site in 
the absence of its substrate, L-Arg. The lid loop closes the active site with multiple polar 
contacts to L-Arg, reducing active-site volume and orienting the substrate. The substrates 
used for aziridination and C–H insertion lack these polar contacts, and as such, it is unclear 
whether the lid-loop region would close. The solvent-exposed active site could explain why 
PsEFE was found to have initial activity. 
I cloned N-terminally polyhistidine-SUMO-tagged constructs of PsEFE VMM and PsEFE 
VHMM to investigate the effects these mutations have on PsEFE’s structure, using the same 
cloning strategy used in the generation of heme protein crystallization constructs in Chapter 
2; crystallization constructs with N-terminally polyhistidine-SUMO tags were also used by 
Schofield and coworkers to purify PsEFE WT.48  I expressed and purified both proteins as 
tagless constructs (Supplementary Information, Figure 4-30). Sparse-matrix screening of the 
purified protein supplemented with manganese resulted in initial crystallization conditions 
in multiple PEG 3350 and PEG 4000 conditions, similar to those reported for the wild-type 
protein.48 Drop-volume ratio screening resulted in large clusters of crystals in 1-2 days in 
several ratios of protein and well solution (PEG 4000, 0.1 M Tris pH 8.0) (Figure 4-24). 
While PsEFE VHMM did not initially crystallize under these conditions, streak-seeding 
from PsEFE VMM crystals using a cat whisker (a gift from Crick Boville) resulted in PsEFE 
VHMM crystals. Short (15 minute) soaking experiments as well as overnight soaking 
experiments were carried out, adding αKG, N-oxalylglycine, and acetate to PsEFE VMM 






Figure 4-24. PsEFE VMM crystals. Using polarized film, the crystal’s birefringence is clearly seen, 
indicating it is proteinogenic (right). 
Crystals were cryoprotected with ethylene glycol and shipped to SSRL 12-2 for X-ray 
diffraction studies. The PsEFE crystals consistently diffracted to 1.5–2.0 Å resolution, and 
data sets were collected for each soaking experiment. Both PsEFE VMM and PsEFE 
VHMM crystallized in the open conformation, with a highly solvent-exposed active site 
(Figure 4-25a). There are no apparent tertiary structure changes near the mutations relative 
to a PsEFE WT structure (PDB ID 5V2Y, 0.44 Å RMSD over 2039 atoms, Figure 4-25b). 
Looking at the side chains, however, one can begin to rationalize potential reasons why 
R171V, F314M, and C317M are beneficial mutations. Both R171V and F314M increase the 
active-site volume; it is reasonable that the intermolecular reaction of two aromatic substrates 
would require more active-site space (Figure 4-25c). The C317M mutation extends the 
thioether methyl group 1.4 Å closer (relative to the C317 thiol in PDB 5V2Y) to the 
guanidino group of L-Arg bound in PsEFE WT (Figure 4-25d); the presence of this thioether 
could disfavor L-Arg binding. Disfavoring the native substrate binding might be key in this 
case, as directed evolution screening was carried out in freeze-thawed whole cells, PsEFE 






Figure 4-25. Structural comparison of Mn- and NOG-bound PsEFE VMM and Mn- and αKG-
bound PsEFE WT (PDB ID 5V2Y). (a) Surface representation of PsEFE VMM, showing the 
solvent-exposed active site; the manganese ion is shown in purple. (b) Cartoon representation of 
aligned PsEFE WT (tan) and PsEFE VMM (gray). (c) Mutations at positions R171 and F314 to 
smaller amino-acid side chains increase the active site’s volume. (d) The C317M mutation in 
PsEFE VMM extends a thioether moiety toward the guanidino group of L-Arg bound in PsEFE 
WT. 
Using ethylene glycol as cryoprotectant with no ligand soak or short ligand soaking 
experiments resulted in bidentate metal binding by ethylene glycol. This led to testing 
additional hydroxy acids as reaction additives, including glycolic acid, which further 
enhanced activity relative to acetate in PsEFE VHMM (Supplementary Information, Figure 
4-31). In the data set collected on a PsEFE crystal soaked overnight with N-oxalylglycine, 
however, there is density in agreement with the NOG ligand binding in the active site. 
Interestingly, the electron density supports two conformations of NOG (Figure 4-26). A 




WT,47 but while the second αKG conformation would not be biochemically productive, it is 
possible that NOG bound in either configuration would modulate nitrene-transfer activity.  
 
 
Figure 4-26. Electron density of NOG-bound PsEFE VMM matches NOG in two conformations. 
Electron density map of the ligand was generated via polder. 
Given the ability to obtain crystal structures of the Mn-NOG-bound PsEFE VMM, I was 
interested in obtaining a structure with molecules relevant to nitrene-transfer reactions. The 
open active site and multiple potential coordination sites on the active-site metal increase 
potential binding modes for each substrate, and insight on these binding modes would be 
beneficial for future site-saturation mutagenesis library design. Due to the large 
conformational changes associated with L-Arg binding, I was concerned that performing 
soaking experiments might result in a structure which is not biochemically relevant and opted 
for co-crystallization of PsEFE VMM with reaction substrates or products instead. I chose 
the intramolecular C–H insertion substrate and sultam product as the C–H insertion reaction 
had higher activity than the aziridination reaction, and the intramolecular reaction only 




set up co-crystallization experiments, in which PsEFE VMM, NOG, manganese chloride, 
and either the sulfonyl azide or sultam were incubated with the protein, followed by 
centrifugal filtration to remove any precipitated protein. The purified protein solution was 
used to set up drop-volume ratio crystallization refinement screens with streak-seeding, and 
crystals grew with the same clustered needle morphology over the same time frame. These 
crystals were cryoprotected with PEG 400 in place of ethylene glycol in the attempt to 
prevent ethylene glycol binding in the active site. While ethylene glycol was no longer found 
in the active site, there was also no electron density supporting the binding of either the 
sulfonyl azide or sultam product. The lid loop also remained open in the structures collected 
from crystals in the co-crystallization attempts. It is possible that the crystallization 
conditions prevent the lid-loop region from closing, though similar conditions are used by 
Schofield to crystallize PsEFE WT. It is also possible that the substrate or product binding 
do not induce the protein to adopt the closed conformation, or that the co-crystallization 
conditions were not conducive to substrate or product binding. 
To investigate whether the lid loop still closes, nitrene-transfer reactions using PsEFE 
variants could be performed in the presence of different amounts of L-Arg. This would 
provide insight into whether L-Arg binding has been impacted in the evolved variants. If L-
Arg inhibits PsEFE nitrene-transfer activity, co-crystallization of PsEFE VMM with L-Arg 
would show whether the lid closing mechanism has been disrupted and whether L-Arg’s 
binding mode has been affected by the mutants as rationalized above. 
4.7 Adaptation of PsEFE for high-throughput screening 
PsEFE is a potential platform for biocatalytic new-to-nature reactions due to its high level of 
expression, demonstrated ability to perform multiple nitrene-transfer biotransformations, and 
the ability to modulate the activity of PsEFE variants through ligand substitution. Two of the 
most important features of useful biocatalysts are their expression and stability; poor 
expression increases the cost of producing the catalyst, while poor stability makes both 
engineering and routine use of the biocatalyst more challenging. PsEFE already expresses 




clear that expanding the diversity of protein variants with activity for new-to-nature reactions 
has led to the discovery of starting points for new reactions for which the wild-type protein 
exhibited no activity.42 
Looking to new PsEFE library generation, I noted that many active-site residues have already 
been targeted for mutagenesis during the evolution of the aziridination enzyme variant 
PsEFE MLHMM, but only 7% of the sites within PsEFE have been targeted. Expanding the 
sequence diversity targeted in future rounds of evolution will improve the probability of 
finding beneficial mutations. Using the tile-based mutagenesis strategy laid out in Chapter 5, 
I designed and ordered a mutagenesis library consisting of a total of 127 amino-acid sites 
targeted over three tiles in PsEFE VMM (Figure 4-27). The tiles include almost all active-
site residues (excluding residues whose side chains comprise the metal’s primary 
coordination sphere), the flexible lid-loop region, and the C-terminus, which is highly 
flexible based on crystallographic B-factors and could contribute to the protein’s instability. 
The goal of this library is to expand the sequence breadth targeted in the next rounds of 
PsEFE evolution on new-to-nature reactions and the identification of residues which stabilize 
or generally activate the PsEFE scaffold. The tiles were also chosen such that three additional 
tiles covering complementary sequence space could be ordered and used to generate libraries 






Figure 4-27. PsEFE VMM 127-site-saturation library. Green regions show amino-acid residues 
targeted for site-saturation mutagenesis in the Twist library for PsEFE VMM. 
With any large library design, it is important to have a screening method to effectively search 
the library’s sequence space for the desired fitness enhancements. As protein stability is a 
potential issue for future PsEFE engineering, developing a rapid screen for protein 
expression and stability would enable the enrichment of stable PsEFE variants, which could 
then be screened for new-to-nature activity. Unlike heme proteins, which can be quantified 
in lysate via carbon monoxide binding assays,50 spectrophotometric assays developed for 
αKG-dependent enzymes typically rely on succinate formation. As my initial goal was to 
assay protein expression and stability, it was only necessary to determine whether the full-
length protein is present and soluble. To this end, I employed a split-fluorescent protein 
system, in which the protein of interest is tagged with a short (16 amino acid) fragment of a 




protein fragment are co-expressed, the two fluorescent protein fragments self-assemble, and 
the protein’s fluorescence is enhanced. This approach was developed and used to assay 
soluble protein expression51 and has more recently been used to normalize enzyme 
concentrations in biocatalytic reactions to enable separately analyzing protein expression and 
specific activity.52 
mNeonGreen2(1-10) (mNG2(1-10), complemented by mNG2(11)) was chosen for the 
fluorescent protein system as it was engineered for decreased background fluorescence in the 
absence of the complementary 11th β-strand, and was readily available through Addgene.53 
The construct from Addgene expressed mNG2(1-10) under IPTG induction control; to allow 
for orthogonal induction control, I subcloned the mNG2(1-10) encoding gene into the 
pBAD33 vector under arabinose induction control. Separately, pET22b constructs 
containing IPTG-inducible PsEFE VMM with and without C-terminal polyhistidine tags 
were C-terminally tagged with mNG2(11). The orthogonal induction allows for the 
independent expression optimization of both proteins. In cases when the fluorescence output 
is not needed, the cellular metabolic load can be reduced by only expressing the protein of 
interest. The arabinose induction is tightly regulated and further repressed under high glucose 
concentrations, leading to minimal expression of mNG2(1-10) without addition of arabinose. 
In cases when the stability of the fluorescent protein is greater than that of a protein to which 
it is fused, the stability of the protein of interest can be assayed by a heat challenge followed 
be centrifugation. The denaturation and aggregation of the protein of interest pulls the soluble 
fluorescent protein into the pellet.54 This approach was feasible with our fluorescent system 
as mNG2(1-10) linked to mNG2(11) is stable at 60 °C for over 1 hour. Lysate from cells co-
expressing PsEFE VMM-His6-mNG2(11) showed fluorescence, but following incubation in 
a water bath at 55 °C for one hour and centrifugation, the supernate fluorescence was 






Figure 4-28. Split-fluorescent protein labeling enables measurement of PsEFE folding and 
aggregation. Fluorescence intensity is proportional to the protein of interest in the solution; as 
PsEFE VMM is denatured and aggregates below 55 °C, the associated split-fluorescent protein 
pellets out with the aggregated PsEFE VMM to reduce supernate fluorescence. 
This fluorescent stability assay is amenable to laboratory automation. With automated colony 
picking and 96-tip head liquid handlers, each liquid transfer can be performed robotically, 
increasing throughput potential. With the addition of single-tip liquid handling, variants with 
improved stability by this screen can be robotically re-arrayed into 96-well plates and assayed 
for an activity of interest. 
4.8 Conclusions 
A collection of non-heme metalloproteins was developed with the goal of expanding the 
scope of new-to-nature reactions. These non-heme metalloproteins were tested for initial 
activity in the hydrosilylation of alkenes, alkynes, and carbonyls, but no enzymatic activity 
was found during screening. The non-heme iron proteins were also tested for carbene- and 
nitrene-transfer activity. PsEFE, an αKG-dependent enzyme, was found to have aziridination 
activity. This activity was enhanced by site-saturation mutagenesis of active-site residues, 


































H insertion. The aziridination and C–H insertion activity and selectivity could be enhanced 
by adding non-native ligands NOG or acetate in place of αKG. To aid in further evolution of 
PsEFE variants, I prepared a mutagenesis library targeting 127 residues in the active site and 
flexible C-terminus and tested the use of a split-fluorescent protein thermostability assay. I 
anticipate that this PsEFE comprehensive active-site saturation library and the mNG2-split-
fluorescent protein reporter for protein expression and stability will be helpful for additional 





4.9 Supplementary information for Chapter 4. 
Table 4-4. Collection of non-heme metalloproteins acquired as synthetic gene fragments from IDT 
DNA or as clonal constructs from other research groups. The DNA and amino-acid sequences for 
these proteins are deposited in CaltechDATA (DOI: 10.22002/D1.1437). 
UniProt ID Protein name Source organism Metal 
P22364 Amicyanin Paracoccus denitrificans Cu 
A9WFS1 Auracyanin D Chloroflexus aurantiacus Cu 
P00282 Azurin Pseudomonas aeruginosa Cu 
P34097 Azurin Pseudomonas putida Cu 
P12335 Azurin iso-2 Methylomonas sp. Cu 
Q72HW2 Laccase Thermus thermophiles Cu 
Q820S6 Nitrosocyanin Nitrosomonas europaea Cu 
P00303 Plantacyanin Cucumus sativus Cu 
P18068 Plastocyanin Chlamodymonas reinhardtii Cu 
Q7SIB8 Plastocyanin Dryopteris crassirhizoma Cu 
Q51883 Plastocyanin Phormodium laminosum Cu 
P04171 Pseudoazurin Methylbacterium extorquens Cu 
Q92M26 Pseudoazurin Rhizobium meliloti Cu 
P0C918 Rusticyanin Alcaligenes faecalis Cu 
Q9X1H0 Cupin-like protein Thermotoga maritima Mn 
O93724 Superoxide dismutase Pyrobaculum aerophilum Mn 
P61503 Superoxide dismutase Thermus thermophilus Mn 
Q81MI9 Acireductone 
dioxygenase 
Bacillus anthracis Ni 
A2VA43 Quercetinase Streptomyces sp. Ni 
C7QJ42 Lysine 3-hydroxylase Catenulispora acidiphila Fe 
P37610 Taurine dioxygenase Escherichia coli Fe 
Q6WZB0 Arginine hydroxylase Streptomyces vinaceus Fe 
A0A0E3URV8 Leucine 5-hydroxylase Streptomyces muensis Fe 






Table 4-5. Collection of non-heme metalloproteins acquired as clonal constructs from Twist 
Biosciences. The process through which these proteins were selected is detailed in section 4.2. The 
DNA and amino-acid sequences for these proteins are deposited in CaltechDATA (DOI: 
10.22002/D1.1437). 
# UniProt ID Protein name Source organism Metal 
1 Q9REI7 
2,4'-Dihydroxyacetophenone 
dioxygenase Alcaligenes sp. Fe 
2 P17109 Succinyl isochorismate synthase Escherichia coli Mn 
3 P77072 Organomercurial lyase MerB D99S Escherichia coli Cu 
4 P0A9S1 
Lactaldehyde:1,2-propanediol 
oxidoreductase Escherichia coli Fe 
5 P0AC81 Glyoxalase Escherichia coli Ni/Co 
6 A0A067YX61 α-Ketoglutarate-dependent halogenase Hapalosiphon welwitschii Fe 
7 Q68RJ8 Glyoxalase I Leishmania major Ni 






10 A9A2G4 Purple Cupredoxin Nitrosopumilus maritimus Cu 
11 Q7MZL9 plu4264 Protein, unknown function Photorhabdus luminescens Ni 
12 Q70AC7 Transcarboxylase 
Propionibacterium 
freudenreichii Co 
13 O50580 D-Tagatose 3-epimerase Pseudomonas cichorii Mn 
14 O58810 Superoxide reductase Pyrococcus horikoshii Fe 
15 Q6N272 




16 Q9X034 Amidohydrolase Thermotoga maritima Ni 
17 Q9X113 Oxalate decarboxylase Thermotoga maritima Mn 
18 Q5AR53 
Fe(II)/α-ketoglutarate-dependent 
dioxygenase  Aspergillus nidulans Fe 
19 B1L4V6 Hydrolase, DNA repair enzyme Korarchaeum cryptofilum 
Mn/Co/C
u 
20 V6TJK7 Superoxide reductase Giardia intestinalis Fe 
21 C7R4I0 Chitinase Jonesia denitrificans Cu 
22 Q74MF3 Superoxide reductase Nanoarchaeum equitans Fe 




# UniProt ID Protein name Source organism Metal 
24 F8LWI3 Cambialistic superoxide dismutase 
Streptococcus 
thermophilus Fe/Mn 
25 P80857 Superoxide dismutase Sulfolobus solfataricus Fe 
26 Q9WYP7 L-Ketose-3-epimerase Thermotoga maritima Mn/Ni 
27 A0A0M3KL01 Phytanoyl-CoA dioxygenase 
Micromonospora 
carbonacea Fe 
28 A5VWI3 Persulfide dioxygenase Pseudomonas putida Fe 
29 A6VKV4 Phosphoenolpyruvate carboxykinase 
Actinobacillus 
succinogenes Mn 
30 B3PJ79 Lytic polysaccharide monooxygenase Cellvibrio japonicus Cu 
31 C6FI44 Hydroxyquinol 1,2-dioxygenase Pseudomonas putida Fe 





dioxygenase Streptomyces sp. Fe 
34 D6EWM4 Lytic polysaccharide monooxygenase Streptomyces lividans Cu 






37 O58691 Dipeptidase Pyrococcus horikoshii Co 
38 O87198 Homocitrate synthase Thermus thermophilus Co/Cu 
39 P0A434 Phosphotriesterase Brevundimonas diminuta Mn 
40 P05050 
2-oxoglutarate iron(II) dependent 
dioxygenase Escherichia coli Fe 
41 P29082 Sulfur oxygenase/reductase Acidianus ambivalens Fe 
42 P30967 Phenylalanine hydroxylase 
Chromobacterium 
violaceum Fe 
43 P32021 Ethylene-forming enzyme Pseudomonas savastanoi Fe 
44 P42106 Quercetin 2,3-dioxygenase Bacillus subtilis Fe 
45 P53608 Arginase [Bacillus] caldovelox Mn 
46 P70080 Tryptophan hydroxylase Gallus gallus Fe 
47 P74334 Apocarotenoid cleavage oxygenase 
Synechocystis sp. PCC 
6803 Fe 




# UniProt ID Protein name Source organism Metal 
49 Q6REQ5 Catechol dioxygenase Rhodococcus sp. DK17 Fe 
50 Q7WYF5 2,3-Dioxygenase LapB 
Pseudomonas 
alkylphenolica Fe 
51 Q9RHA2 Fructose-1,6-bisphosphate aldolase Thermus aquaticus Co 
52 Q9WZS1 
N-Acetylglucosamine-6-phosphate 
deacetylase Thermotoga maritima Fe 
53 Q9WZS7 
NADH-dependent butanol 
dehydrogenase Thermotoga maritima Fe 
54 Q9X0P5 Metallo-β -lactamase H8A Thermotoga maritima Ni 
55 Q9X1T8 Transcription regulator Thermotoga maritima Ni 
56 Q672W7 Peptide deformylase Helicobacter pylori Co 
57 Q838S1 Polysaccharide monooxygenase Enterococcus faecalis Cu 
58 Q53586 Dioxygenase Streptomyces avermitilis Fe 
59 Q56185 
Hydroxypropylphosphonic acid 
epoxidase Streptomyces wedmorensis Co 
60 Q96323 Anthocyanidin synthase Arabidopsis thaliana Fe 
61 Q07XY2 Putative hydrolase Shewanella frigidimarina Ni 
62 Q9UXT7 
tRNA N6-adenosine 
threonylcarbamoyltransferase Pyrococcus abyssi Fe 
 
The MetalPDB queries included the following information: 
molecule type: protein. site type: mononuclear. representatives only: yes. Metal: any. 
Geometry: selected from the following list: square pyramid, trigonal bipyramid with a 
vacancy (axial / equatorial), trigonal bipyramid, square plane with a vacancy, square 
plane, square pyramid with a vacancy, square antiprism, square antiprism with a 
vacancy, tetrahedron, tetrahedron with a vacancy, trigonal plane, linear, octahedron, 




          
 
 
Figure 4-29. Expression tests of the non-heme metalloprotein collection. Protein numbers refer to 
numbering in Table 4-5. The molecular weight for each protein is given in kDa. L* denotes the 






HPLC-MS analysis for initial activity determination was performed on an Agilent 1290 
UPLC-MS equipped with a C18 silica column (1.8 μm packing, 2.1×50 mm). HPLC-MS 
analysis of site-saturation mutagenesis libraries was performed on an Agilent 1260 Infinity 
HPLC with an Agilent 6120 quadrupole mass spectrometer. Reverse-phase HPLC-UV 
analysis was performed with an Agilent 1200 series HPLC or an Agilent 1260 Series Infinity 
II HPLC using an Agilent Poroshell 120 EC-C18 column (4 μm packing, 2.1×50 mm) fitted 
with a Poroshell 120 guard column (1.7 μm packing, 2.1×5 mm). Normal-phase HPLC-UV 
analysis for chiral separations was performed with a Hewlett Packard Series 1100 HPLC 
instrument using a Daicel Chiralcel OJ-H column, (5 μm packing, 4.6×250 mm) or a Daicel 
Chiralpak IB column (5 μm packing, 4.6×250 mm). 
NMR spectra were recorded on a Varian Unity/Inova 500 spectrometer operating at 500 
MHz and 125 MHz for 1H and 13C, respectively, or a Bruker Avance 400 spectrometer 
operating at 400 MHz and 100 MHz for 1H and 13C, respectively. NMR data were analyzed 
in MestReNova (MestreLab Research). Chemical shifts are reported in ppm with the solvent 
resonance as the internal standard. For 1H NMR: CDCl3,  7.26. For 
13C NMR: CDCl3, 
 77.16. Data are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, spt = 
septet, m = multiplet, br = broad; coupling constants in Hz; integration. 
Materials 
Oligonucleotides were purchased from IDT DNA. PCRs were run with Phusion® High-
Fidelity PCR Kit (New England Biolabs). Gibson assembly mix55 is prepared with 
isothermal master mix in-house and enzymes T5 exonuclease, Phusion® DNA polymerase, 
and Taq DNA ligase purchased from New England Biolabs.  
Cloning 
Plasmids encoding Pseudomonas savastanoi ethylene-forming enzyme (Uniprot ID 
P32021), Streptomyces sp. 2-aminobutyric acid chlorinase (UniProt ID D0VX22), and 
Arabidopsis thaliana anthocyanidin synthase (UniProt ID Q96323), with the coding 




Plasmids encoding Gluconobacter oxydans leucine dioxygenase (UniProt ID Q5FQD2), 
Streptomyces vinaceus arginine hydroxylase (UniProt ID Q6WZB0), and Streptomyces 
muensis leucine hydroxylase (UniProt ID A0A0E3URV8) were obtained from the laboratory 
of Prof. Hans Renata (Scripps Research Institute). The plasmid encoding E. coli taurine 
dioxygenase (UniProt ID P37610) was obtained from the laboratory of Prof. Harry Gray 
(Caltech). All genes were encoded with a C-terminal His6-tag for purification and inserted 
between the NdeI and XhoI cut sites in the pET-22b(+) vector (Novagen).  
Plasmids were used to transform E. cloni BL21(DE3) cells (Lucigen) by electroporation. 
SOC medium (0.75 mL) was added and the cells were incubated at 37 °C for 45 minutes 
before being plated on Luria-Bertani medium (Research Products International) 
supplemented with ampicillin (100 μg mL-1, LB-amp) agar plates. Plasmids were isolated 
from stationary-phase cultures by miniprep (Qiagen) and Sanger sequencing was performed 
by Laragen, Inc. (Culver City, CA) using T7 promoter and T7 terminator primers. 
Protein expression and purification 
Starter cultures of LB-amp were inoculated from a single E. coli colony on an agar plate 
harboring a plasmid encoding the protein of interest and grown overnight to stationary phase 
at 37 °C. Expression cultures of Terrific Broth (Research Products International) 
supplemented with ampicillin (100 mg L-1, TB-amp) were inoculated from the starter 
cultures (1% v/v) and shaken at 37 °C and 160 rpm in a Multitron Infors incubator. When 
the expression cultures reached OD600 ~ 0.8 (typically 2–3 hours), they were cooled on ice 
for 20 minutes. Protein expression was induced by addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG, 0.5 mM). Cultures were incubated at 22 °C and 110 rpm 
overnight (16–24 hours). Cells were pelleted by centrifugation (5000×g, 10 minutes).  
For reactions with whole cells, cell pellets were resuspended in MOPS buffer (20 mM pH 
7.0) to OD600 30. For reactions with cell lysate, the whole cell suspensions were lysed by 
sonication (QSonica Q500 sonicator, 25% amplitude, 33% duty cycle, 3 minutes). The lysate 




For purification, cell pellets were frozen at −20 °C for at least 24 hours. Cells were 
resuspended in binding buffer (20 mM Tris∙HCl, 100 mM sodium chloride, 20 mM 
imidazole, pH 7.0, ~5 mL/g wet cells) and lysed by sonication (QSonica Q500 sonicator, 
25% amplitude, 33% duty cycle, 4 minutes). The lysate was clarified by centrifugation 
(20,817 g, 10 minutes) followed by filtration (0.45 μm syringe filter). The protein was 
purified using an Äkta Purifier with a HisTrap HP column (GE Healthcare), eluting with a 
gradient of 20–500 mM imidazole. Fractions containing the protein of interest were pooled 
and dialyzed at 4 °C against MOPS buffer (20 mM pH 7.0) containing 1 mM EDTA (>100:1 
v/v) (Spectrum Laboratories Spectra/Por 12–14 kD membrane) for four hours, then against 
MOPS buffer (20 mM pH 7.0) overnight (12–16 hours). The dialyzed protein was 
concentrated by centrifugal filtration (Amicon Ultra-15 10 kD MWCO) to a final 
concentration of 40–100 mg mL−1. The concentrated protein was divided into aliquots (50–
100 μL), flash-frozen on powdered dry ice, and stored at −80 °C. Protein concentration was 
determined by Bradford assay (Bio-Rad Quick Start Bradford). 
Site-saturation mutagenesis and library screening 
Site-saturation mutagenesis was performed using the 22-codon method.56 Oligonucleotides 
including the three 22-codon trick codons (NDT, VHG, TGG) and oligonucleotides within 
the ampicillin resistance cassette were used to amplify the plasmid in two pieces, with an 
overlap for Gibson assembly in the gene encoding the protein of interest (and where the 
mutation is introduced) and an overlap for Gibson assembly in the gene encoding β-
lactamase (which confers ampicillin resistance). This two-piece assembly can prevent mis-
assembled constructs from conferring antibiotic resistance. PCR products were loaded on 
1% agarose gels with loading dye containing SYBR Gold nucleic acid gel stain (Thermo 
Fisher) and visualized on a blue transilluminator. The DNA bands at the expected size were 
excised and the DNA was extracted with a Zymoclean Gel DNA recovery kit. The two linear 
PCR products for a given site-saturation mutagenesis library were assembled via isothermal 
Gibson assembly (50 °C, 1 hour). E. cloni BL21(DE3) cells (Lucigen) were transformed by 
electroporation with the Gibson assembly product without further purification. SOC medium 




minutes before being plated on LB-amp agar plates. The LB-amp agar plates with the plated 
cells were incubated at 37 °C for 12–18 hours and stored at 4 °C until the libraries were 
picked. Single colonies from the agar plates were picked with sterile toothpicks and used to 
inoculate starter cultures (0.5 mL LB-amp) in 96 deep-well plates. The starter culture plates 
were grown at 37 °C, 250 rpm, and 80% humidity in a Multitron Infors shaker overnight 
(14–16 hours). The starter cultures (50 μL) were used to inoculate expression cultures (1 mL 
TB-amp) in 96 deep-well plates. In parallel, glycerol stock plates were prepared for long-
term storage by mixing starter culture (50 μL) with sterile glycerol (50% v/v, 50 μL) and 
frozen at −80 °C. The expression cultures were grown at 37 °C, 250 rpm, and 80% humidity 
for three hours, then cooled on ice for 20 minutes. Protein expression was induced by addition 
of IPTG (0.5 mM). Cultures were incubated at 22 °C and 220 rpm overnight (18–20 hours). 
Cells were pelleted (5000×g, 5 minutes) and the cell pellets were frozen at −20 °C for at least 
24 hours prior to use. 
In site-saturation mutagenesis round 1, cells were resuspended in MOPS buffer (20 mM pH 
7.0) and brought into the Coy anaerobic chamber. Ferrous ammonium sulfate (40 mM in 
water, 10 μL, 1 mM final concentration, prepared immediately before use), disodium α-
ketoglutarate (40 mM in water, 10 μL, 1 mM final concentration), L-ascorbic acid (40 mM 
in water, 10 μL, 1 mM final concentration, prepared immediately before use), styrene (400 
mM in ethanol, 10 μL, 10 mM final concentration), and p-toluenesulfonyl azide (400 mM in 
ethanol, 10 μL, 10 mM final concentration) were added to each well. The plates were sealed 
with foil covers and shaken at room temperature for two hours. To quench the reactions, 
acetonitrile (400 μL) was added and the reaction plate was shaken for an additional 30 
minutes. Insoluble material was pelleted by centrifugation (6000×g, 10 minutes) and 200 μL 
of the supernate was filtered through a 0.2 μm PTFE 96-well filter plate into a 96-well 
microplate (3000×g, 2 minutes). The microplate was sealed with a pierceable cover and 
analyzed via HPLC-MS (Analytical instrumentation). 
After site-saturation mutagenesis round 1, cells were resuspended in MOPS buffer (20 mM 




water, 10 μL, 1 mM final concentration, prepared immediately before use), L-ascorbic acid 
(40 mM in water, 10 μL, 1 mM final concentration, prepared immediately before use), 
styrene (400 mM in ethanol, 10 μL, 10 mM final concentration), and p-toluenesulfonyl azide 
(400 mM in ethanol, 10 μL, 10 mM final concentration) were added to each well. The plates 
were sealed with foil covers and shaken at room temperature for two hours. To quench the 
reactions, acetonitrile (400 μL) was added and the reaction plate was shaken for an additional 
30 minutes. Insoluble material was pelleted by centrifugation (6000×g, 10 minutes) and 200 
μL of the supernate was filtered through a 0.2 μm PTFE 96-well filter plate into a 96-well 
microplate (3000×g, 2 minutes). The microplate was sealed with a pierceable cover and 
analyzed via HPLC-MS (Analytical instrumentation). 
Wells which showed an apparent enhancement in aziridine product formation were streaked 
out (from the glycerol stock plates prepared in parallel) onto LB-amp agar plates and 
incubated at 37 °C. Starter cultures (5 mL LB-amp) were inoculated from single colonies 
and incubated overnight at 37 °C. Plasmids were isolated from these cultures and sequenced 
as described above (Cloning). Unique variants were then regrown in Erlenmeyer flasks as 
described above (Protein expression and purification) and assayed in clarified cell lysate for 
nitrene-transfer activity. 
Analytical-scale biocatalytic aziridination reactions 
Biocatalytic reactions were set up in 2-mL screw-cap vials (Agilent). Purified apoprotein 
(350 μL, 22.9 μM in 20 mM MOPS pH 7.0, final concentration 20 μM) was added to the 
vial. Solutions of ferrous ammonium sulfate and L-ascorbic acid were prepared immediately 
prior to use. Reactions to be set up anaerobically were brought into a vinyl anaerobic chamber 
(Coy Laboratory Products, nitrogen atmosphere, 0–10 ppm oxygen). To each reaction was 
added in order ferrous ammonium sulfate (40 mM in water, 10 μL, 1 mM final 
concentration), sodium acetate or other additive (40 mM in water, 10 μL, 1 mM final 
concentration), and L-ascorbic acid (40 mM in water, 10 μL, 1 mM final concentration). Each 
reaction was then charged with styrene (400 mM in ethanol, 10 μL, 10 mM final 




10 mM final concentration, 500 max. TTN). The reactions were sealed and shaken at room 
temperature for three hours unless otherwise noted. To quench the reactions, acetonitrile 
(350 μL) was added to each vial, followed by internal standard propiophenone (0.1% v/v in 
acetonitrile, 50 μL). The sample was transferred to a 1.7-mL Eppendorf tube, vortexed, and 
then centrifuged (20817×g, 5 minutes). 250 μL of the supernate was transferred to HPLC 
vial inserts for reverse-phase HPLC analysis. The remaining supernate was partially 
concentrated in vacuo to remove acetonitrile and ethanol. Cyclohexane (500 μL) was added 
to the resulting aqueous suspension. The mixture was thoroughly shaken and then 
centrifuged (20817×g, 5 minutes). 250 μL of the organic layer was transferred to HPLC vial 
inserts for normal-phase chiral HPLC analysis. 
Analytical-scale biocatalytic C–H insertion reactions 
Biocatalytic reactions were set up in 2-mL screw-cap vials (Agilent). Purified apoprotein 
(360 μL, 22.2 μM in 20 mM MOPS pH 7.0, final concentration 20 μM) was added to the 
vial. Solutions of ferrous ammonium sulfate and L-ascorbic acid were prepared immediately 
prior to use. Reactions to be set up anaerobically were brought into a Coy vinyl anaerobic 
chamber (nitrogen atmosphere, 0–10 ppm oxygen). To each reaction was added in order 
ferrous ammonium sulfate (40 mM in water, 10 μL, 1 mM final concentration), sodium 
acetate or other additive (40 mM in water, 10 μL, 1 mM final concentration), L-ascorbic acid 
(40 mM in water, 10 μL, 1 mM final concentration). Each reaction was then charged with 2-
ethylbenzenesulfonyl azide (400 mM in ethanol, 10 μL, 10 mM final concentration, 500 max. 
TTN). The reactions were sealed and shaken at room temperature for six hours unless 
otherwise noted. To quench the reactions, acetonitrile (350 μL) was added to each vial, 
followed by internal standard propiophenone (0.5% v/v in acetonitrile, 50 μL). The sample 
was transferred to a 1.7-mL Eppendorf tube, vortexed, and then centrifuged (20817×g, 5 
minutes). 250 μL of the supernate was transferred to HPLC vial inserts for reverse-phase 
HPLC analysis. The remaining supernate was partially concentrated in vacuo to remove 
acetonitrile and ethanol. Hexanes (250 μL, HPLC grade) and ethyl acetate (250 μL, HPLC 




(20817×g, 5 minutes). 250 μL of the organic layer was transferred to HPLC vial inserts for 
normal-phase chiral HPLC analysis. 
Thermostability measurement via thermal shift assay 
Thermal shift assay samples were prepared in triplicate anaerobically, adding all components 
within a vinyl anaerobic chamber (Coy Laboratory Products). To a PCR tube with purified 
PsEFE wild type or a PsEFE variant (stripped and dialyzed, 10–15 µM final concentration) 
was added (to a final concentration of 1.25 mM each) either: 
• ferrous ammonium sulfate 
• ferrous ammonium sulfate, L-ascorbic acid, and α-ketoglutarate 
• ferrous ammonium sulfate, L-ascorbic acid, and sodium acetate 
Following these additions, to each tube was added 5 µL SYPRO orange (25-fold diluted in 
water). The PCR tubes were sealed, brought out of the anaerobic chamber, and analyzed on 
a Stratagene Mx3005P qPCR machine (Agilent Technologies, Inc.). The temperature 
program ran from 25 °C to 99 °C, holding for 30 seconds per degree before measuring 
fluorescence on the SYPRO channel and increasing temperature. The melting temperature 







Figure 4-30. SDS-PAGE showing purification of the cleavable N-His6-SUMO-PsEFE variant 
constructs. Lane 1 is the molecular weight ladder, with molecular weights labeled in kDa. Lanes 2-
8 are PsEFE VMM at induction, harvest, clarified lysate, Ulp1 digested, resin flow-through, and 
dialysis. Lanes 10-15 are PsEFE VHMM at induction, harvest, clarified lysate, Ulp1 digested, resin 















Figure 4-32 SDS-PAGE of PsEFE aziridination variant T97M R171L R277H F314M C317M 
(PsEFE MLHMM). The protein is shown from left to right as whole-cell sample, clarified lysate 
sample, and purified protein sample. Whole cells and lysates were diluted 25-fold; purified protein 
was diluted 50-fold (each dilution is prior to addition of 2X Laemmli loading dye). The ladder and 
sample were run on the same gel; unrelated protein samples were cropped out for image clarity. 
The SDS-PAGE image brightness was increased in Microsoft Word for image clarity and is not 
being used for quantitation. 
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C h a p t e r  5  
INCREASING ROBUSTNESS OF CYTOCHROME P411BM3 TO 






A.M.K conceived of the project. A.M.K. designed comprehensive site-saturation 
mutagenesis libraries for truncated cytochrome P411BM3 variant C10. A.M.K. generated the 








The self-sufficient Bacillus megaterium cytochrome P450 (P450BM3) has been engineered to 
perform selective hydroxylation reactions on myriad substrates. Recently, P450BM3 and its 
serine-ligated variant P411BM3 have been established as a platform for new-to-nature 
carbene- and nitrene-transfer reactions. Even though the enzyme platform has undergone 
many rounds of mutagenesis, only a small fraction of the possible sequence space has been 
touched, leaving the vast majority unexplored. In this Chapter, I describe the design criteria 
used in the generation of a tile-based mutagenesis approach to generate amino-acid 
substitutions at 504 residues in P411BM3, propose a combination of expression and stability 
screening methods to evaluate these variants, and describe a method for recombining 








5.1 Effect of protein stability in directed evolution 
The main mantra in the field of directed evolution is, “You get what you screen for.”1 The 
converse is also true: if one does not screen or select for a current feature of a protein, it is 
possible to lose that feature (you might not keep what you do not screen for). As new-function 
mutations have a high probability of being destabilizing,2 starting with a poorly stable protein 
as the parent and/or not monitoring the potentially destabilizing effects of introduced 
mutations can rapidly result in a protein for which any mutations are deleterious. A prime 
example of this was reported on the evolutionary lineage to convert cytochrome P450BM3 
from a fatty acid hydroxylase to a propane monooxygenase. Researchers found that in order 
to continue evolution toward the desired activity, they had to halt these efforts and, instead, 
perform a round of evolution focused on stabilizing the variant.3 In contrast, thermostable 
proteins – naturally or engineered – tend to be highly evolvable;4 empirically, proteins stable 
to far above operating conditions are desirable starting points for directed evolution, because 
they can tolerate the introduction of more deleterious mutations than a less stable starting 
point.5 While the desired feature is a protein’s long-term stability to its reaction conditions, 
thermostability is positively correlated to a protein’s robustness when exposed to harsh 
reaction conditions such as, for example, high organic solvent concentrations for a long 
period of time,6,7 Even though this correlation does not equate causation, protein engineers 
often choose a naturally thermostable parent enzyme or, if no thermostable parent enzyme 
has been found, thermostabilize a mesostable one before any other engineering efforts are 
made. Current methods for evolving protein stability involve a combination of standard 
mutagenesis library construction and screening, data-driven modeling of protein stability,8 
and rational design to predict stabilizing mutations.9,10 
5.2 Cytochrome P411BM3 as a platform for evolving new-to-nature 
biocatalysts 
Cytochrome P450BM3 was the first protein scaffold demonstrated to perform carbene transfer, 
as described in Coelho et. al's seminal report of enzymatic styrene cyclopropanation.11 
Shortly thereafter, it was shown that the mutation of the axial cysteine to serine (C400S = 




cytochromes P450,12 enhanced carbene transfer activity and enabled the use of in vivo 
reductants.13 Globins, cytochromes c, and other members of the cytochrome P450 family 
also have been engineered for a variety of carbene- and nitrene-transfer reactions,14,15 but the 
majority of these new-to-nature transformations has been reported with variants of P411BM3. 
One P411BM3 variant of note as part of this biocatalytic platform is P411BM3-C10, which was 
discovered as part of the C–H alkylation lineage.16 Due to its broad reaction and substrate 
scope, P411BM3-C10 has been used as a starting point for several successful engineering 
campaigns in the Arnold laboratory, including the cyclopropenation of internal alkynes, 
synthesis of substituted lactones, and further unpublished work.  
Despite being the target for several directed evolution projects aiming to expand the 
repertoire of carbene- and nitrene-transfer biocatalysis, most sequence diversification in the 
P411BM3 evolutionary family so far has been focused on a handful of amino-acid residues in 
the distal heme pocket. This makes sense because these positions are known to have a major 
effect on the enzyme’s stereo- and regioselectivity17, likely through modulating substrate 
binding. At the same time, mutations at these positions have also been shown to negatively 
affect the stability of P450BM3 and P411BM3.
11
 Unlike cytochromes c and protoglobins used 
in other carbene- and nitrene-transfer projects, P411BM3 and its variants are not particularly 
thermostable. Efforts to determine thermostabilizing mutations in P411BM3 could offset the 
destabilization of new gain-of-function mutations,2,11 further improving the utility of this 
biocatalytic platform. Additionally, improved robustness will make this versatile biocatalytic 
platform more useful and attractive for industrial applications.  
5.3 High-throughput techniques to assay protein fitness 
Efficient sampling of a large fraction of the sequence space typically generated with 
mutagenesis libraries requires a screen which can rapidly assess variants for fitness. The 
highest throughput techniques are selection-based approaches; if protein fitness can be tied 
to gene expression in some way, these techniques can be applied to enrich the library with 




phage-assisted continuous evolution (PACE)18 and error-prone orthogonal replication 
(OrthoRep)19 are prominent examples. 
If the fitness can be linked to fluorescence, (e.g. by using a fluorogenic substrate or producing 
a fluorescent protein), ultra-high throughput sorting techniques such as fluorescence-
activated cell sorting20 and fluorescence-activated droplet sorting21 can be used to screen 103 
samples per second. Fitness linked to absorbance has also been shown to work in 
microfluidic droplet-sorting methods.22 Spectrophotometric-based measurements rely on the 
change in absorbance intensity at a particular wavelength. Even minor (5–10 nm) shifts in 
absorbance spectra or changes in extinction coefficients can be sufficient to develop a rapid 
and effective assay. Such spectrophotometric methods have been used in the study of 
transaminases23 and tryptophan synthase,24 and indirect assays based on cofactor depletion 
can be applied to many enzyme classes.25 
So far, most screening methods used for protein engineering campaigns with P411BM3 as a 
scaffold have been based on chromatographic separations such as liquid chromatography 
(LC) or gas chromatography (GC), which typically are considered low- to medium-
throughput. These chromatographic methods enable a sensitive and quantitative 
measurement of the molecule of interest, rather than using an indirect readout or surrogate 
molecules – ensuring that “you get what you screen for.” While highly optimized analytical 
methods and rapid techniques such as multiple injections in a single experimental run 
(MISER) exist26,  the majority of LC and GC screens takes on the order of minutes per 
sample, compared to chromogenic or fluorescent assays which can be screened in a matter 
of seconds, or even faster, per sample. This lengthy screening time has led to the almost 
exclusive use of site-saturation mutagenesis techniques and the generation of very small 
libraries to generate protein variants of P411BM3. As a result, amino-acid positions distant 
from the heme-binding pocket in P411BM3 have been largely neglected, and the few reported 
mutations introduced into the reductase domain of P411BM3 have been the result of random 
mutagenesis via error-prone PCR.27 In fact, only two efforts to engineer P411BM3 variants 




substantially more samples than a targeted one. In the first, variants were screened via HPLC 
for C–H alkylation activity; this resulted in the identification of additional positions which 
were targeted with site-saturation mutagenesis in following rounds of evolution.16 In the 
second effort, a high-throughput assay was developed based on a UV-visible absorbance 
shift between 1-methylindole and the C3-alkylated product, enabling screening thousands of 
variants in a single experimental day.27  
In order to search the so far untouched sequence space of the P411BM3 for stabilizing 
mutations that do not abolish the activities of the enzymes, I envisioned applying the 
mutagenesis and screening approach described below to the P411BM3 scaffold.  
5.4 Developing a screen to discover stabilizing mutations in P411BM3 
variants  
Cytochromes P450 and P411 are named for the wavelength at which they display a 
characteristic spectral peak in difference spectroscopy measurements in the presence and 
absence of carbon monoxide (CO-binding assay). Researchers have taken advantage of this 
behavior to quantify the concentration of properly folded cytochrome P450 in solution28 and 
to screen for thermostabilizing mutations.8 This absorbance-based screen can be performed 
rapidly in lysate on the order of one sample per second in 96-well plate format with a plate 
reader, enabling the assessment of the proper folding of thousands of P411BM3 variants per 
day. 
The ability to only pick colonies known to contain the fully translated protein of interest 
increases the chances of finding hits because misassembled cloning constructs variants will 
be excluded from the screen. Toward this goal, I prepared a colony-based pre-screen in form 
of a direct fluorescence report for protein expression. Colonies which can express full-length 
proteins can then be picked, cultured, heat challenged, and assayed with CO-binding assay. 
For the colony-based prescreen, I chose a split-fluorescent protein system, in which the 
protein of interest is tagged with a short (16 amino acid) fragment of a fluorescent protein. 




co-expressed, the two fluorescent protein fragments self-assemble, and the protein’s 
fluorescence is enhanced. This approach was developed and used to assay soluble protein 
expression29 and has more recently been used to normalize enzyme concentrations in 
biocatalytic reactions to enable separately analyzing protein expression and specific 
activity.30 Fluorescence is only reported in colonies which have a full-length expressed 
P411BM3-C10 as the split-fluorescent protein fragment is on the C-terminus of the protein – 
any incorrectly assembled or truncated proteins will not fluoresce. As this is a split-
fluorescent protein under orthogonal induction conditions rather than a protein fusion, culture 
growth can be performed with only the target protein expressed, decreasing metabolic load. 
Sequential induction of the tagged protein of interest followed by the complementary split 
fluorescent protein fragment can also be used to ensure the protein of interest is soluble upon 
expression.29 
As discussed in Chapter 4, mNeonGreen2(1-10) (mNG2(1-10), complemented by 
mNG2(11)) was chosen as the split-fluorescent protein of choice because it was engineered 
for decreased background fluorescence in the absence of the complementary 11th β-strand.31 
The construct, as available from Addgene, expressed mNG2(1-10) under IPTG induction 
control; to allow for orthogonal induction control, the gene encoding mNG2(1-10) was 
subcloned into the pBAD33 vector under arabinose induction control. By C-terminally 
tagging P411BM3-C10 with mNeonGreen2(11) (mNG2(11))
31 and co-expressing 
mNeonGreen2(1-10) (mNG2(1-10), expression can be detected via fluorescence on LB-agar 





Figure 5-1. Colony-based detection of P411BM3 expression via split-fluorescent protein tagging. (a) 
E. coli colonies transformed with plasmids encoding mNG2(1-10) and P411BM3-C10-mNG2(11), 
grown on LB-carb-chlor-agar plates. (b) E. coli colonies transformed with plasmids encoding 
mNG2(1-10) and P411BM3-C10-mNG2(11), grown on LB-carb-chlor-agar plates, followed by the 
addition of arabinose and IPTG to induce expression of mNG2(1-10) and P411BM3-C10-mNG2(11), 
respectively. 
If the stability of the fluorescent protein is greater than that of a protein to which it is fused, 
the stability of the protein of interest can be assayed by a heat challenge followed by 
centrifugation. The denaturation and aggregation of the protein of interest pulls the soluble 
fluorescent protein into the pellet; the loss of supernate fluorescence is proportional to the 
fraction of the protein of interest which aggregated.32 This approach was feasible with our 
fluorescent system as mNG2(1-10) linked to mNG2(11) is stable at 60 °C for over 1 hour. In 
contrast, full-length P411BM3-C10 has a TM of 50 °C (determined by CO binding assay)
28, 
and the TM of the heme domain of P411BM3-CIS had been determined to be 60.6 °C.
13 While 
P411BM3-C10’s broad reaction scope has led to its identification as a potential starting point 
in new projects, its stability — and thus robustness to destabilizing mutations — has played 
an important part in its further evolution toward new activities.   
When testing for loss of fluorescence for P411BM3-C10-mNG2 following a heat challenge 
(at 55 °C based on P411BM3-C10’s measured TM), however, I was surprised to find that the 
fluorescence increased by a factor of two (Figure 5-2); fluorescence increased similarly 





scans led to the conclusion that this increased fluorescence is due to the release of flavin 
mononucleotide (FMN) from P411BM3 and oxidation in solution.
33 Indeed, the fluorescence 
is lost upon addition of sodium dithionite (reducing FMN), while addition of sodium 
dithionite to lysate containing mNG2-tagged PsEFE VMM does not attenuate fluorescence. 
As the absorbance and fluorescence spectra for mNG2 and FMN are completely overlapping, 
incomplete FMN reduction would confound the mNG2 fluorescence measurements, 
assaying thermostability with mNG2 is challenging for P411BM3 constructs still containing 
the FMN domain. The mNG2 system can still be used as a colony-based pre-screen to a CO-
binding assay to determine expression and stability. In addition, in the absence of the fully 
assembled and fluorescent mNG2, the increased fluorescence from oxidized FMN can be 




Figure 5-2. Supernate fluorescence of P450BM3-C10 tagged with mNG2(11) and co-expressed with 
the complementary mNG2(1-10) fragment. The increased fluorescence can be attributed to FMN 































To further accelerate directed evolution experiments, the CO-binding assay is fully amenable 
to robotic automation steps. An automated colony picker and 96-head liquid handlers can 
perform all transfer operations, from inoculating cultures with single E. coli colonies on a 
Petri dish to preparing clarified cell lysate for CO-binding analysis. With a total analysis time 
of approximately 5 minutes per 96-well plate and a plate reader with a plate stacker to 
measure tens of plates in series, the throughput bottleneck becomes the space available to 
grow 96-deep-well plates of libraries. This combination of automation and high-throughput 
assay reduces screening effort and enables screening of tens of thousands of variants per 
week.  
5.5 Design of tile-based comprehensive site-saturation mutagenesis 
libraries 
Despite the focus on a subset of active-site residues in P411BM3 engineering, protein fitness 
has been shown to be globally encoded.34 Random mutagenesis and other library designs 
exploring global sequence space often uncover beneficial amino-acid substitutions at 
positions unlikely to be prioritized by structure-guided mutagenesis strategies. My goal was 
to design a library which could be inexpensively constructed, provide sequence coverage of 
the majority of P411BM3 amino-acid positions, and have the potential to be used for various 
other P411 variants and more than a single mutagenesis campaign.  
There are myriad methods developed to perform targeted or random mutagenesis. 
Techniques like random mutagenesis via error-prone PCR will cover the entirety of a protein 
sequence, but single nucleotide substitution only enables access to a subset of the available 
amino-acid sequence space. Unlike mutagenesis methods such as error-prone PCR and 
sequence-saturation mutagenesis (SeSaM)35, which introduce single-nucleotide 
substitutions, libraries with single-codon substitutions enable access to all single steps in 
protein sequence space. The concept of single-codon substitutions throughout a full gene has 
been established in the protein engineering community since the early 2000s.36,37 While the 
cost to synthesize full genes continues to drop, the price of a commercially purchased whole-




particularly for academic work. As the cost for DNA synthesis is typically priced per base 
pair, synthesizing shorter segments of DNA is a straightforward way to reduce the financial 
strain of library preparation. This cost is further reduced when purchasing these 
oligonucleotides as a single, pooled sample. The use of such commercial oligo pools to 
generate sets of site-saturation mutagenesis libraries has been demonstrated with nicking 
mutagenesis38 and orthogonal replication (OrthoRep)19 systems.  
Inspired by these commercial oligo pool mutagenesis methods and SCHEMA library design, 
in which homologous proteins are divided into blocks which are recombined,39 I envisioned 
splitting the P411BM3 primary sequence into several distinct tiles encoding comprehensive 
single amino-acid substitutions. Using this tile-based mutagenesis approach, 12 mutagenesis 
tiles were designed spanning the length of P411BM3-C10, targeting 504 of the 665 residues 
(Figure 5-3). The tile set was designed such that each tile was up to 200 nucleotides in length; 
oligos longer than 200 nucleotides increased the price and turnaround time for the oligo pool 
and paired-end reads on next-generation sequencing platforms will not give full sequencing 
coverage if the sequenced region is longer than 200 nucleotides. Conversely, shorter tiles 
(<120 bp) have reduced yields from PCR amplification and gel extraction protocols. The 
primer-binding sites between tiles were designed to have secondary structure predictions 
conducive to efficient PCR amplification, which were then validated experimentally 
(Supplementary Information, Figure 5-6). The tile positions were also chosen to maximize 
the number of commonly targeted residues in the primer binding sites between tiles, such 
that primers complementary to the parent variant can be used to amplify a tile. The oligo pool 
was designed such that each position targeted for saturation has 19 codon substitutions, using 
the most abundant codon in E. coli to encode each amino acid. The use of 19 single-codon 
substitutions in place of degenerate codons (22-codon trick or NNK degeneracy) reduces the 
library size and necessary screening effort without decreasing the protein sequence space 
covered. The entire library of 12 P411BM3-C10 tiles was ordered as a single pool and was 





Figure 5-3. Overview of sites targeted in cytochrome P450BM3 heme and FMN domains (PDB ID: 
1BVY). Positions which are mutated as part of a tile are shown in green. The heme domain has 9 
tiles and the FMN domain has 3. Together these 12 tiles constitute 504 sites at which all amino-
acid substitutions are encoded. 
The individual tiles, each containing 39–45 positions at which mutations are programmed, 
can be amplified out of the synthetic oligo pool via PCR with tile-specific amplification 
primers (Figure 5-4). Following PCR amplification, the tiles can be assembled with the 
complementary DNA fragment containing the remainder of the protein and vector via a 
standard Gibson assembly molecular biology pipeline.40 As Gibson assembly is amenable to 
multiple fragment assemblies, multiple degenerate tiles can be combined within the same 








Figure 5-4. Example tile in P411BM3-C10. A mutation region of 40-45 codons is flanked by two 
overlapping regions without programmed mutations. The tile can be amplified via PCR with 
complementary primers and assembled to generate a plasmid with full-length protein.   
Library coverage during screening is always a concern in a directed evolution campaign. 
With 19 single-codon substitutions per position targeted, the single-tile libraries designed 
contain 741–855 programmed single amino-acid substitutions. Screening eight 96-well 
plates (704 colonies after factoring in eight control wells per plate) per tile mutagenesis 
library (39–45 positions targeted per tile) would result in 50–60% library coverage. Although 
single site-saturation mutagenesis libraries have been screened at 86% to 98% library 
coverage, the amount of additional screening required to reach these library coverages is not 
worth the fractional increase in coverage. In random mutagenesis approaches, one screens 
only a tiny fraction of the complete library in a round of directed evolution, and machine 
learning approaches to directed evolution have been carried out collecting data with library 
coverage of 5% or less.41 A combinatorial mutagenesis library built from two tiles targeting 
39 residues each would contain 549,081 variants (two single-substitution libraries (39 × 19 
= 741), combined pairwise (7412 = 549,081)), which could still be screened if ultra-high-
throughput screening methods are available or low library coverage is acceptable. 
Combining larger tile libraries or more than two tiles simultaneously would further increase 
the library size. 
When ordering oligonucleotides and larger libraries, the ability to reuse the primers for future 
mutagenesis on the same or related directed evolution projects becomes a concern. I designed 
the tile overlap regions to coincide with the amino-acid positions targeted most often for site-




used in mutagenesis projects to complement the generation of site-saturation mutagenesis 
libraries at commonly targeted positions. This allows for great flexibility: one can either first 
target the positions most often mutated in P411s, followed by use of the tiles (or a subset of 
the tile mutations found to be beneficial), or vice versa. The plasmid containing a tile 
mutagenesis library can be stored in the -20 °C freezer and can be amplified and assembled 
for reuse with a new P411BM3 variant. 
5.6 Identification and recombination of stabilizing mutations 
Due to the costs associated with Sanger sequencing, only a handful of the best variants are 
sequenced in each round of traditional directed evolution experiments. The increased use of 
machine learning methods for protein engineering applications has led to the push for 
collecting sequence information for all variants screened, so that machine learning models 
can be built on data that show which mutations are beneficial and which are detrimental to 
the target function.42 Collecting sequence information for all variants tested is also useful to 
determine the true library coverage when screening a large, defined library at low 
redundancy. A multiplexed approach to make sequencing the full libraries economically 
viable has been developed recently in the lab, which would enable sequencing of all tile-
based mutagenesis library plates. I have contributed code to extend its use to tile-based 
mutagenesis libraries: the initial code requires user specified mutation positions, which are 
not known within a tile mutagenesis library. The code I wrote removes the need to specify 
the mutation position; codon frequencies at each position are compared to the reference 
sequence codon, and codons which do not match the reference are reported, making the rapid 
analysis of mutations feasible.  
When beneficial mutations are found, they can be recombined in libraries to find 
combinations of mutations which are better than individual mutations. There are several 
options based on library size and complexity. For small libraries, recombination can be 
performed with standard PCR amplification with degenerate primers, which can be 
challenging to design with larger libraries. In larger libraries, early recombination was 




processes;44 as with other library synthesis strategies, the decreased cost of DNA synthesis 
makes it feasible to synthesize combinatorial libraries which would be too complex to 
generate with PCR-based approaches. For tile-based mutagenesis libraries, it is possible to 
generate combinatorial libraries within a single tile, between multiple tiles, or a combination 
of the two. To generate a recombination library of multiple mutations within the same tile, it 
is most time efficient to order an additional oligo pool library consisting of each combination 
of mutations desired within the tile (Figure 5-5a). This tile can then be assembled and 
screened as a standard tile mutagenesis library. To generate a recombination library with 
individual mutations from different tiles, one can purchase the synthetic library as above. 
Alternatively, one can grow a culture for each variant to be combined from the same tile and 
isolate the plasmid. This mixture of plasmids can be used as a PCR template to prepare that 
tile library. Multi-fragment Gibson assembly can be used to assemble multiple tile libraries 
together, whether the libraries are each composed of single mutations (Figure 5-5b) or are 





Figure 5-5. Potential recombination methods to generate combinatorial diversity from beneficial 
mutations found in tile libraries. (a) Recombination within a single region of DNA (e.g. gene or 
tile) can be performed with several molecular biology methods or by direct DNA synthesis, then 
assembled into the plasmid. (b) Single mutations in multiple tiles can be assembled to generate 
combinatorial libraries. (c) Combinatorial tile libraries can also be assembled to generate more 
complex, multi-tile combinatorial libraries. (d) Libraries (whether single mutations or 
combinatorial) can be transferred into other P411BM3 variants if the variant does not have any key 




Mutations found to enhance protein expression and/or stability can also be transferred into 
other P411BM3 variants through the same process; this transfer of mutations could be applied 
to stabilize variants already engineered for other functions. If there are no other mutations in 
the P411BM3 variant in the tile’s region, the tile (with any mutations to be transferred) can be 
amplified and assembled with the P411BM3 variant (Figure 5-5d). These mutations could also 
be transferred to P450BM3 variants using the same approach. As a new mutation in the context 
of a different P411BM3 scaffold will not necessarily provide the same fitness enhancement, it 
is vital to test this new variant – ideally transferring a combination of mutations as a library 
and screening for enhanced fitness. 
Sequencing all variants screened in these libraries will generate a large data set mapping 
sequence to fitness globally on P411BM3-C10. These data will be extremely valuable for 
machine-learning approaches to directed evolution to both predict beneficial combinations 
of mutations which were observed in the library and predict variants which were not 
observed, but could display enhanced fitness. As the anticipated library coverage is 50% and 
models can be trained on 5% or less of the data,41 it is possible to compare machine learning 
predictions to a large experimental test data set. This ground truth dataset could therefore be 
used to compare the accuracy of different models on global mutational fitness predictions. 
5.7 Conclusions 
Protein stability is a crucial parameter for the evolution of enzymes for synthetic applications. 
The biocatalytic platform based on P411BM3 variants could be further enhanced by focusing 
on stabilizing the P411BM3 scaffold. In this chapter, I have shown a tile-based mutagenesis 
library design which enables the exploration of largely untapped sequence space in P411BM3 
and demonstrated fluorescent and spectrophotometric assays which can be used to efficiently 
screen the library for mutations which enhance stability and expression. I lay out methods 
which could be used to recombine these mutations and transfer beneficial mutations to other 
P411BM3 variants and the potential utility of the sequence-fitness data set to benchmark 




and methods have the potential to improve the robustness of the P411BM3 platform and ensure 
that it can continue to be used to develop more remarkable new-to-nature biotransformations. 
5.8 Supplementary information for Chapter 5 
Materials 
Oligonucleotide primers were obtained from IDT DNA. Synthetic oligonucleotide pool 
libraries were obtained from Twist Biosciences. PCRs were run with Phusion® High-
Fidelity PCR Kit (New England Biolabs). Gibson assembly mix40 is prepared with 
isothermal master mix in-house, and enzymes T5 exonuclease, Phusion® DNA polymerase, 
and Taq DNA ligase purchased from New England Biolabs.  
Cloning 
Plasmids were used to transform E. coli BL21(DE3) cells (Lucigen) by electroporation. SOC 
medium (0.75 mL) was added, and the cells were incubated at 37 °C for 45 minutes before 
being plated on Luria-Bertani medium (Research Products International) agar plates 
supplemented with carbenicillin (100 μg mL-1, LB-carb-agar). To prepare E. coli harboring 
two plasmids, E. coli BL21(DE3) cells were co-transformed with both plasmids; future 
library transformations should be performed using competent E. coli BL21(DE3) cells 
already harboring the second plasmid to improve efficiency. Plasmids were isolated from 
stationary-phase cultures by miniprep (Qiagen) and Sanger sequencing was performed by 







Figure 5-6. Agarose gel of PCR-amplified tile regions of P411BM3. L: DNA ladder (1 kbp ladder, 
NEB), 1-12: PR products from P411BM3-C10 tile regions. The larger molecular-weight band is the 
tile fragment; the lower band is primer dimer. Gel excision of the DNA fragment and Gibson 
assembly with linear DNA containing the expression vector and the remainder of the gene encoding 
P411BM3-C10 can be used to transform E. coli. 
Protein expression  
Starter cultures of LB-amp were inoculated from a single E. coli colony on an agar plate 
harboring a plasmid encoding the protein of interest with a sterile toothpick and grown 
overnight to stationary phase at 37 °C. Expression cultures of Terrific Broth (Research 
Products International) supplemented with ampicillin (100 mg L-1, TB-amp) were inoculated 
from the starter cultures (1% v/v) and shaken at 37 °C and 160 rpm in a Multitron Infors 
incubator. When the expression cultures reached OD600 ~ 0.8 (2–3 hours), they were cooled 
on ice for 20 minutes. Protein expression was induced by addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG, 0.5 mM). Cultures were incubated at 22 °C and 110 rpm 





Agar plate induction of protein expression  
E. coli BL21(DE3) cells were co-transformed with pET22b_P411BM3C10_mNG2(11) and 
pBAD33_mNG2(1-10) plasmids and grown on LB agar supplemented with carbenicillin 
(100 µg mL-1) and chloramphenicol (25 µg mL-1) (LB-carb-chlor-agar) at 37 °C for 12–16 
hours. Following colony formation, the plates were stored at 4 °C until induction. Using an 
Echo acoustic liquid handler (Labcyte), induction media (18%(w/w) L-arabinose, 100 mM 
IPTG) was patterned across the single-well LB-agar plate in 1536 applications of 50-nL 
droplets. The plates were then incubated at room temperature for 24 hours. Colony 
fluorescence was observed using a blue-light transilluminator. 
Cell lysis 
Cells grown in 96-well plates were frozen at -20 °C for at least 24 hours and rapidly thawed 
in room-temperature water. Lysis buffer (400 µL of 1×M9-N buffer supplemented with 1 mg 
mL-1 hen egg white lysozyme and 0.1 mg mL-1 Dnase I) was added, and the plate was 
vortexed until all cell pellets were visually resuspended. The plate was incubated at 37 °C 
for 1 hour, then centrifuged (5000×g, 10 minutes) to clarify the lysate. 
Thermostability assay 
Purified protein or clarified cell lysate were incubated in a water bath set to the specified 
temperature for 30 or 60 minutes. Single samples were incubated in 1.7-mL plastic tubes. 
96-Well plate format samples were incubated using semi-skirted PCR plates to facilitate even 
heat transfer across the wells. Following heat incubation, the samples were centrifuged (10 
minutes; single samples at 20817×g, 96-well plates at 5000×g). The supernate was used for 
CO-binding assays. 
Carbon monoxide binding assay 
The carbon monoxide binding assay was performed as described previously.11 Briefly, 
sodium dithionite (40 µL of 150 mM solution, 30 mM final concentration) was added to 
clarified cell lysate containing P411BM3 variants (160 µL). Absorbance measurements at 411 




microtiter plates were placed in a vacuum chamber. The chamber was sealed, evacuated to 
approximately -15 inHg, filled with carbon monoxide gas to atmospheric pressure, and 
incubated for 30 min. The plates were then removed, and the absorbance at 411 nm and 490 
nm was again recorded using the plate reader. The difference spectra were then used to 
determine the P411BM3 lysate concentration in each well.
28 
Table 5-1. P411BM3-C10 tile locations. Indices are based on nucleotide sequence and are 0-indexed 
(i.e., the first nucleotide of the start-codon is A0). Tile start and end indices include the overlap 
regions in which primer binding sites were designed. Mutation indices show the region in which 






















P411C10_tile_01 1 199 33 167 199 135 45 
P411C10_tile_02 168 363 201 332 196 132 44 
P411C10_tile_03 334 517 366 482 184 117 39 
P411C10_tile_04 484 681 519 647 198 129 43 
P411C10_tile_05 648 845 684 806 198 123 41 
P411C10_tile_06 808 998 846 968 191 123 41 
P411C10_tile_07 970 1167 1002 1139 198 138 46 
P411C10_tile_08 1142 1338 1170 1292 197 123 41 
P411C10_tile_09 1295 1489 1341 1457 195 117 39 
P411C10_tile_10 1459 1652 1491 1616 194 126 42 
P411C10_tile_11 1619 1802 1653 1769 184 117 39 











Amplification primer sequence 
P411C10_tile_01 Forward TGACAATTAAAGAAATGCCTCAGCCAAAAACG 
P411C10_tile_02 Forward CGTCTAATTAAAGAAGCATGCGATGAATCACG 
P411C10_tile_03 Forward CAATGAAAGGCTATCATGCGAGTATGGTCG 
P411C10_tile_04 Forward GCCTTAACAGCTTTTACCGAGATCAGCC 
P411C10_tile_05 Forward GTAGATAAAATTATTGCAGATCGCAAAGCAAGGG 
P411C10_tile_06 Forward CAAGTGGTCTTTTATCATTTGCGCTGTATTTCTTAGTG 
P411C10_tile_07 Forward GCTTATGGCCAACGGTTCCTTATTTTTCCC 
P411C10_tile_08 Forward AAATCCAAGTGCGATTCCGCAGCATG 
P411C10_tile_09 Forward CGATATTAAAGAACTGCAGACGTTAAAACCTAAAGGC 
P411C10_tile_10 Forward ACGGTTCAAATATGGGTACCGCTGAAGGA 
P411C10_tile_11 Forward TCCGCCTGATAACGCAAAGCAATTTGTC 
P411C10_tile_12 Forward GCCGCTAAAGGGGCAGAAAACATCG 
P411C10_tile_01 Reverse CGTGATTCATCGCATGCTTCTTTAATTAGACG 
P411C10_tile_02 Reverse CGACCATACTCGCATGATAGCCTTTCATTG 
P411C10_tile_03 Reverse GGATGAGGCTGATCTCGGTAAAAGCTGTTAAG 




P411C10_tile_06 Reverse GGAAAAATAAGGAACCGTTGGCCATAAGCG 
P411C10_tile_07 Reverse CATGCTGCGGAATCGCACTTGGATTT 
P411C10_tile_08 Reverse CCACAAAGCCTTTAGGTTTTAACGTCTGCAG 
P411C10_tile_09 Reverse GTTCCTTCAGCGGTACCCATATTTGAACC 
P411C10_tile_10 Reverse CCAGTCGACAAATTGCTTTGCGTTATCAGG 
P411C10_tile_11 Reverse GCGGTCAGCGATGTTTTCTGCCC 
P411C10_tile_12 Reverse CGCGGCGCTGTCGACAAATTG 
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APPENDIX A: SEQUENCE INFORMATION 
The sequences of expression vectors (DNA sequence) and proteins (DNA and amino-acid 
sequence) used in this study are deposited in csv format on CaltechDATA. The 
oligonucleotide primer sequences used in this work are also deposited to CaltechDATA. 
These data can be found at DOI: 10.22002/D1.1437. 
Table A-1. Proteins (and expression vectors) for which sequences are given in the worksheet 
deposited to CaltechDATA (DOI: 10.22002/D1.1437). The UniProt ID for the wild-type protein is 











SUMO-tagged P411BM3-UA-V87C heme domain only P14779 




RmaNOD Y32G D0MGT2 
RmaNOD wild type (WT) D0MGT2 
RmaNOD Q52V D0MGT2 
SUMO-tagged RmaNOD Q52V D0MGT2 
RmaNOD Q52A D0MGT2 
RmaNOD Y32T Q52A  D0MGT2 
RmaNOD Y32T Y39H L48R Q52A R79W (THRAW)  D0MGT2 
RmaNOD Q52A L101N D0MGT2 
RmaNOD Q52A 60H L101N D0MGT2 
RmaNOD Q52A 60H L101N I105M D0MGT2 
RmaNOD L20W Q52A L56I 60H L101N I105M (WAIHNM) D0MGT2 
ApePgb WT Q9YFF4  
ApePgb Y60G Q9YFF4  
ApePgb W59A Y60G Q9YFF4  
ApePgb W59A Y60G F145W (AGW) Q9YFF4  
ApePgb Y60G F145N Q9YFF4  





PsEFE WT P32021 
PsEFE C317M P32021 
PsEFE H189A D191A P32021 
PsEFE R171V F314M C317M P32021 
PsEFE R171V R277H F314M C317M P32021 
SUMO-tagged PsEFE R171V F314M C317M P32021 
SUMO-tagged PsEFE R171V R277H F314M C317M P32021 
PsEFE T97M R171L R277H F314M C317M P32021 
PsEFE T97M R171L I186L R277H F314M C317M P32021 
PsEFE T97M R171V R277H R314L C317M P32021 
Streptomyces vinaceus Arginine hydroxylase  Q6WZB0 
Streptomyces muensis Leucine hydroxylase  A0A0E3URV8 
Gluconobacter oxydans Leucine hydroxylase  Q5FQD2 
Escherichia coli Taurine dioxygenase  P37610 
Arabidopsis thaliana Anthocyanidin synthase  Q96323 
Streptomyces sp. 2-aminobutyric acid chlorinase  D0VX22 
Paracoccus denitrificans Amicyanin P22364 
Chloroflexus aurantiacus Auracyanin D A9WFS1 
Pseudomonas aeruginosa Azurin P00282 
Pseudomonas putida Azurin P34097 
Methylomonas sp. Azurin iso-2 P12335 
Thermus thermophilus Laccase Q72HW2 
Nitrosomonas europaea Nitrosocyanin Q820S6 
Cucumus sativus Plantacyanin P00303 
Chlamodymonas reinhardtii Plastocyanin P18068 
Dryopteris crassirhizoma Plastocyanin Q7SIB8 
Phormodium laminosum Plastocyanin Q51883 
Methylbacterium extorquens Pseudoazurin P04171 
Rhizobium meliloti Pseudoazurin Q92M26 
Alcaligenes faecalis Rusticyanin P0C918 
Thermotoga maritima Cupin-like protein Q9X1H0 
Pyrobaculum aerophilum Superoxide dismutase O93724 
Thermus thermophilus Superoxide dismutase P61503 
Bacillus anthracis Acireductone dioxygenase Q81MI9 
Streptomyces sp. Quercetinase A2VA43 
Alcaligenes sp. dihydroxyacetophenone dioxygenase Q9REI7 
Escherichia coli 2-succinyl-5-enolpyruvyl-6-hydroxy- 3-cyclohexadiene-1-
carboxylate synthase 
P17109 
Escherichia coli Organomercurial Lyase MerB P77072 
Escherichia coli Lactaldehyde:propanediol oxidoreductase P0A9S1 
Escherichia coli Glyoxalase P0AC81 
Hapalosiphon welwitschii 2-OG Halogenase A0A067YX61 
Leishmania major Glyoxalase I Q68RJ8 





Mycobacterium thermoresistibile Ergothioneine-biosynthetic sulfoxide synthase G7CFI3 
Nitrosopumilus maritimus Purple Cupredoxin A9A2G4 
Photorhabdus laumondii cupin Q7MZL9 
Propionibacterium freudenreichii transcarboxylase Q70AC7 
Pseudomonas cichorii D-tagatose 3-epimerase O50580 
Pyrococcus horikoshii superoxide reductase O58810 
Rhodopseudomonas palustris cupin Q6N272 
Thermotoga maritima Amidohydrolase Q9X034 
Thermotoga maritima Oxalate decarboxylase Q9X113 
Aspergillus nidulans Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ Q5AR53 
Candidatus Korarchaeum cryptofilum hydrolase DNA repair enzyme B1L4V6 
Giardia intestinalis Superoxide reductase V6TJK7 
Jonesia denitrificans Chitinase C7R4I0 
Nanoarchaeum equitans Superoxide reductase Q74MF3 
Oryctolagus cuniculus Glycogenin P13280 
Streptococcus thermophilus cambialistic superoxide dismutase F8LWI3 
Sulfolobus solfataricus superoxide dismutase P80857 
Thermotoga maritima L-ketose-3-epimerase Q9WYP7 
Micromonospora carbonacea EvdO2 A0A0M3KL01 
Pseudomonas putida Persulfide dioxygenase A5VWI3 
Actinobacillus succinogenes Phosphoenolpyruvate Carboxykinase A6VKV4 
Cellvibrio japonicus Lytic Polysaccharide Monooxygenase B3PJ79 
Pseudomonas putida Hydroxyquinol dioxygenase C6FI44 
Acinetobacter radioresistens catechol dioxygenase C6RPG2 
Streptomyces sp. Alpha-Ketoglutarate dependent enzyme D0VX22 
Streptomyces lividans lytic polysaccharide monooxygenase D6EWM4 
Vulcanisaeta moutnovskia Lactonase F0QXN6 
Mycobacterium tuberculosis 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase O53512 
Pyrococcus horikoshii Dipeptidase O58691 
Thermus thermophilus homocitrate synthase O87198 
Brevundimonas diminuta Phosphotriesterase P0A434 
Escherichia coli alpha-ketoglutarate dependent dioxygenase P05050 
Acidianus ambivalens sulfur oxygenase P29082 
Chromobacterium violaceum Phenylalanine hydroxylase P30967 
Pseudomonas savastanoi Ethylene forming enzyme P32021 
Bacillus subtilis Quercetin dioxygenase P42106 
Bacillus caldovelox arginase P53608 
Gallus gallus Tryptophan hydroxylase P70080 
Synechocystis sp. PCC 6803 apocarotenoid cleavage oxygenase P74334 
Myxococcus xanthus Persulfide Dioxygenase Q1D4C9 
Rhodococcus sp. DK17 Catechol dioxygenase Q6REQ5 
Pseudomonas alkylphenolica dioxygenase LapB Q7WYF5 
Thermus aquaticus fructose bisphosphate aldolase Q9RHA2 





Thermotoga maritima NADH-dependent butanol dehydrogenase Q9WZS7 
Thermotoga maritima metallo-beta-lactamase Q9X0P5 
Thermotoga maritima Transcription regulator Q9X1T8 
Helicobacter pylori Peptide deformylase Q672W7 
Enterococcus faecalis Polysaccharide monooxygenase Q838S1 
Streptomyces avermitilis dioxygenase Q53586 
Streptomyces wedmorensis Hydroxypropylphosphonic acid epoxidase Q56185 
Arabidopsis thaliana Anthocyanidin synthase Q96323 
Shewanella frigidimarina Putative hydrolase Q07XY2 
Pyrococcus abyssi tRNA N6-adenosine threonylcarbamoyltransferase Q9UXT7 
 
 
 
